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INTRODUCTION
The term “brain tumour” refers to a collection of neoplasms, each with its own 
biology, prognosis and treatment. These tumours are better identified as 
“intracranial neoplasms”, since some do not arise from brain tissue (e.g. 
meningiomas and lymphomas). However, for most intracranial tumours, the 
clinical presentation, diagnostic approach, and initial treatment are similar. 
Brain tumours are characterised by a vast array of different histological types, 
complexity of clinical presentations and modest success in therapy.
Meningioma was first described in an autopsy report by Felix Plater, 1614, 
as a round, fleshy, hard tumour full of holes and as large as a medium-sized 
apple, covered with its own membrane and entwined with veins. The first 
operation for intracranial tumour was carried out in 1835 by Zanobi Pecchioli. 
He removed a “fungus of dura matter” presented as a large extra-cranial mass 
(Green and Stem, 1967). In 1884, Rickman Godlee performed the first 
recognised resection of a primary brain tumour. The patient died on the 28th 
post-operative day. The post-mortem examination revealed evidence of menin­
gitis and infarction, but no residual tumour (Kirkpatrick, 1984).
Neuroepithelial tumours, the so-called gliomas of the brain constitute about 
half of all primary intracranial tumours. All gliomas, particularly the astrocytic 
neoplasms, are histologically and genetically heterogeneous. Accurate patholo­
gical grading is essential because it defines treatment and prognosis. Tumours 
of meningothelial cells, including all meningiomas, account for approximately 
13-20% of all intracranial tumours in men and 24-38% in women (Preston- 
Martin et al., 1989; Helseth et al., 1989; Longstreth et al., 1993). Meningiomas 
are benign tumours that rarely invade the substance of the brain. In 1922, 
Harvey Cushing (Bondy and Ligon, 1996) coined the term “meningioma” to 
characterise a group of different pathological tumour types arising from the 
meninges.
Intracranial tumours are an important cause of morbidity and mortality, 
particularly in relatively young people. According to the data of the Estonian 
Cancer Registry (Thomson et al. 1996; Aareleid and Mägi, 1999), brain 
tumours have not been among the ten most frequent tumour types diagnosed 
during recent years. At the same time, it has been recorded as the 9th (in males) 
and 10th (in females) site among cancers which caused death of patients. In 
children (0-14 years) and young people (15-29 years), brain tumours rank 
among the second or the third most common primary sites of cancer, both 
among males and females. In 1996-1998, the mean annual number of new 
primary brain tumours reported to the Estonian Cancer Registry was 98, 
comprising 1.7% of all reported tumours.
Most of the published studies concerning survival of central nervous system 
(CNS) tumours are hospital-based and restricted to gliomas or their histological 
subtypes. Few population-based studies, including survival of all primary
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benign and malignant tumours, have been published. The range of survival 
times in brain tumours is broad and may be unpredictable. In children, primary 
central nervous system tumours are the leading cancer-related cause of death 
and illness. Epidemiologic data confirm that survival patterns vary by histology. 
The prognoses of intracranial tumours can be more dependent on tumour 
location than the benign or malignant nature of the lesion. Cure is not rare in 
cerebellar astrocytomas in children or adolescents. At the same time, despite 
aggressive treatment, most patients die of glioblastoma during the first year 
after diagnosis.
However, little is known about the aetiology of intracranial tumours. Studies 
of the incidence of disease provide valuable information for health service 
planning, but they can also enhance research into aetiology. Geographical or 
secular changes in incidence can highlight potential risk factors for a disease 
which can then be studied in further detail (Doll et al., 1981).
Meningiomas are found more frequently in women than in men, leading to 
the speculation that hormones may play a role in their development. Other 
possible aetiologic factors are head trauma (Preston-Martin et al., 1989), which 
has yet to be established; both high- and low-dose irradiation, which have 
several associations with meningiomas; infections including viruses (Davis and 
McCarthy, 2000), which may act alone or with other mutagens in this 
formation; and chromosomal abnormalities, deletion of loci on chromosome 
22q occurs in approximately 30% of sporadic meningiomas. Genetic alterations 
discovered in gliomas include p53 mutations reported in approximately 40% of 
astrocytic tumours of all grades, deletions of chromosome 10 occurring 
frequently in astrocytic tumours and loss of heterozygosity at 10q23 reported in 
as many as 70% of glioblastomas (Hill et al., 1999).
The aim of the present study was to evaluate the epidemiological 
characteristics of primary brain tumours in Estonia; to find out the survival rate 
of patients with primary CNS tumours diagnosed between 1986 and 1996 and to 
examine variations in different age and histological groups, evaluating changes 
in the length of survival that have occurred over these years.
10
REVIEW OF LITERATURE
1. Histological classification 
General aspects
Numerically, gliomas constitute the most important group of intracranial 
tumours. Their complexity is due to the considerable number of cell types 
involved in neoplasia. The variations are found both within the major classes of 
glioma and often in different parts of one individual tumour. Most 
classifications have reflected a general acceptance of histological tumour types 
that are based on the identification of reasonably precise cytological features 
linking neoplastic elements to normal cell types found in the mature and 
developing CNS (Russell and Rubinstein, 1989). Accurate histological 
diagnosis is fundamentally important from both clinical and experimental 
perspectives.
History
The origin of systematic classification of brain tumours can be attributed to 
Virchow. He described neuroglia and related this to brain tumours. During the 
second half of the 19th century, he continued to develop tumour classification, 
separating gliomas from sarcomas of the brain and describing also ependy­
momas.
Most modem classifications are based upon that of Bailey and Cushing 
(1926). Having enumerated 20 cell types, they divided brain tumours into 14 
main groups including astrocytomas, oligodendrogliomas and ependymomas. 
Subsequent to the publication of Bailey and Cushing’s classification, increasing 
attention was directed to the frequency with which anaplasia determines the 
morphological characteristics of tumour cell populations and their diversity in 
malignant gliomas. The problem was especially applicable in the case of the 
common glioblastoma and its multiple variants (Russell and Rubinstein, 1989). 
Later, the concept became accepted that neoplasms derive from mature cells 
through a process of anaplastic transformation.
In 1949, Kemohan and his co-workers (Kemohan and Sayre, 1952) reduced 
the glioma types to five main groups by introducing a four-tiered grading 
system of gliomas, classifying them as grade I (well differentiated) to grade IV 
(poorly differentiated) according to the histological criteria of (de)different- 
tation. This resulted in the elimination of several tumour entities, including the 
glioblastoma multiforme. The validity of the Kemohan grading system of 
astrocytomas has been questioned ever since its introduction. The system has
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been found difficult to apply and its reproducibility has been low because grade 
is determined according to the degree of presence of multiple features, i.e. 
anaplasia, cellular and nuclear pleomorphism, hyperchromasia, vascularity, 
cellularity, necrosis, endothelial proliferation, and mitotic rate and abnormal- 
lities, as well as tumour delimitation. Daumas-Duport et al. (1988) found that 
the Kemohan grading system accurately distinguished only two major groups, 
i.e., those with low-grade ordinary astrocytomas (grades 1 and 2) and those with 
high-grade neoplasms (grades 3 and 4).
The practice of grading, if used in all tumours of the glioma group, presents 
considerable problems. Anaplasia is so often a localised development that the 
prognostic value, to be attached to the grading of biopsies, carries serious 
limitations. Furthermore, it cannot be assumed that any tumour will be static in 
its cytology. In practice, and within a particular type of glioma, grading can 
perhaps most consistently be applied to the diffuse cerebral astrocytomas 
(Russell and Rubinstein, 1989).
WHO Classifications
The International Classification of Central Nervous System Tumours approved 
by the World Health Organisation (WHO) (Ziilch, 1979) represents a consensus 
attempting to combine the different approaches to the typing and grading of 
CNS tumours. It is, in its essential lines, derived from Bailey’s and Cushing’s 
classifications. Subsequently, some disagreements have persisted and slightly 
modified classifications have later been published (Nelson et al., 1983; Ziilch, 
1986; Russell and Rubinstein, 1989). In 1988, Daumas-Duport et al. proposed a 
grading method for use on astrocytomas. The method is based upon the 
recognition of the presence or absence of four morphologic criteria: nuclear 
atypia, mitoses, endothelial proliferation and necrosis resulting in a summary 
score, which is translated into a grade as follows: 0 criteria = grade 1, 1 criteria 
= grade 2, 2 criteria = grade 3, 3 or 4 criteria = grade 4.
The revised WHO classification, where several new tumour types have been 
added, was published (Kleihues, Burger and Scheithauer, 1993) in 1993 (Table 
la). This WHO classification was considered as an international standard to 
facilitate communication and to avoid current conceptual controversies between 
different schools of thought. In the first edition of the WHO classification, the 
biological behaviour of CNS tumours was, in addition to describing histological 
evidence of differentiation or anaplasia, characterised by assigning a histo­
logical grade ranging form I (benign) to IV (malignant). The WHO grading is a 
malignancy scale ranging across a wide variety of intracranial neoplasms rather 
than a histological grading system. The vast majority of gliomas are typed 
according to histological criteria of (de)differentation, by name rather than by 
number (low-grade, anaplastic and for the most malignant astrocytic tumours, 
glioblastoma). Specific clinicopathological entities are defined, such as pilocytic
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astrocytoma, myxopapillary ependymoma, subependymal giant cell astocytoma 
and pleomorphic xantoastrocytoma. Yet, the distinction between astrocytomas 
from oligoastrocytomas and oligodendrogliomas (Krouwer et al., 1997) and an 
unequivocal interpretation, of certain histological features with respect of 
definition of the grade of differentation, remains unresolved (Coons et a l, 
1997).
The latest WHO classification of CNS tumours has been published in 2000 
(Table lb) where some new clinicopathologial entities like chordoid glioma of 
the third ventricle, cerebellar liponeurocytoma and peripheral neuroblastic 
tumours, new terms like diffusely infiltrating astrocytomas, have been intro­
duced. New histological variants of meningiomas, which must be recognised by 
pathologists but most of these have no bearing on clinical outcome, have been 
included. Remarkable attention has been paid to the molecular and cytogenetics 
basis in formation and histological diagnosis of brain tumours (Kleihues and 
Cavenee, 2000).
4 13
Table 1 a. WHO 1993 histological typing of tumours of the central nervous system 
(abbreviated)
I. Tumours of neuroepithelial tissue П. Tumours of cranial and spinal nerves
A. Astrocytic tumours A. Schwannoma (with variants)
1. Astrocytoma (with variants) B. Neurofibroma (with variants)
2. Anaplastic astocytoma C. Malignant peripheral nerve sheath
3. Glioblastoma (with variants) tumour (MPNST) (with variants)
4. Pilocytic astrocytoma Ш. Tumours of meninges
5. Pleomorphic xanthoastrocytoma A. Tumours of meningothelial cells
6. Subependymal giant cell astrocytoma 1. Meningioma (with variants)
B. Oligodendroglial tumours 2. Atypical meningioma
1. Oligodendroglioma 3. Papillary meningioma
2. Anaplastic oligodendroglioma 4. Anaplastic meningioma
C. Ependymal tumours B. Mesenchymal, non-meningothelial
1. Ependymoma (with variants) tumours
2. Anaplastic ependymoma 1. Benign
3. Myxopapillary ependymoma 2. Malignant neoplasms
4. Subependymoma 3. Primary melanocytic lesions
D. Mixed gliomas 4. Tumours of uncertain histogenesis
1. Oligo-astrocytoma IV. Lymphomas and haemopoietic
2. Anaplastic oligo-astrocytoma neoplasms
3. Others A. Malignant lymphomas
E. Chorioid plexus tumours B. Plasmacytoma
1. Chorioid plexus papilloma c. Granulocytic sarcoma
2. Chorioid plexus carcinoma D. Others
F. Neuroepithelial tumours of uncertain origin V. Germ cell tumours
1. Astroblastoma A. Germinoma
2. Polar spongioblastoma B. Embryonal carcinoma
3. Gliomatosis cerebri C. Yolk sac tumour
G. Neuronal and mixed neuronal-glial tumours D. Choriocarcinoma
1. Gangliocytoma E. Teratoma
2. Dysplastic gangliocytoma of cerebellum F. Mixed germ cell tumours
3. Desmoplastic infantile ganglioglioma VI. Cysts and tumour-like lesions
4. Dysembryoplastic neuroepithelial VII. Tumours of the sellar region
tumour A. Pituitary adenoma
5. Ganglioglioma B. Pituitary carcinoma
6. Anaplastic ganglioglioma C. Cranopharyngioma (with variants)
7. Central neurocytoma VIU Local extensions from regional
8. Paraganglioma of the filum terminale tumours
9. Olfactory neuroblastoma IX. Metastatic tumours
H. Pineal parenchymal tumours X. Unclassified tumours
1. Pineocytoma
2. Pineoblastoma
3. Mixed/transitional pineal tumours
I. Embryonal tumours
1. Medulloepithelioma
2. Neuroblastoma
3. Ependymoblastoma
4. Primitive neuroectodermal tumours 
(PNETs)
5. Medulloblastoma (with variants)______
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Table 1 b. WHO classification of CNS tumours, 2000
Tumours of neuroepithelial tissue
Astrocytic tumours
Diffuse astrocytoma (variants: fibrillary, 
protoplasmic, gemistocytic)
Anaplastic astocytoma 
Glioblastoma (variants: giant cell 
glioblastoma, gliosarcoma)
Pilocytic astrocytoma 
Pleomorphic xanthoastrocytoma 
Subependymal giant cell astrocytoma 
Oligodendroglial tumours 
Oligodendroglioma 
Anaplastic oligodendroglioma 
Mixed gliomas 
Oligoastrocytoma 
Anaplastic oligoastrocytoma 
Ependymal tumours
Ependymoma (variants: cellular, papillary, 
clear cell, tanycytic)
Anaplastic ependymoma 
Myxopapillary ependymoma 
Subependymoma 
Chorioid plexus tumours 
Chorioid plexus papilloma 
Chorioid plexus carcinoma 
Glial tumours of uncertain origin 
Astroblastoma 
Gliomatosis cerebri 
Chorioid glioma of the 3rd ventricle 
Neuronal and mixed neuronal-glial tumours 
Gangliocytoma
Dysplastic gangliocytoma of cerebellum 
Desmoplastic infantile astrocytoma/ 
ganglioglioma
Dysembryoplastic neuroepithelial tumour 
Ganglioglioma 
Anaplastic ganglioglioma 
Central neurocytoma 
Cerebellar liponeurocytoma 
Paraganglioma of the filum terminale 
Neuroblastic tumours
Olfactory neuroblastoma 
Olfactory neuroepithelioma 
Neuroblastomas of the adrenal gland and 
sympathetic nervous system 
Pineal parenchymal tumours 
Pineocytoma 
Pineoblastoma
Pineal parenchymal tumour of intermediate 
differentiation 
Embryonal tumours
Medulloepithelioma
Ependymoblastoma__________________
Medulloblastoma (variants: desmo­
plastic, large cell, medullomyoblasto- 
ma, melanotic)
Supratentorial primitive neuroecto­
dermal tumour (PNETs) (variants: 
neuroblastoma, ganglioneuroblastoma) 
Atypical teratoid/rhabdoid tumour 
Tumours of peripheral nerves 
Schwannoma/Neurinoma/Neurilemmoma 
(variants: cellular, plexiform, melanotic) 
Neurofibroma (variants: plexiform) 
Perineurioma (variants: intra-neural, soft 
tissue perineurinoma)
Malignant peripheral nerve sheath tumour 
(MPNST) (variants: epithelioid, MPNST 
with divergent mesenchymal and/or 
epithelial differentation, melanotic, 
melanotic psammomatous)
Tumours of the meninges 
Tumours of meningothelial cells
Meningioma (variants: meningothelial, 
fibrous, transitional, psammomatous, 
angiomatous, microcystic, secretory, 
lymphoplasmacyte-rich, metaplastic, 
clear cell, chordoid, atypical, papillary, 
rhabdoid, anaplastic)
Mesenchymal, non-meningothelial 
tumours
Primary melanocytic lesions 
Diffuse melanocytosis 
Melanocytoma 
Malignant melanoma 
Meningeal melanomatosis 
Tumours of uncertain histogenesis 
Haemangioblastoma 
Lymphomas and haemopoietic 
neoplasms
Malignant lymphomas 
Plasmacytoma 
Granulocytic sarcoma 
Germ cell tumours
Germinoma 
Embryonal carcinoma 
Yolk sac tumour 
Choriocarcinoma
Teratoma (variants: mature, immature, 
with malignant transformation)
Mixed germ cell tumour 
Tumours of the sellar region 
Craniopharyngioma (variants: 
adamantinomatous, papillary)
Granular cell tumour 
Metastatic tumours
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2. Limitations of using a cancer registry 
to identify incidence of CNS tumours
National and regional cancer registries routinely collect data on CNS tumours. 
A few studies, concerning quality control of the tumour registration, have been 
published. Helseth and co-workers (1988) found that the data from the 
Norwegian Cancer Registry were sufficiently valid for a thorough study of CNS 
neoplasms. Under-estimation of brain tumours has been found in Great Britain 
and Ireland (Pobereskin, 2001; Ogungbo et al., 2002). Counsell, with co­
workers (1997), showed that the Scottish Cancer Registry significantly under­
estimated the incidence of all primary intracranial tumours and of malignant 
intracranial tumours. It is apparent that a significant number of tumours, 
especially benign varieties, are not recorded in cancer registries.
Population-based cancer registries can provide information on a large group 
of unselected patients with primary CNS tumours relatively quickly. But 
histological data may not be interpreted directly because diagnostic criteria for 
histological classification of CNS tumours have not been applied uniformly. 
This occurs because there is no meaningful link between the ICD coding system 
used in cancer registries and the WHO classification system used by 
neuropathologists (Counsell et al., 1997; Davis et al., 1997; Van der Sanden et 
al., 1998). The original histological diagnosis of the pathologist is coded 
according to the International Classification of Diseases for Oncology (ICD-O-1 
or ICD-O-2) (WHO: International Classification of Diseases for Oncology, 
1976; 1990). The ICD-O incorporates the nomenclature of different histological 
classification systems. This results in an imperfect description of tumour type 
currently in all population-based brain and CNS tumour databanks. Definition 
of malignancy within the ICD-O is of limited significance for primary CNS 
tumours, especially for gliomas (Van der Sanden, et al., 1998). Due to the rarity 
of many histological types, diagnostic terms, which seem to represent the same 
group of clinically relevant entities, are usually clustered.
A preliminary' integration of the ICD-O and WHO codes has been proposed 
by Davis et al. (1997). They proposed incorporation of site codes recognising 
all brain and CNS tumours including those that cannot be readily distinguished 
as benign or malignant to facilitate use of histology groupings consistent with 
the WHO classification. In 1998, Van der Sanden and co-workers proposed 
ICD-O gradings for the distinction according to differentiation with less specific 
histological terms and these were recorded or the grade was not explicitly 
expressed by name. Astrocytomas were simply divided into low-grade and 
high-grade astrocytomas. Nevertheless, the need for standard definitions 
concerning site and morphology codes has been outlined and discussed.
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3. Histological distribution of primary CNS tumours
Gliomas constitute 23-39% and spinal tumours 8-12% of all CNS tumours. The 
most frequent histologies of primary CNS tumours include glioblastoma multi­
forme (15-30%), astrocytoma (12-26%), meningioma (14-35%), anaplastic 
astrocytoma (3-5%), pituitary tumours (5-18%), neurinoma (2-9%), oligo­
dendroglioma (1-5%) and medulloblastoma (0.3-4.5%), (Gudmundsson, 1970; 
Percy et al., 1972; Schoenberg et al., 1976; Mahaley et al., 1989; Kuratsu et al., 
1996; Surawicz et al., 1998). Meningiomas constitute 13% of all histologically 
verified primary intracranial neoplasms among males and 24% among females; 
95% of these tumours are histologically benign (Helseth et al., 1988; 1989).
In children, the most common brain tumours are astrocytoma (26-42%), 
medulloblastoma (11-25%), ependymoma (10-13%), supratentorial primitive 
neuroectodermal tumours (2-7%) and craniopharyngioma (4-12%) (bannering 
et al., 1990; Agerlin et al., 1999; Kuratsu et al., 2001; Kaatsch et al., 2001;).
4. Diagnosis 
Clinical presentation
Brain tumours can cause either focal or generalised neurological symptoms. 
Generalised symptoms reflect increased intracranial pressure and consist of 
headache and, when the illness is severe, nausea and vomiting. Focal symptoms 
and signs are caused by local irritation or destruction of brain tissue reflecting 
the intracranial location of the tumour. The frequency and duration of symptoms 
vary with the type and location of the tumour.
Headache occurs in about half of all patients with brain tumours. Typically, 
the headache is diffuse, lasting for hours but not permanent, developing in 
weeks or months. It can accurately indicate the hemisphere in which the tumour 
is located in one-third of headache patients and occasionally mimic migraine or 
even cluster headaches (Forsyth and Posner, 1993). Headache has shown a close 
relationship with the prevailing edema, but not with the size of the tumour. It 
has been reported as the most frequent symptom in metastatic brain tumours 
and different astrocytomas (Pfund et al., 1999).
Other symptoms that reflect the location of tumours, such as hemiparesis, 
aphasia or some other neurological deficits not associated with seizures, 
typically have a sub-acute onset and a progressive course. The frequency and 
duration of symptoms vary with the type of tumour. A rapidly evolving 
neurological deficit is more typical of a high-grade than low-grade glioma.
Kamiguchi et al. (1996) studying 1155 brain tumour patients found 9.5% of 
tumour patients asymptomatic. Most frequent accidentally diagnosed histolo­
gies included meningiomas (mostly convexity and falx location) and pituitary 
adenomas.
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Epileptic seizures
Brain neoplasms account for about 4-5% of all cases with seizure disorders 
(Hauser et al., 1993; Morris et al., 1989). Of cerebral neoplasms 25 to 50% 
present with seizures (Shady et al., 1994; Moots et al., 1995). Patients with 
slowly growing chronic lesions are more likely to have a seizure disorder, with 
an incidence as high as 75% (Morris and Estes, 1993). Le Blanc and Rasmussen 
(1974) found the highest seizure incidences in patients with oligodendrogliomas 
(92%), astrocytomas (70%), meningiomas (67%) and glioblastomas (37%). 
According to reported data, seizures as the first manifestation of brain tumours 
are very variable (11-50%) (Le Blanc and Rasmussen, 1974; Ketz, 1974).
Seizures are often reported as being the first and sometimes the only 
presenting symptom of intracranial tumours (Morris et al., 1993). In a retro­
spective study of 222 meningiomas, 26.6% of the patients presented epilepsy as 
their initial symptom (Lieu and Howling, 2000). Lühdorf and co-authors (1986) 
found seizures to be the first sign of brain tumour in 50% of patients who 
developed seizures after the age of 60 years.
Several authors have reported the mean interval from onset of seizures to 
tumour diagnosis or surgery to be from 2 to 11 years with a maximum of more 
than 20 years (Bartolomei et al., 1997; Hirsch et al., 1989; Smith et al., 1991; 
Afra et al., 1999). In a study carried out in 6 countries (Schlehofer et al., 1999) 
including 1,178 glioma and 331 meningioma cases, there was an increased risk 
associated with epilepsy at least 2 years before brain tumour diagnosis in 
glioma patients. In epilepsy, of more than 20 years duration, the risk was 
significantly weaker.
Data on the incidence of seizure activity and patients’ age are controversial. 
The age distribution of cases depends largely on the biological type of the 
tumours.
The probability of diagnosing an underlying tumour in a patient with 
epilepsy is related to seizure type, with simple and complex partial seizures 
being the most common. Many authors consider tumour location the most 
important factor (Shady et al., 1994; Dam et al., 1985).
Imaging
The standard methods for diagnosing brain tumours during the pre-CT era were 
plain skull x-rays, angiography, pneumoencephalography, ventriculography for 
intracranial and myelography for spinal tumours. In Estonia, the first CT was 
installed in 1983. From this time the number of CT scans has been steadily 
increased and all bigger centres have now been equipped. An ultra low field 
MRI scan was introduced in 1993. For several years it was the only scan for the 
whole republic and during our study period it has not been frequently used for 
diagnosis of brain tumours.
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At the moment, MRI has been considered the best imaging method for 
diagnosing a brain tumour. CT can miss structural lesions, particularly in the 
posterior fossa, or non-enhancing tumours such as low-grade gliomas. 
Therefore, if a brain tumour is a diagnostic consideration, MRI with gadolinium 
enhancement is the best choice of test.
Histological diagnosis
Relevance of histological diagnosis to patient management is obvious and 
cannot be underestimated. An incorrect diagnosis may result in inadequate 
therapy for a high-grade tumour or, worse, harmfully aggressive therapy for 
low-grade glioma. Several factors affect diagnostic accuracy. Diagnostic errors 
may be caused by insufficient biopsy size and regional heterogeneity. 
Significant problems also relate to the interpretation of histological criteria used 
to classify and grade gliomas. Subjective interpretation promotes inter-observer 
variation and decrease diagnostic reproducibility among pathologists, resulting 
in classification and/or grading errors that lead to failure to predict tumour 
behaviour (Coons et a l,  1997). Aldape, and co-workers (2000), has found 
diagnostic discrepancies in a population-based adult glioma study by speciality 
training of the original diagnosing pathologist. Clinically significant 
discrepancies were much more likely to have originated at a hospital without a 
neuropathologist. This study highlights the importance of the review of brain 
tumours by a neuropathologist prior to decision-making regarding treatment. 
Mittler and co-workers (1996) studied the inter-observer and intra-observer 
reliability of histological grading of astrocytoma specimens obtained using 
stereotactic biopsy. They found a significantly greater degree of reliability in 
histopathological diagnosis of low- or high-grade astrocytomas than in those of 
intermediate-grade astrocytomas. Therefore, the highest variability occurred at 
the point of clinical decision making (intermediate-grade tumours that may or 
may not be selected to receive adjuvant therapy).
Problems of classification are most apparent with respect to differentiating 
astrocytomas from oligodendroglial tumours. In oligodendroglioma the 
diagnosis is complicated by the fact that many oligodendrogliomas contain an 
astrocytic component, which may be substantial at times; such mixed tumours 
are termed oligoastrocytomas. In practice, the distinction of oligodendroglioma 
from oligoastrocytoma is probably not as important as the distinction between 
these 2 oligodendroglial lesions and pure astrocytoma, since many 
oligoastrocytomas, grade for grade, behave clinically and respond to both radio­
therapy and chemotherapy in a fashion very similar to pure oligodendrogliomas 
(Perry et a l,  1999). High-grade oligodendrogliomas should not be equated with 
typical glioblastomas; they may also be chemo-sensitive (Caimcross et a l,
1994).
19
5. Incidence rates
General data
The earliest reports dealing with the frequency of CNS neoplasms have been 
based on the experience of neurosurgeons, autopsy series and hospital 
admissions. While providing valuable descriptions of clinical or pathologic 
experiences, these data do not reflect the real incidence of neoplasms or their 
frequency by type in the population. It is desirable to have such statistics for 
various populations, which might disclose trends and population selection of 
disease providing relevant clues to aetiology. Comparisons can be extended to 
regional and national population.
Incidence of primary central nervous system neoplasms in a defined 
population has been reported in a number of studies. It varies from 4.9 to 25.5 
per 100,000 population (Table 2), while higher rates are generally found in 
socio-economically advanced societies with sufficient availability of medical 
care, better organised registries for data collection and possibly higher autopsy 
rate. The observed differences in different populations, races and sexes suggest 
the possible role of environmental, genetic and hormonal factors in the etiology 
of brain tumours (Bahemuka, 1988).
There are wide variations in the age-standardised incidence of all primary 
intracranial tumours and the crude incidence of specific tumour types in 
different studies. Much of this is due to differences in study methodology. 
Counsell and Grant (1998) found higher incidences of primary tumours in 
studies that used many methods to identify cases, included a high percentage of 
asymptomatic patients and did not require histological conformation of the 
diagnosis. The high number of CNS tumour categories, combined with a 
relatively low incidence of CNS tumours, hinders the collection of an adequate 
number of similar tumour types for study.
Studies based solely on existing cancer registries give consistently lower 
incidences (Percy et al., 1972; Counsell et al., 1997). This was not because the 
registries were excluding benign tumours but may be because they relied on 
voluntary registration and routine data collection, which can be incomplete 
(Davis et al. 1996). When interpreting the results of incidence studies it is also 
important to note whether some patients were excluded on the basis of age, 
tumour type or lack of histology, and also to know the percentage of 
asymptomatic patients who were included. Prospective studies have not 
identified more cases than retrospective studies (Counsell and Grant, 1998).
Most studies confirm that the incidence of primary tumours — especially 
neuroepithelial and meningeal tumours — increase markedly with age except in 
the very elderly (Percy et al., 1972; D’Alessandro et al., 1995; Kuratsu et al.. 
1996; Van der Sanden et al., 1998; Counsell et al., 1996; Fogeholm et al., 1984; 
Heshmat et al., 1976; Schoenberg et al., 1976). Only a few authors (Barker et 
al., 1976; Kallio, 1988) confirm that the peak incidence of gliomas occurs in the
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Table 2. Incidence rates (per 100,000 population) of CNS tumours
Reference Region Period Gliomas Meningiomas All brain tumours
Gudmundsson 1970 Iceland 1954-1963 7.8 (CR)
Leibowitz et al. 1971 Israel 1961-1965 3.8 (CR) 2.2 (CR) 12.8 (CR)
B ark e rs  al. 1976 Southern England, United 
Kingdom
1964-1974 M 4.76, F 3.22 (CR) M 0.6, F 1.8 (CR) M 7.2, F 6.8 (CR)
Heshm atera/. 1976 Washington, DC 
(Caucasians); US
1960-1969 M 4.4, F 2.5* M 0.2, F 0.3* M 5.5, F 3.6*
Schoenberg et al. 1976 Connecticut, US 1935-1964 M 0.5, F 0.7* M 4.9, F 4.0*
Lukas 1979 Estonia, USSR 1951-1970 2.9 (CR) 0.9 (CR) 5.9 (CR)
Fogelholm et al. 1984 Central Finland 1975-1982 12.3*
Helseth et al. 1988 Norway 1955-1984 M 8.2, F 6.8**
Kallio 1988 Southern Finland 1978-1980 M 6.4, F 4.9*
Cole et al 1989 Wales (South East) 1981-1987 3.6* 1.3* 5,6*
Rohringer et al. 1989 Manitoba, Canada 1980-1987 2.3 (CR)
Preston-Martin 1993 Victoria, Australia 1982-1990 M 5.5, F 3.8*** M 1.3, F 2.6*** M 8.8, F 8.1***
Tola et al. 1994 Ferrara, Italy 1986-1991 M 7.0, F 4.0*
Radhakrishnan 1995 Rochester, Minnesota; US 1950-1989 5.7* 7.8* 19.1*
D’ Alessandro et al. 1995 Valle d’Aosta, Italy 1986-1991 M 10, F 8.1* M 5.3, F 13.9* M 21.7, F 28.1*
Counsell et al. 1996 Lothians, Scotland 1989-1990 7.7 (CR) 2.7 (CR) 15.3 (CR)
Davis et al. 1996 Connecticut, Missouri, 
Massachusetts, Utah; US
1985-1989 9.4*
Helseth 1997 Norway 1983-1992 M 1.5, F 2.8**
Van der Sanden et al. 1998 South and East Netherlands 1989-1994 M 6.5, F 4.4***
Surawicz et al. 1999 US (11 cancer registries) 1990-1994 M 12.1,F 11.0*
Kuratsu et al. 2001 Kumamoto, Japan 1989-1998 M 9.7, F 11.9*
Cordera et al. 2002 Valle d ’Aosta, Italy 1992-1999 M 10.6,F8.1* M 9.8, F 16.7* 25.5*
Christensen et al. 2003 Denmark (patients <20 years 
not included)
1993-1997 3 '-j*** 2 4* * *
M=male, F=female, CR=crude rate 
Standard population:
Local
European
***World
age group of 50-59 years. The decline in incidence in the elderly proba у 
reflects under-diagnosis. Elderly patients may be less likely to present 
themselves to a doctor if they have symptoms of an intracranial tumour, and 
less likely to be referred for a CT scan or to have an autopsy (Asplund et al.,
1996). There may also be a diagnostic bias in the very elderly: patients with 
intracranial symptoms or signs may be diagnosed as having a stroke rather than 
a tumour, particularly if they did not have a CT.
Previous data about Estonia
A previous study of primary brain neoplasms in Estonia carried out between 
1951 and 1970 was a retrospective, population-based epidemiological survey 
using histological classifications proposed by Smirnov and Hominski (Lukas, 
1979). However, it included only primary intracranial tumours establishing the 
crude rate of primary intracranial tumours as 5.9 (6.1 for men and 5.8 for 
women) per 100,000 population. The incidence rate increased significantly 
during the study period from 5.0 (1951-1960) to 6.9 (1961-1970). Age-specific 
incidence rate was the highest in the age groups of 50-59 and 60-69 years (12.5 
and 12.3 per 100,000 population, respectively). The most frequent histologies 
were glioblastoma (21.5%), meningioma (14.7%), astrocytoma (8.8%) and 
pituitary adenoma (5.9%); unclassified brain tumours consisted 15.8%. Inci­
dence of glioblastoma was 1.29 for men and 1.18 for women, astrocytoma 0.55 
for men and 0.47 for women and meningioma 0.62 for men and 1.13 for 
women.
Data reported by the Estonian Cancer Registry (1994-1996) show the values 
of 6.2/100,000 for men and 5.6/100,000 for women for brain and other central 
nervous system (CNS) tumours (Thomson et al., 1996). Recent data show the 
crude rate of 6.2 (1994-1996) and 8.0 (1996-1998) for males, 5.6 (both time 
periods) for females. Age-standardised incidence rates were 7.2 (1996) and 6.4 
(1998) for males, 5.0 (1996) and 4.5 (1998) for females (Aareleid and Mägi, 
1999; 2001).
Histology-, race-, sex- and age-specific incidence rates
The incidence rate of glioblastoma ranges from 1.3 to 2.6 per 100,000 
population.
The age-specific incidence rates for glioblastoma are low among children, dip 
slightly in the ages 10-20, then rise steadily to a peak among those aged 70-74 
and decline in the oldest age groups. A male preponderance for the whole 
glioma group and for glioblastoma has been found in most studies.
Incidence rates for low-grade astocytomas has been reported 0.5-1.4 per
100,000 population (Fleury et al., 1997; Van der Sanden et al., 1998; Kallio
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et al., 1991; Preston-Martin et al., 1993; Barker et al., 1976; Davis et al., 1996). 
In astrocytoma, the rates in the younger age groups are relatively high, astro­
cytoma is the most common type of brain tumour among children (Polednak 
and Flannery, 1995; Preston-Martin et al., 1993). Age-specific incidence of 
low-grade astrocytoma is the highest in the 30-39 years' age group. Considering 
the sex in astrocytoma, no significant differences has been reported (Tola et al., 
1994; Fleury et al., 1997).
Incidence of oligodendroglioma ranges from 0.1 to 0.6 per 100,000 
population peaking in the forties and fifties with no significant differences 
between genders (Fleury et al., 1997)
Medulloblastoma is the second most common type of tumour among 
children and can be called predominantly a paediatric brain tumour with 
reported incidence rates of about 0.2-0.5 per 100,000 population (Van der 
Sanden et al., 1998; McNeil et al., 2002). Age-specific incidence rates have a 
marked peak at ages 0-4 years in boys but not in girls. The incidence of 
medulloblastomas falls to zero after 45 years of age.
Incidence rates for ependymoma has been reported about 0.2 per 100,000 
population (Birgisson et al., 1992; Davis et al., 1996). Ependymoma shows a 
peak at age 0-4  years (Polednak and Flannery, 1995), whereas a horizontal age- 
curve is seen in adulthood.
The reported incidence rates for pituitary tumours is 1.8-2.3 per 100,000 
population. In the Japanese study, (Kuratsu et al., 1996), women evidenced two 
peaks in the incidence of pituitary adenomas in the 20-29 and 60-69-year-old 
age groups. In males, the rate increased with age. The Scottish study (Counsell 
et al., 1996) found no obvious relation between age and the incidence of sellar 
tumours.
The frequency of meningiomas has been the topic of relatively few reports. 
Population-based studies indicate an overall incidence of 2.3-2.8 per 100,000 
population. More females than males are shown to get meningiomas in a 
number of surveys (Helseth et al., 1988, 1997; Sankila et al., 1992; Kurland et 
al., 1982; Gudmundsson, 1970). The female predominance has been shown to 
be age dependent (Helseth, 1997). Below 20 years of age, no gender difference 
was noted. The sex ratio peaked at 30-39 years of age and fell towards unity 
among those 80-89 years of age. Several series of studies have shown that the 
incidence of meningioma increases with age (Longstreth et al., 1993; Rohringer 
et al., 1989). The increased use of CT and MRI has led to an increase in the 
detection of asymptomatic meningiomas. Kuratsu and co-workers (2000) found 
39% of diagnosed meningiomas asymptomatic. The incidence of asymptomatic 
meningiomas was significantly higher in individuals older than 70 years. 
Meningiomas in children are rare and differ from those in adults and other 
childhood tumours, including a male preponderance, more frequent incidence of 
intraventricular and posterior fossa meningiomas than in adults. Children 
meningiomas are characterised by a significantly higher incidence of tumour
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calcification, sarcomatous elements and a high recurrence rate (Bondy and 
Ligon, 1996).
Regarding Caucasians and Africans, African-Americans, and Asians, 
certain differences have also been noted. The African groups show equal gender 
distribution or a male preponderance (Bondy and Ligon, 1996). In the Los 
Angeles County population-based survey, a higher incidence in Africans than in 
Caucasians was observed. Asians were found to have the lowest rates (Preston- 
Martin, 1989). The US study including 20,765 cases of primary brain tumours 
(Surawicz et al., 1999) reported the higher incidence in whites (11.6 per
100,000 population) than blacks (7.8).
Time trend studies
Some investigators have reported that the frequency of primary brain tumours, 
especially in the elderly, has increased substantially during the past two decades 
in several countries (Greig et al., 1990; Werner et al., 1995; Polednak, 1996). 
The results of a Rochester study (Radhakrishan et al., 1995), which had a very 
high autopsy rate, indicate that the increase in incidence is an element reflecting 
improvement in diagnostic technology and practice. Helseth (1995) who studied 
the incidence of primary CNS tumours in Norway before, during and after the 
introduction of CT found that in the elderly a large part of the three-fold 
incidence increase from the pre-CT era to the post-CT era can be attributed to 
improved tumour detection. A similar study carried out in Canada (Desmeules 
et al., 1992) estimated that modem imaging technology is responsible for the 
newly seen detection of about 20% of brain tumours in both younger and older 
patients.
As in different age groups, time trend studies of different histological 
groups show very controversial results. The Japanese study (Kanako et al., 
2002) pointed out 3 patterns of time trends between 1973 and 1993. These were 
a gradual linear increasing trend before the 1980s followed by a plateau for 
gliomas and meningioma; a step-up increase before 1980s followed by a plateau 
in germ cell tumour and pituitary tumour and a linear increasing throughout the 
study period for lymphoma and neurinoma. Data from US SEER program 
analysing histology-specific incidence between 1980-1990 (Ahsan et al., 1995) 
found no significant increase in the incidence of different histological types, 
except for lymphomas in men. The increase of lymphomas in specific age 
groups has been supported by other authors (Jukich et al., 2001). In the 
Canadian study (Hao et al., 1999) no significant increase in lymphomas has 
been established during the past 20 years. Analysis based on Surveillance, 
Epidemiology and End Results (SEER) data from 1973-1998 showed that 
primary CNS lymphomas rates have been decreasing in the majority of 
demographic groups since the mid-1990s (Kadan-Lottick et al., 2002).
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Fleury et al. (1997) observed an increasing trend of 5% per year in the 
incidence of malignant astrocytomas between 1983 and 1990 in the population 
older than 65 years. Mao and co-workers (1991), has indicated that the increase 
has been more pronounced for glioblastomas. In a Florida study (Werner et al.,
1995) the rise in brain tumour incidence was observed in anaplastic astrocytoma 
in all ages and in glioblastoma among the elderly. As malignant gliomas are 
generally easier to diagnose than low-grade astrocytomas, the increased brain 
cancer rates may not be entirely attributable to improved diagnostic techniques.
In ependymomas, some increase in the population aged 20 to 64 has been 
reported (Jukich et al., 2001).
In meningiomas, the incidence has markedly increased in Norway from 1963 
to 1992 (Helseth, 1997). With the available descriptive data, it has not been 
possible to determine to what extent the increase was caused by improved case 
investigation, or was it a real increase, or both? Many old patients have small 
and asymptomatic meningiomas. It has been established that the case detail 
discovery, especially for small meningiomas in the elderly, is dependent on the 
autopsy rate in the population (Kurland et al., 1982). Thus, the complete 
meningioma incidence will only be detected in populations with high autopsy 
rates, good health care systems and easy access to CT and MRI without major 
economic barriers for individual patients (Helseth, 1993; 1997).
6. Survival rates 
General data
Most of the published studies, concerning the survival of central nervous system 
tumours, are hospital-based and restricted to gliomas or their histological sub- 
types. Very few population-based studies, including survival of all primary 
benign and malignant tumours, have been published. Increased mortality rates 
for malignant CNS tumours, particularly among the elderly, have been attri­
buted to improved diagnostic techniques and increased environmental carcino­
gens (Modan et al., 1992). A study from the Estonian Cancer Registry (Thom­
son et al., 1996) reported the 5-year relative survival rate among patients of 
diagnosed CNS tumours in Estonia (1983-1987) 11.2% for males and 24.6% 
for females and mortality rate (1988-1992) 4.9 and 3.5 per 100,000 population, 
respectively. In a recent EUROCARE survey (Sant et al., 1998), including 
malignant CNS tumours diagnosed between 1985 and 1989 in 17 European 
countries, the mean European age-standardised 5-year relative survival was 
17% in men and 20% in women with markedly lower rates in Scotland, Estonia 
and Poland. In the U.S.A., in 1973-1991, 5-year relative survival of malignant 
CNS tumours was 20% according to the US SEER program (Davis et al., 1998).
7 25
Survival by histological types
In gliomas, the most favourable prognosis includes pilocytic astrocytoma and 
ependymoma (5 year survival 77-84% and 60-68%, respectively). The worst 
outcome has patients with glioblastoma, the most common CNS malignancy (5- 
year survival 1-2.5%). Other histologies of poor outcome include anaplastic 
astrocytoma, astrocytoma and anaplastic oligodendroglioma (5-year survival 
20-40%). Mixed gliomas and anaplastic ependymomas have a slightly better 
prognosis (5 year survival-about 50%). In oligodendroglioma, a 5-year survival 
rate has been reported at 45-65%. In medulloblastomas diagnosed during the 
last 20-30 years, 5-year survival rates show values of 55-60% (Surawicz et al., 
1998; Davis et al., 1998). In Victoria, Australia, the survival of benign menin­
giomas was 94% in women and 87% in men (Preston Martin et al., 1993). The 
Finnish study reported an overall relative survival of 83% at 1 year, 79% at 5 
years and 74% at 10 years for the time period 1953-1984 (Sankila et al., 1992). 
The results based on the National Cancer Data Base (McCarthy et al., 1998) 
showed a 5-year survival rate 69% for all meningiomas, 70% for benign and 
75% for atypical meningiomas. In Norway, a 5-year relative survival for benign 
meningiomas was 94% or better for patients below 75 years and 78% for 
patients 75 years of age or more (Helseth, 1997). For malignant meningiomas, 
survival prospects are poor, long-term relative survival ranging between 49% 
and 55% (Helseth, 1997; McCarthy et al., 1998). Survival of another more 
frequent non-malignant tumour, neurinoma, is even slightly better than the 
prognosis of meningioma, reaching 85% (Surawicz. et al., 1998)
Time trend studies
Clinically significant improvement in survival of patients with CNS tumours 
has taken place over the past 25 to 30 years (Sant et al., 1998; Davis et al., 
1998; Levin, 1999). Improvement in survival has been histology specific, being 
more evident in medulloblastoma, astrocytoma and oligodendroglioma. In low- 
grade astrocytomas, it is not possible to attribute this increased survival to a 
specific method of management, because the trend has been noted with the use 
of a variety of treatments.
The SEER program (Davis et al., 1998) found statistically significant 
improvements in survival rates for patients with astrocytoma, medulloblastoma 
and oligodendroglioma. Clinically significant improvements in survival rates 
were not apparent in those patients aged 65 years and older.
The median survival for patients, with anaplastic astrocytoma, has increased 
from 82 weeks to 4 years and patients with anaplastic oligodendroglioma have a 
median survival of more than 7 years. For glioblastoma, the most frequent 
primary CNS tumour, no striking improvement has taken place (Polednak and 
Flannery, 1995; Paszat etal., 2001).
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The prognosis of meningiomas has improved following the introduction of 
CT. In time-trend studies, both short-term and long-term survival has improved 
during the last decades. The improved 1-year survival is likely to be caused by 
improved operative technique and improved post-operative care. Other causes 
that could account for the increased long-term survival include selection bias 
reflecting the likelihood that more patients with small meningiomas are 
diagnosed early since CT became available (Helseth, 1997). Sankila and co­
workers. (1992), has reported an increase in long-term mortality for male 
meningioma patients, which can be explained by more malignant meningiomas 
among males.
Treatment and survival
The obvious optimal purpose of treatment is to cure the patient by suppressing 
the disease. This goal in unfortunately very rarely achieved when dealing with 
cerebral neuroepithelial tumours. In most of these cases, it is necessarily being 
limited to offering the longest and best quality survival, without producing or 
further increasing neurological deficits. Within these limitations, respective 
surgery is generally regarded as the most fruitful means of treatment, even if, in 
several cases, it is the first step of a multi-modality management. Even if the 
tumour cannot be completely eradicated, a substantial reduction of its mass can 
be achieved, thus enhancing the efficacy of other subsequent treatments, such as 
radiotherapy or chemotherapy. For low-grade gliomas, however, the utility of 
surgical resection has been questioned. Uncertainties regarding their natural 
history and the possibility of long survival in untreated cases are at the basis of 
the controversy. Although natural history of a low-grade astrocytoma may be 
difficult to predict, once the tumour has changed to an anaplastic lesion, the 
prognosis becomes predictably poor. Piepmeier with co-workers (1996) 
suggests that aggressive surgery may delay the time of recurrence and prolong 
survival.
The role of adjuvant chemotherapy in glioblastomas in unclear. Gundersen 
with co-workers (1998) observed a markedly increased survival among patients 
under 55 years of age with anaplastic gliomas, which were receiving adjuvant 
chemotherapy. Meta-analysis of radiation therapy with and without adjuvant 
chemotherapy for malignant gliomas in adults showed some benefit in some 
subgroups of patients, particularly in anaplastic astrocytomas, after combined 
treatment (Fine et a l, 1993). Lindegaard with co-workers (1987) suggests that 
post-operative radiotherapy significantly prolongs the median survival time in 
oligodendroglioma patients with sub-total surgery.
Consequently, a critical analysis of operative risks versus the risk of the 
natural course is necessary to answer the question of the benefit of doing 
operations on meningiomas (Meixensberger et a l, 1996). Operative mortality of 
meningiomas ranges from 4% to 16% (Chan and Thomson, 1984; Cornu et a l,
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1990). There is a general agreement about the importance of the completeness 
of surgical resection on tumour recurrence and it is clear that sub-totally 
removed meningiomas continue to grow (McCarthy et al., 1998; Ayerbe et al., 
1999) Some authors emphasise that a balanced strategy is necessary in the 
treatment of asymptomatic meningiomas in elderly and high risk patients 
(Meixenberger et al., 1996).
7. Prognostic factors
Patient-related factors
Practically all studies identify age as a strong independent prognostic factor. 
Generally, in CNS tumours, survival rates are declining with the increasing age 
at diagnosis. The differences are more pronounced for low-grade than high- 
grade astrocytomas (Takeuchi et al., 1991). Exceptions to this pattern are noted 
for meningiomas and two paediatric tumours: medulloblastomas and epen­
dymomas (Surawicz et al., 1998). The survival rates for meningiomas remain 
relatively constant across the younger age groups with a decline in survival of 
patients, aged 75 and older. In medulloblastomas the youngest patients 
(< 5 years) have the lowest survival rate. Younger patients (< 15 years) with 
ependymomas also have a poorer survival statistic than adults.
Another important patient-related prognostic factor for survival is clinical 
condition of the patient. Only very few studies have found no significant 
association of the pre-treatment and post-treatment Kamofsky score with 
survival in contrast with most of the others (Massimo et al., 1996).
Concerning clinical symptoms before the diagnosis, Scott and Gibberd 
(1980) found that a young patient who presents epilepsy and has a low 
histological grade of glioma would have the best prognosis. Earlier diagnosis in 
the patients, without chronic epilepsy, has been proposed as a potential factor in 
the extended survival noted in several work series (Piepmeier, 1987; Vertostic 
etal., 1991).
In most studies in multivariate analysis, gender has been reported to have no 
significant influence on survival, only a few studies have found a better prog­
nosis in women. In a study based on cancer registries of 17 European countries, 
(Sant et al., 1998), a better prognosis for women was observed in most 
countries. The same tendency has been reported in the Finnish study (Kallio et 
al., 1991). This finding has been explained by the occurrence of higher-grade 
gliomas and glioblastomas in men. Davis with co-workers (1998) observed 
modest gender differences in survival in astrocytomas and other gliomas.
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Tumour- and treatment-related factors
Histology and anatomical location are important tumour-related agents in 
estimating survival. Prognosis is worse for grade IV tumours than less malig­
nant tumours. Glioblastomas remain the most fatal of all brain tumours despite 
other prognostic factors. Some studies have shown that frontal lobe location is 
associated with improved survival for malignant gliomas. Large variations, in 
survival by site, are noted for astrocytomas and anaplastic astrocytomas with 
poorest outcomes associated with tumours located in the supratentorial regions 
and higher survival rates for tumours in the ventricles and cerebellum (Surawicz 
etal., 1998).
The influence of pre-operative tumour size in gliomas has not been so far 
extensively investigated and is still controversial.
Unfortunately, earlier detection of malignant brain tumours, particularly 
glioblastoma multiforme, has little impact on survival, especially in elderly 
patients (Lowry et al., 1998). Treatment related prognostic factors include sur­
gery, radiation therapy and chemotherapy, which can improve the survival of 
patients with favourable histology, tumour location and good performance 
status (Flowers, 2000).
Prognostic factors in different histologies
In malignant gliomas, age, symptom duration, histology, pre-operative Kar- 
nofsky performance status, radiation dose and epilepsy at onset have been 
considered independent prognostic factors (Salminen et al., 1996; Kowalczuk et 
al., 1997; Smith et al., 1991; Billiar et al., 1999; Lote et al., 1998). Patients of 
younger age, longer duration of symptoms, lower tumour grade, better Kar- 
nofsky performance status and receiving a higher radiation dose have been 
reported to have a better prognosis. Aggressive surgical resection does not 
impart a significant increase in survival time.
In low-grade astrocytomas, younger age, gross-total resection, long duration 
of pre-operative symptoms, pre-operative neurological deficit and CT-contrast 
enhancement are associated with longer survival in multivariate analysis 
(Schuurman et al., 1997). Piepmeier (1996) suggests that low-grade astrocyto­
mas, occurring among patients having relatively short pre-operative symptoms, 
more commonly transform into anaplastic tumours. Tumours causing chronic 
epilepsy are much less likely to evolve into anaplastic lesions and more typi­
cally behave as “benign” astrocytomas. Scott and Gibberd (1980) confirmed 
that the prognosis was better if epilepsy had occurred, but epilepsy was not 
more likely to occur with lower histological grades of tumour. If epilepsy 
occurs, then it is usually the first symptom, rarely it begins after the diagnosis as 
been made (except post-operative epilepsy).
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In oligodendrogliomas age at surgery, duration of symptoms, tumour 
calcification, extent of surgical resection, performance status (Kamofsky score) 
and some immunohistochemical parameters (МШ-1, Labelling Index) are 
associated with survival. Sex and location has been found to have no statisti­
cally significant influence on survival in oligodendrogliomas (M0rk et al., 
1985; Ludwig et al., 1986). Generally, oligoastrocytomas have the same 
outcome and prognostic factors as pure oligodendrogliomas (Schiffer et al.,
1997).
In primitive neuroectodermal tumours (PNETs) of the CNS multivariate 
analysis, using Cox regression, has revealed a significantly worse outcome in 
those patients with a supratentorial tumour location, advanced metastatic stage 
(M l-3 ) and treatment with radiation or chemotherapy alone. Age, sex and the 
extent of surgical resection did not have significant prognostic value (Janss et 
al., 1996).
The prognosis for patients with benign, atypical and malignant meningiomas 
is better for females and depends on the patients age (Preston-Martin et al., 
1993; Meixensberger et al., 1996; McCarthy et al., 1998) being more favou­
rable for patients below 60 years. Helseth (1997) analysed benign and malignant 
meningiomas separately and found that below 60 years of age, females have a 
better survival prognosis than males. The cause of this difference is unknown. 
Atypical meningiomas represent a heterogenous prognostic group whose limits 
with a benign and malignant type remains to be determined (Ayerbe et al., 
1999). In benign meningiomas, besides patient age, the outcome is also 
influenced by poor clinical condition, tumour size and extent of surgery. 
Additional operative difficulties related to location, vascularisation of the 
tumour and disturbances of cerebrospinal fluid circulation has been pointed out 
(Meixensberger et al., 1996). In malignant meningiomas, age at diagnosis, 
surgery and no radiation treatment in those patients who had survived at least 12 
months were estimated as significant predictors of survival time (McCarthy et 
al., 1998). It has been reported that up to 4% of benign meningiomas show 
brain invasion (Jääskeläinen et al., 1985). Brain infiltration is difficult to assess 
and has little prognostic significance by itself (Jellinger and Slowik, 1975).
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PURPOSE OF THE STUDY
The general objective of the study was to evaluate the epidemiological
characteristics of primary brain tumours in Estonia diagnosed during the period 
1986-1996.
The specific objectives were:
1) to analyse in detail the clinical and morphological data of patients with 
diagnosed brain tumours presented with seizure disorders.
2) to find out age-specific incidence rates of primary brain tumours in specific 
histological groups.
3) to compare those of investigations, carried out in other populations and with 
data from the pre-CT diagnostic era (1951-1970) in Estonia, with the aim of 
assessing the changes in incidence rates in Estonia
4) to find out 1- and 5-year survival of patients with primary CNS tumours, 
examine variation in different ages and histological groups and evaluate 
changes in the length of survival that have occurred over these years.
5) to compare survival rates of brain tumours in Estonia with those in other 
countries
6) to evaluate prognostic factors influencing survival rates using the Cox model
7) to evaluate the reporting of brain tumours in the Estonian Cancer Registry.
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PATIENTS AND METHODS
1. Study population and case finding
The study was based on the Estonian population of approximately 1.5 million 
served by two neurosurgical centres (Tartu University Clinics and Tallinn 
Mustamäe Hospital), which admit or consult all patients suspected of having 
CNS tumours. The records of all intracranial and spinal tumours (including 
suspicious cases and brain metastases) at these hospitals from 1986 to 1996 
were retrospectively reviewed. The criteria for inclusion were either histological 
confirmation, or verification of neoplasms by radiological or clinical methods. 
To maximise case ascertainment, we obtained material from several sources 
including hospital records (case histories, autopsy protocols, pathology reports), 
the Estonian Cancer Registry (founded in 1978) and the Estonian State 
Statistical Office.
2. The Estonian Cancer Registry
The Estonian Cancer Registry (ECR) is population-based covering the whole of 
Estonia. The registry was founded in 1978, but its data are retrospective to 
1968. Reporting on cancer cases is compulsory by the Decree, issued by the 
Minister of Social Affairs of Estonia. All treating physicians, pathology and 
haematology laboratories are requested to report all cases of cancer that come to 
their attention. The cancer patients are followed by the ECR up to their death or 
emigration. The Registry links its data with death certificates filed at the 
Estonian State Statistical Office and with the inpatient data from two major 
hospitals — Tallinn Mustamäe hospital and Tartu University Clinics. If the 
hospital files contain information on patients not recorded in the registry, the 
registry staff performs a trace-back of these patients to their original medical 
records.
The overall reporting to the Registry is estimated to be 95-98% of all 
diagnosed cancers. Since meningiomas and other histologically benign brain 
tumours were not recorded until recently, the registry can be considered 
complete with regard to malignant brain tumours but incomplete for benign 
tumours. Since 1998, the Cancer Registry includes information on all primary 
brain tumours. Improvement of brain tumour reporting in Estonia is important 
for our understanding of the occurrence of these complex tumours and for our 
ability to conduct large-scale epidemiologic investigations.
In the registry, the anatomical site and histology of tumours are coded 
according to the International Classification of Diseases for Oncology (ICD-O, 
first edition 1976, second edition 1990) by the WHO. For statistical purposes, 
the ICD-O codes are converted into the International Classification of Diseases
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(ICD-9, ICD-10). To maximise case ascertainment and assess the reporting of 
brain tumours, electronic record linkage of the study population with the cancer 
registry database was used.
3. Selection of patients
Selection of patients was carried out according to the guidelines of the 
International Classification of Diseases for Oncology (ICD-O-2) including the 
following topography codes: C71.0-C71.9 for brain, C70.0 and C70.9 for 
meninges, C72.2-C72.9 for cranial nerves and other intracranial parts of the 
CNS, C75.1-C75.3 for pituitary gland, pineal gland and craniopharyngeal duct. 
Metastatic tumours were also reviewed but included only in the analysis of 
clinical manifestation and seizure incidence. Cases discovered at autopsy, 
patients diagnosed with another tumour previously or during the follow-up 
period and patients of lost to follow-up, (no contacts after diagnosis, not 
included in the Registry of Inhabitants) were excluded from survival analyses.
4. Classification of tumours
Tumours were classified according to the histopathological type of brain tumour 
following the scheme approved by the World Health Organization (Kleihues, 
Burger and Scheithauer, 1993). All histologically obscure cases (with the 
majority of pathological material having been preserved) were retrospectively 
overviewed by a neuropathologist. Tumours of the skull and vascular malfor­
mations were excluded. Patients were analysed for tumour pathology and grade 
according to individual WHO histological diagnosis as well as groups. The 
following categories were used: astrocytoma (low-grade), anaplastic astro­
cytoma, glioblastoma, oligodendroglioma, ependymoma, mixed glioma, 
medulloblastoma, neurinoma (schwannoma), meningioma, hemangioblastoma, 
lymphoma, pituitary adenoma, craniopharyngioma, metastatic tumour and cases 
without microscopic conformation.
5. Clinical data
The medical records were reviewed for the following information: patient 
gender, age at diagnosis, patient clinical condition, diagnostic method, histo­
logical type, grade and location of a tumour and performed treatment.
Information on tumour location was obtained from CT or MRT and from 
surgery reports. Additional data of patients with primary and secondary intra­
cranial brain tumours diagnosed between 1991 and 1995 were recorded to
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analyse the clinical data of patients with epileptic seizures. These data included 
nature and duration of signs and symptoms, seizure type, time of the first 
seizure and the first symptom and seizure incidence.
The study population was divided into 4 age groups: children (< 20 years at 
diagnosis), younger adults (21-44 years), older adults (45-64 years) and the 
elderly (> 65 years), reflecting the fact that CNS tumours have specific 
characteristics including histology, behaviour, anatomical location depending 
on age, and survival rates are varying by age at diagnosis.
The clinical functional ability of the patient before therapy was assessed 
according to the Kamofsky Performance Status scale. Three groups were conside­
red: score 80-100% (no evidence of disease or minor signs and symptoms, nor­
mal activity even with effort) 60-70% (unable to carry on normal activity or to 
do active work, able to care for most of his needs, may require occasional assis­
tance) and less than 60% (disabled, requires assistance and frequent medical or 
special care, needs hospitalisation) (Kamofsky and Burchenal, 1949).
As clinical data varied in quality and quantity, symptoms were grouped in 
the simplest way: headache, papilledema (reflecting intracranial hypertension), 
epileptic seizures, neurological deficit (motor deficit, lesions of cranial nerves, 
speech disorders, disorders of sensation, ataxia etc) and mental disturbances. 
A sign or a symptom was recorded if any physician described its presence.
According to seizure types patients were classified as having simple or 
complex partial and secondarily generalised seizures. When seizures were not 
described adequately, to be classified according to the guidelines of the 
International League against Epilepsy (Commission on Classification and 
Terminology of the International League against Epilepsy, 1981) the term 
unclassified seizures was used.
Tumour location was analysed as supra (hemispheres)- and infratentorial and 
by individual sites: lobes, central structures, parasagittal and hypophyseal region.
6. Time periods and follow-up
Our study included CNS tumours diagnosed between 1986 and 1996 in Estonia. 
Follow-up of vital status was until January 1, 1998. In glioma patients, the 
follow up period was lengthened until January 1, 2000. Following-up of patients 
was performed by using case histories, autopsy protocols and pathology reports. 
Additional information on date and cause of death was received from the 
Estonian Cancer Registry and the Estonian State Statistical Office.
To estimate potential changes in 1-year survival rates over time in different 
age and histological groups, three time periods were defined according to the 
year of diagnosis: 1986 to 1989, 1990 to 1993 and 1994 to 1996. Advances in 
diagnostic procedures (the introduction of computerised tomography and mag­
netic resonance imaging) should not affect potential changes in survival, as the
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first CT scan was introduced in 1983 in Estonia. Changes in 5-year survival 
were not estimated because of the too short follow up period.
7. Epidemiological and statistical methods
Average annual incidence rates per 100,000 population for primary CNS 
neoplasms 1986 through 1996 were computed. Annual age-specific and age- 
adjusted incidence rates were calculated for all CNS tumours and for each type 
separately. Population figures were obtained from the annual publications of the 
Statistical Office of Estonia for each year between 1986 and 1996. Age adjust­
ment was performed by direct standardisation according to the World Standard 
Population (Waterhouse at al., 1976) and the Estonian Standard Population 
(1989 census). To compare our data with those of a previous study carried out 
in Estonia (Lukas, 1979), the 95% confidence limits (95% Cl) for incidence 
rates were estimated assuming a Poisson distribution for the studied cases. The 
difference in incidence between the CT and pre-CT eras was expressed as the 
incidence rate ratio and presented with 95% confidence intervals.
Multivariable analysis was used to identify the factors that associate with 
seizures. The tested categories were patient age at diagnosis, their gender, 
tumour histology as well as anatomical location of tumour and duration of 
symptoms, y j and Fisher’s Exact Test was used in comparisons involving cate­
gory variables, and Wilcoxon Rank-Sum test was employed for continuous 
variables.
Survival time was calculated from date of diagnosis. One- and five-year 
observed survival rates were estimated overall, by the above-mentioned age 
groups, for each histological group using life table method with intervals of one 
month. Kaplan-Meyer estimation was used to compute the median length of 
survival by gender, age and clinical condition, histology and location of tumour, 
based on the whole study period. The log-rank-test was used to compare 
survival in sub-groups. Proportional hazards models (Cox’s models with 
stepwise procedure) were used to determine the effect of different patient 
(gender, age, clinical condition before treatment) and tumour related (anato­
mical location, histology) factors on survival. In all analyses, the statistical 
significance was chosen to be p<0.05.
All analyses were performed by using the STATISTIC A programme 
(STATISTICA for Windows operating system 1994) and the SAS Version 6.12 
(SAS Institute, Cary, NC).
8. Ethics
The study was approved by the Medical Research Ethics Committee of the 
University of Tartu.
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RESULTS
1. General characteristics
In the period from 1986-1996, 1665 cases (739 males, 926 females) of primary 
CNS neoplasms and 330 cases (220 males, 110 females) of metastatic 
neoplasms were identified in the resident population of Estonia. During the 
same period, 996 patients (179 without histological confirmation) with primary 
CNS tumours were identified at the Cancer Registry. Mean age at diagnosis was 
47 years (45 for males and 49 for females) and median age was 52 years (52 for 
males and 50 for females; range 1 month to 85 years). Histological verification 
was available in 1346 (80.8%) cases. This percentage varied depending on 
tumour site, being lower (58%) in pituitary region tumours and higher in 
tumours of the cerebral hemisphere and tumours of spinal location (86 and 85%, 
respectively). Histological confirmation according to tumour location is shown 
in table 3. Before histological confirmation, the majority, (76%), of tumours 
were diagnosed by CT or MRI (Table 4). Taking into account the low pro­
portion of autopsies in Estonia, a remarkable number of tumours (5.3%) were 
diagnosed on autopsy, including both incidental findings and mis-diagnosed 
cases. Forty-three per cent of cases diagnosed post mortem were identified as 
glioblastomas, 19% were astrocytomas and only 8% were meningiomas.
Table 3. Histological confirmation (%) according to tumour location (n=1665)
Tumour location All cases 
N
Histologically confirmed cases 
n (%)
Supratentorial
Cerebral hemispheres 803 694 (86.3)
Central structures 63 39 (61.9)
Pituitary or pineal region 121 70 (57.8)
Other 162 138 (85.2)
Infratentorial 323 255 (79.0)
Intra-cranial, not localised 55 33 (60.0)
Spinal 138 117(84.8)
Total 1665 1346 (80.8)
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Table 4. Frequency of diagnostic methods before histological confirmation used in 
verification of primary brain tumours (n=1665)
Method Number of cases (%)
CT 1085 (65.2)
MRI 176(10.6)
Autopsy 88(5.3)
Myelography 81 (4.9)
Angiography 67 (4.0)
Clinical 35 (2.1)
Ventriculography 13 (0.8)
X-rays 11 (0.7)
Histology 4 (0.2)
Pneumoencephalography 6 (0.4)
No diagnostic method recorded 99 (5.9)
2. Histological distribution
Table 5 illustrates the distribution of histologically confirmed cases of 
neoplasms according to sex and average age at diagnosis. The most common 
histological type was glioblastoma, which accounted for 29.9% of all brain 
tumours among males and for 21.2% among females, and meningioma 
(including both spinal and intracranial), which accounted for 13.1% and 32.8% 
of cases in males and females, respectively. Fourteen per cent (47 cases) of 
meningiomas were spinal. The other two most common major histological 
groups were astrocytoma (12.5% in males, 10.1% in females) and neurinoma 
(5% in males and 7% in females). Among patients below 20 years of age the 
most frequent were astrocytoma (25%), medulloblastoma (17%), ependymoma 
and glioblastoma (both 6%); 42 cases (22%) were not histologically confirmed.
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Table 5. Distribution of pathologically confirmed primary brain tumours (n=1346) by histological diagnosis, sex and mean age of patients 
(Estonia 1986-1996).
Tumour type ICD-O Morphology Codes
Male
No. of cases (%)
Female Total
Mean age (years) 
at diagnosis
Neuroepithelial tumours
Astrocytoma (G l-2 ) 9400/3, 9410/3, 9411/3, 9420/3, 
9421/3
73 (12.5) 77(10.1) 150(11.2) 36.4
Anaplastic astrocytoma 9401/3 35 (6.0) 44 (5.8) 79 (5.9) 48.7
Glioblastoma 9440/3, 9441/3, 9442/3 174 (29.9) 162 (21.2) 336 (25.0) 53.4
Oligodendroglioma 9450/3, 9451/3 25 (4.3) 17 (2.2) 42 (3.1) 44.0
Ependymoma 9391/3,9393/1,9392/3 24 (4.1) 13 (1.7) 37 (2.8) 34.5
Mixed glioma 9382/3 10(1.7) 13 (1.7) 23(1.7) 46.6
Pineal tumours 9361/1,9362/3 4 (0.7) 0 4 (0.3) 39.8
Medulloblastoma 9470/3, 9471/3, 9472/3 23 (4.0) 19(2.5) 42 (3.1) 14.8
Tumours of cranial and spinal nerves
Neurinoma 9560/0 29 (5.0) 53 (7.0) 82 (6.1) 47.8
Neurofibroma 9540/0, 9550/0 2 (0.3) 7 (0.9) 9 (0.7) 38.9
Meningeal tumours
Meningioma 9530/0, 9531/0, 9532/0, 9533/0, 
9534/0, 9537/0, 9530/1, 9538/1
76(13.1) 250 (32.8) 326 (24.2) 54.6
Anaplastic meningioma 9530/3 5 (0.9) 13 (1.7) 18 (1.3) 56.5
Haemangioblastoma 9161/1 8(1.4) 14 (1.8) 22(1.6) 48.4
Malignant lymphomas 9590/3 12(2.1) 8 (0.9) 20(1.5) 49.8
Germ cell tumours 9064/3, 9070/3, 9080/1, 9084/3 4 (0.7) 2 (0.3) 6 (0.5) 33.7
Sellar region tumours
Pituitary adenoma 8140/0 16(2.6) 20 (2.6) 35 (2.6) 48.7
Craniopharyngioma 9350/1 8(1.4) 6 (0.8) 14 (1.0) 30.1
Other, specified* 8140/3, 9390/0, 9390/3, 9430/3, 
9443/3, 9381/3, 9084/0
55 (9.5) 45 (5.9) 100 (7.4) 40.7
Total specified 583 (100) 763 (100) 1346(100) 47.4
* due to small number o f cases not given separately
3. Seizures in patients with brain tumours
We analysed 721 patients with diagnosed primary and secondary brain tumours. 
Out of these, 711 patients remained in the study group, while 10 patients were 
excluded because of incomplete data. 165 (23.2%) patients experienced at least 
one seizure before their tumour diagnosis, 546 patients had no history of 
seizures. Mean age in the seizure group was 47.4 years (95% Cl 45.0-49.8 
years) ranging from 2 to 83 years, in the seizure free group 49.2 years (95% Cl 
47.4-50.1 years) ranging from 1 to 87 years. Age was associated (p<0.05) with 
the presence of seizures. Occurrence of seizures was remarkably higher in 30 to 
39-year (p<0.005) and 40 to 49-year (p=0.001) age groups (Table 6). The male 
to female ratio was 1:1.04 in the seizure group and 1:1.2 in those patients 
without seizures. Gender was not associated with occurrence of seizures.
Table 6. Incidence of seizures and patients age (n=711).
All patients Patients with seizures
N N %
0-9 37 5 13.5
10-19 31 4 12.9
20-29 36 10 27.8
30-39 70 26 37.1*
40-49 123 43 35.0**
50-59 196 39 19.9
60-69 170 30 17.7
70+ 48 8 16.7
All 711 165 23.2
*p=0.004
**p=0.001
According to the histological typing, the most common histological types were 
glioblastoma, meningioma and low-grade astrocytoma (Table 7). Patients with 
mixed gliomas (62%), oligodendrogliomas (53%), anaplastic astrocytomas 
(42%), low grade astrocytomas (41%) and meningiomas (37%) experienced 
seizures most frequently. Association between tumour pathology and seizures at 
presentation was highly significant (pcO.OOl).
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Table 7. Tumour pathology and occurrence of seizures (n=711).
Number of 
patients N
With seizures
%
Low-grade astrocytoma 53 22 41.5*
Anaplastic astrocytoma 30 13 43.3**
Glioblastoma 106 27 25.5*
Oligodendroglioma 19 10 52.6**
Ependymoma 8 2 25
Mixed glioma 8 5 62.5***
Medulloblastoma 15 0 0
Schwannoma 27 0 0
Meningioma 124 47 37.9*
Anaplastic meningioma 8 1 12.5
Hemangioblastoma 7 0 0
Lymphoma 6 1 16.7
Metastatic tumour 105 16 2***
Without histology 138 17 12.3*
Pathology of 59 tumour patients with very low incidence (<5) is not given. 
*p<0.001 
**p<0.005 
***p<0.05
Tumour location and seizures
Of the 711 tumours, 71% had supratentorial and 21% had infratentorial 
location, 8% were multilocular; in the seizure group 94% of tumours were 
supratentorial, 2% were infratentorial and 4% were multilocular. The incidence 
of seizure occurrence for different lobes was significantly different (pcO.OOl) 
(Table 8). Higher incidences of seizures were found in tumours involving the 
frontoparietal (58%), frontotemporal (44%), parasagittal (41%) and temporal 
(40%) regions. Seizures occurred in only 11% of patients with tumours of the 
occipital lobe and the multilocular tumours. Only 3 patients out of 148 with 
infratentorial tumours experienced seizures. Association with seizure occur­
rence was found for tumours involving the frontal and fronto-parietal, temporal 
and fronto-temporal, as well as the parietal and parasagittal regions. Seizures as 
the first manifestation of the tumour had no significant association with tumour 
location.
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Table 8. Tumour location and the incidence of seizures (n=711).
Location
Number of With seizures
patients N %
Frontal lobe 83 32 38.5*
Frontal and parietal 38 22 57.9*
Frontal and temporal 36 16 4 4  4* *
Frontal, temporal and parietal 11 5 45.4
Parietal lobe 64 22 43 .4* * *
Temporal lobe 52 21 40.4**
Temporal and parietal 49 11 22.5
Occipital lobe 9 1 11.1
Occipital and parietal or temporal 26 4 15.4
Central structures 30 6 20.0
Parasagittal region 29 12 41 4* * *
Hypophyseal region 46 0 0
Other supratentorial 30 4 13.3
Multilocular 55 6 10.9* * *
Infratentorial 148 3 2.0*
* pcO.OOl 
** p<0.005 
*** p<0.05
Factors predicting seizure occurrence
In multivariable analysis, patients gender and age were not associated with 
seizures. Categories that influenced the occurrence of seizures were the duration 
of symptoms, tumour location and histology. Epileptic seizures occurred more 
frequently in those patients, with a long duration of symptoms (6 months and 
more), who were diagnosed of astrocytoma, anaplastic astrocytoma, some other 
glioma or meningioma. Infrequently, seizures occurred in tumours of infra­
tentorial, central or multiple location.
Presentation and duration of epileptic seizures
Epileptic seizures were the single presenting symptom at diagnosis in 44, and 
the first manifestation in 123, patients; 121 patients presented simultaneously 
seizures and some other sign or symptom. Patients with seizures showed a 
significantly lower incidence of neurological deficit, headache (p=0.001) and 
mental disturbances (p<0.05) compared with seizure free patients (Table 9). We 
found no association between occurrence of epileptic seizures and increased 
intracranial pressure. Table 10 presents the clinical characteristics of seizures. In 
26.7% of seizure patients, seizures were their only complaint and in 74.6% were 
the first manifestation. Thirteen per cent of patients presented only one seizure,
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55% presented recurrent seizures and 21% had seizures at diagnosis (the tumour 
was diagnosed less than one month after presentation). Median time from the 
first epileptic seizure to diagnosis was 3 months, with a mean of 16 months 
(range from 0 to 240 months). Most brain tumours (72.8%) were diagnosed 
during the first year after seizure presentation, while 5 patients had had seizures 
for more than 10 years (one of them for 20 years). The mean time was different 
(p=0.02) for seizures as the single presenting sign (mean time 18 months) and 
for seizures presented with other symptoms (mean time 12 months).
Table 9. Presenting signs and symptoms (n=711)
Number of patients
Without seizures With seizures
(n=546) (n=165)
Seizures with other symptoms 121
Other symptoms
Headache 367 58*
Papilledema 141 31
Neurological deficit 429 92*
Mental disturbances 126 25**
*p=0.001
**p<0.05
Table 10. Clinical characteristics of seizures.
%
N Patients with All patients
seizures (n=165) (n=721)
Seizures 165 22.9
As the first manifestation 123 74.6 17.1
As the single presentation 44 26.7 6.1
At diagnosis 35 21.2 4.9
One seizure 22 13.3 3.1
Recurrent (>2 seizures) 95 57.6 13.2
Seizure types and EEG findings
Seizures could be classified in 91.5% (151 cases) of patients with epilepsy 
(Table 11). Secondarily generalised and simple partial seizures, existing as the 
only type in a patient, were the most common and occurred in 51% and 36.5% 
of patients, respectively. Epileptic seizures were of complex partial type and 
simple partial type with secondary generalisation in 9.3% of cases. Only 83 
(50.3%) of the 165 patients who presented with seizures underwent EEG 
evaluation (Table 12). Electroencephalography was considered abnormal in
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84% of cases. In 12% of cases EEG only lateralised the tumor and in 13% of 
cases it localised but did not lateralise the tumor. Local manifestations localised 
exactly the lobe and hemisphere involved by the tumor in 41% of patients.
Table 11. Classification of seizures (n=151)
Seizure type Number of patients %
Secondarily generalised 77 51.0
Simple partial
Without secondary generalisation 
With secondary generalisation
41
14
27.2
9.3
Complex partial
Without secondary generalisation 
With secondary generalisation
14
1
9.3
0.7
Both simple partial and complex 
Partial
1 0.7
Seizures were classifiable in 151 of 164 patients
Table 12. EEG abnormalities in patients with seizures (n=83)
EEG Number of patients (%)
Focal slow activity 
Epileptiform/paroxysmal activity 
Sharp waves 
Spikes 
Normal
65 (78)
22 (27) 
7(8) 
13 (16)
Only 83 of 165 patients with seizures underwent EEG evaluation.
4. Incidence rates
The average annual incidence rate for all primary CNS neoplasms was 9.8 per
100,000 population (9.0 for intracranial tumours and 0.8 for intra-spinal 
tumours). The age-specific incidence rate of intracranial tumours was much 
lower in childhood (3.7), increased in the 30- to 39-year age group (6.5), 
reached a maximum in the age range of 50-69 years (20.6) and then declined 
abruptly in the elderly (7.6) (Figure 1). Intra-spinal neoplasms revealed a steady 
increase in incidence up to the age of 60-69 years. Age-specific incidence rates 
for glioblastoma, astrocytoma, meningioma and tumours without microscopic 
confirmation, including both intracranial and intra-spinal cases, are shown in 
figure 2. Some variations of the curves of individual histological types of brain 
tumours are noteworthy. Specifically, that the annual incidence rate of 
astrocytoma showed a small peak in childhood (1.0) and a plateau in the age 
range 30 to 49 years, then increased in the 50- to 69-year age group (2.4), and
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fell significantly in those aged 70 and older. Age-specific incidence rate for 
glioblastoma increased with age, reaching a maximum of 6.1 at the age of 60- 
69 and declined in the more elderly. Meningioma had a similar pattern with a 
peak incidence of 6.1 in the age range 60 to 69 year.
Age (years)
Figure 1. Age-specific incidence rates for intra-cranial and intra-spinal tumours and for 
all brain tumours in Estonia (1986-1996).
Figure 2. Average annual age-specific incidence rates for astrocytoma, glioblastoma, 
meningioma and cases without microscopic confirmation. Estonia 1986-1996.
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There were no statistically significant differences between the sexes either in 
the total incidence of tumours, or in the incidence of astrocytomas and gli­
oblastomas (Table 13). However, neuroepithelial tumours (p<0.01) and gliomas 
(p<0.05) were more common in males (male/female ratio 1.2), while 
meningiomas and tumours of cranial and spinal nerves (including neurinomas) 
were significantly more frequent (p=0.001 and <0.005, respectively) in females 
(male/female ratios 0.35 and 0.59, respectively).
Table 13. Incidence rates (per 100,000 person-years) by histological types and 
male/female ratios for primary brain tumours in Estonia (1986-1996)
Tumour type Crude rate (95% Cl) Male/female
Males Females ratio
Neuroepithelial tumours 4.90 (4.41-5.39) 4.01 (3.60-4.42) 1.22c
All gliomas 4.32 (3.86-1.78) 3.60 (3.21-3.99) 1.2b
Astrocytoma 1.37(1.11-1.63) 1.34(1.10-1.58) 1.02
Glioblastoma 2.20(1.87-2.48) 1.79(1.51-2.07) 1.23
Oligodendroglioma 0.32 (0.20-0.44) 0.19(0.10-0.28) 1.68
Ependymoma 0.30 (0.18-0.42) 0.14(0.06-0.22) 2.14b
Mixed glioma 0.13(0.05-0.21) 0.14(0.06-0.22) 0.93
Medulloblastoma 0.29 (0.17-0.41) 0.21 (0.11-0.31) 1.38
Tumours of cranial and
spinal nerves 0.39 (0.25-0.53) 0.66 (0.49-0.83) 0.59b
Neurinoma 0.37 (0.24-0.50) 0.59 (0.43-0.75) 0.63b
Meningeal tumours 1.46(1.19-1.72) 3.32 (2.94-3.70) 0.47d
Meningioma 0.96 (0.74-1.18) 2.77 (2.43-3.11) 0.35d
Haemangioblastoma 0.10(0.03-0.17) 0.16(0.08-0.24) 0.63
Malignant lymphomas 0.15 (0.06-0.24) 0.09 (0.03-0.15) 1.67
Sellar region tumours
Pituitary adenoma* 0.42 (0.28-0.56) 0.44 (0.30-0.58) 0.96
Craniopharyngioma 0.10(0.03-0.17) 0.07 (0.02-0.12) 1.43
No histological 1.98 (1.67-2.29) 1.80(1.52-2.08) 1.10
confirmation
Intra-cranial tumours 8.62 (7.97-9.27) 9.37 (8.74-10.00) 0.92
Spinal tumours 0.73 (0.54-0.92) 0.89 (0.70-1.08) 0.82
All tumours 9.36 (8.68-10.04) 10.25 (9.59-10.91) 0.91
a includes 38 unconfirmed cases of pituitary tumours diagnosed clinically as adenomas 
b p<0.05 
c p<0.01 
dp=0.001
Average annual age-adjusted incidence rates for various histological types of 
primary brain tumours in Estonia are shown in table 14. Age-adjusted incidence 
was 3.41 for gliomas, 1.63 for meningiomas and 8.46 for all primary brain 
tumours. Among gliomas, the most common types were glioblastoma and 
astrocytoma (incidence rates of 1.58 and 1.27, respectively), oligodendroglioma
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and ependymoma being less frequent (incidence rate of 0.22 for both). The 
incidence rate for cases without microscopic confirmation was 1.63.
Table 14. Age-adjusted incidence rates (ASIR) per 100,000 population for brain tu­
mours by histological types in Estonia 1986-1996.
Tumour type ASIRa (95% Cl)
Astrocytoma 1.27(1 .10-1 .44)
Glioblastoma 1.58 (1.39-1.77)
Oligodendroglioma 0.22 (0.15-0.29)
Ependymoma 0.22 (0.15-0.29)
Mixed glioma 0.11 (0.06-0.16)
All gliomas 3.41 (3.13-3.69)
Medulloblastoma 0.32 (0.23-0.41)
Neurinoma 0.40 (0.30-0.50)
Meningioma 1.63 (1.44-1.82)
Pituitary adenoma6 0.36 (0.27-0.45)
Other specified 0.96 (0.81-1.11)
No microscopic confirmation 1.63(1.44-1.82)
All tumours 8.46 (8.02-8.90)
a rates are age-adjusted to the World Standard Population
1 includes 38 unconfirmed cases of pituitary tumours diagnosed clinically as adenomas
Changes in incidence
A comparison of current rates with those of a previous study, carried out from 
1951 to 1970, suggests that the increase in the incidence rates of intracranial 
tumours is histology-specific (Table 15). A significant increase was observed in 
incidence rates for astrocytoma, glioblastoma and meningioma (incidence rate 
ratios of 1.49, 1.50 and 1.97 respectively, p=0.001). Looking at age-specific 
incidence rates, a significant increase is evident across all age groups (Table 
16), with the increase being most apparent in children, adolescents, and age 
groups over 50 (incidence rate ratio over 1.5).
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Table 15. Changing incidence rates (IRa) over time for primary intra-cranial tumours in 
Estonia during 1951-1970 and 1986-1996
Tumour type 1951-1970 1986-1996 Incidence rate P value
No. of intra­ No. of intra­ ratio (IRR)
cranial cranial (95% Cl)
tumours (IRa) tumours (IRa)
Astrocytoma 128 (0.51) 150(0.76) 1 .49(1.18-1.89) 0.001
Anaplatic astrocytoma 61 (0.25) 78 (0.46) 1 .84(1.32-2.57) 0.001
Glioblastoma 313 (1.30) 336(1.95) 1.50(1.29-1.75) 0.001
Oligodendroglioma 45 (0.18) 42 (0.25) 1.39 (0.91-2.12) 0.125
Ependymoma 34 (0.14) 24 (0.15) 1.07 (0.64-1.80) 0.789
All gliomas 678 (2.77) 651 (3.81) 1.38 (1.24-1.54) 0.001
Medulloblastoma 45 (0.18) 42 (0.26) 1.44 (0.95-2.19) 0.083
Neurinoma 76 (0.31) 59 (0.35) 1 .13(0.76-1.65) 0.478
Meningioma 214 (0.87) 297 (1.71) 1 .97(1.65-2.35) 0.001
Pituitary adenoma 86 (0.35) 73 (0.43) 1.23 (0.90-1.68) 0.195
No histological
confirmation 229 (0.89) 299(1.75) 1.97(1.66-2.34) 0.001
All types 1454 (5.91) 1527 (8.93) 1.51 (1.41-1.62) 0.001
a Rates are age-adjusted to the Estonian Standard Population (1989 census)
Table 16. Changing age-specific incidence rates (per 100,000 population) of intra­
cranial tumours in Estonia, 1951-1970 and 1986-1996.
Age
(years)
1951-1970 1986-1996 Incidence rate ratio 
(IRR) (95% Cl)No. of 
cases
Age-specific
incidence
No. of 
cases
Age-specific
incidence
0-9 95 2.5 96 3.9 1.6 (1.2—2.1 )b
10-19 74 2.2 83 3.5 1.6 (1.2-2.2)c
20-29 119 3.0 97 4.1 1.4 (1.1—1.8)b
30-39 204 5.2 164 6.5 1.3 (1 .0-1 .5)b
40-49 277 8.5 241 11.3 1.3 (1.1—1.6)c
50-59 340 12.5 422 20.6 1.7 (1 .4 -1 ,9)c
60-69 270 12.3 322 19.7 1 .6 (1 .4 -1 .9)c
70+ 75 4.4 100 7.6 1.7 (1.3-2.3)°
Total 1454 5.9 (5.9a) 1525 9.0 (8.9a) 1.5 (1.4—1.6)c
a Rates are age-adjusted to the Estonian Standard Population (1989 census) 
b p<0.005 
cp=0.001
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5. Survival rates
Survival analysis included 1417 patients (628 men and 789 female) with CNS 
tumours. 88 cases discovered at autopsy, 2 patients with incomplete data, 17 
patients diagnosed with another tumour, previously or during the follow-up period, 
and 141 patients lost to follow-up were excluded from the survival analysis.
The distribution and median survival of patients by gender, age, tumour 
location and clinical condition are shown in table 17. Univariate analysis found 
that females (p=0.002), patients of younger age (<45 years, p=0.0001) and 
better clinical condition before treatment, (p=0.0001) had the highest survival. 
Concerning tumour location, the worst prognosis was associated with those of 
central structures or ventricular location and the best prognosis with infra- 
tentorial and pituitary location.
Table 17. Median survival time (ST) of 1417 brain tumour patients diagnosed in 
Estonia from 1986 to 1996
Characteristic No of patients (%) No of deaths Median ST (months)
Gender
male 628 (44.4) 371 18.6
female 789 (56.6) 396 62.8
p=0.002
Age group
0 -2 0 191 (13.5) 90 88.3
21-44 344 (24.3) 140 136.9
45-64 677 (47.8) 401 15.8
65+ 205 (14.5) 136 5.7
p=0.0001
Location
frontal 164(11.6) 107 17.8
parietal 113(8.0) 63 14.7
temporal 108 (7.6) 71 13.9
2 or more lobes 336 (23.7) 231 10.4
central structures and
ventricles 58 (4.1) 36 7.3
other supratentorial 175 (12.1) 82 nc
pituitary or pineal 114(8.1) 28 nc
infratentorial 311 (21.9) 133 nc
location not available 38 (2.7)
p=0.0001
Kamofsky PS
80-100 370 (26.1) 105 nc
60-70 558 (39.4) 289 48.0
<60 321 (22.7) 251 5.3
KPS not available 168 (11.9)
p=0.0001
nc = median could not be computed, over 50% survived
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In gliomas (566 cases), univariate analysis (Table 18) found no differences 
between sexes. Patients of a younger age have a very significantly better median 
survival: in children and adolescents more than 50% of patients survived till the 
end of the study period so that the median cannot be computed. Among the 
elderly, the median survival time was only 2.6 months. Concerning the patients’ 
clinical condition before treatment, the higher the Kamofsky Performance 
Status score was before treatment, the better the survival rate. The distribution 
of treatment strategy was not homogenous. Most patients underwent only 
surgery or surgery combined with radiation therapy. Only a few patients 
received chemotherapy. Median survival was the best in combined treatment 
groups and the worse in the symptomatic treatment group, which mainly 
includes patients in a terminal condition. In the surgery group, the survival 
period was only about 3 months.
Table 18. Median survival time (ST) of 566 glioma patients (Estonia, 1986-1996)
Characteristic N Median ST (months) P value
Gender:
Male 294 7.8
Female 272 7.9 ns
Age group (years)
<21 68 nc
21-44 142 16.5
45-64 273 5.8
>64 83 2.6 <0.0001
KPS (%):
80-100 108 47.2
60-70 217 9.5
<60 170 3.6
not available 71 <0.0001
Treatment:
surgery 288 3.3
radiation 4 6.1
surgery+radiation 187 16.0
surgery+chemotherapy 6 8.9
surgery+radiation+chemotherapy 32 12.0
symptomatic 19 0.7
incomplete data 34 <0.0001
nc = median could not be computed, over 50% survived
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Survival by histology
One- and five-year survival rates and median survival time by histology are 
presented in table 19. The overall 1-year survival was 59%, 5-year survival 46% 
and median survival 33 months. Tumours with the most favourable prognosis 
included pituitary adenoma (89%, both 1- and 5-year survival), meningioma (1- 
year survival 86% and 5-year survival 82%) and neurinoma (76%, both). 
Patients with glioblastoma and anaplastic astrocytoma had the worst outcome 
(5-year survival 9% and 16%, respectively). In contrast, about half of the low- 
grade astrocytoma patients survived beyond 5 years. The long-term prognosis 
for patients with medulloblastoma, ependymoma, oligodendroglioma and mixed 
glioma appeared similar to each other (23%, 27%, 28% and 28%, respectively), 
at the same time, median survival was not so homogenous. The prognosis of 
craniopharyngioma was about the same as astrocytoma.
Table 19. One-year and five-year survival rates (SR) and median survival time (ST) by 
histology for patients with primary brain tumours in Estonia (1986-1996)
Histology N 1-year SR (%) 5-year SR (%) Median ST
(95% Cl) (95% Cl) (months)
Astrocytoma (G l-2 ) 138 64.5 (60.4-68.6) 49.8 (45.2-54.4) 54.2
Anaplastic astrocytoma 72 36.1 (30.4-41.8) 15.8 (11.3-20.4) 8.3
Glioblastoma 297 28.0 (25.4-30.6) 8.6 (6.8-10.3) 6.2
Ependymoma 22 50.0 (39.3-60.7) 26.9 (16.5-37.4) 10.7
Oligodendroglioma 38 60.5 (52.6-68.5) 28.1 (18.7-37.3) 22.9
Mixed glioma 23 56.5 (46.2-66.9) 28.1 (18.2-37.9) 22.4
Medulloblastoma 39 53.9 (45.9-61.8) 22.5 (15.3-29.7) 12.7
Meningioma 284 85.9 (83.9-88.0) 82.4 (80.0-84.8) nc
Neurinoma 55 76.4 (70.6-82.1) 76.4 (70.6-82.1) nc
Pituitary adenoma 37 89.2 (78.4-94.3) 89.2 (78.4-94.3) nc
Craniopharyngioma 15 73.3 (61.9-84.8) 52.4 (37.4-67.3) nc
Other specified 119 62.6 (57.9-67.3) 43.8 (38.8-48.8) 36.5
Without histology 278 61.9 (59.0-64.8) 53.8 (50.7-56.8) nc
Total 1417 59.3 (58.0-60.6) 46.0 (44.6-47.4) 33.2
nc = median could not be computed, over 50% survived
Survival by age at diagnosis
Observed survival rates by age at diagnosis for all CNS tumours and selected 
histology groups are given in table 20. Including all histological groups, the 
worst outcome occurred in those patients older than 65 years. Decreased 
survival associated with older age at diagnosis was observed in all histological 
groups. Differences were the most evident in the astrocytoma group (1-year 
survival 17% in the elderly and 87% in children, 5-year survival 7% and 79%, 
respectively) where survival was decreasing with age.
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Table 20. One- and five-year survival rates (SR) by age at diagnosis for selected histology groups
Histology
Age at diagnosis
<20 21—44
N 1-year SR (95%CI) 5-year SR (95%CI) N 1-year SR (95%CI) 5-year SR (95%CI)
Astrocytoma 46 87.0 (82.0-91.9) 79.3 (73.1-85.6) 43 76.7 (70.3-83.2) 64.6 (56.8-72.5)
Anaplastic astrocytoma 4 * * 21 52.4 (41.5-63.3) 26.8 (16.8-36.8)
Glioblastoma 12 41.7 (27.5-55.9) 21.6(8 .9-34.3) 55 43.6 (37.0-50.3) 13.8 (8.6-19.0)
Other glioma 13 76.9 (65.2-88.6) 46.2 (30.3-62.0) 30 63.3 (54.5-72.1) 40.8 (30.8-50.8)
Meningioma 3 * * 58 93.1 (89.8-96.4) 93.1 (89.8-96.4)
Neurinoma 5 * * 18 88.9 (81.5-96.3) 88.9 (81.5-96.3)
Other specified 65 58.5 (52.4-64.6) 35.6 (29.3-41.8) 53 87.8 (83.1-92.4) 77.1 (70.6-83.6)
Without histology 43 69.8 (62.8-76.8) 55.3 (47.6-62.9) 66 81.8 (77.1-86.6) 72.8 (67.1-78.6)
Total 191 70.2 (66.9-73.5) 52.9 (49.1-56.6) 344 74.7 (72.4-77.1) 60.9 (58.1-63.7)
45-64 65+
N 1-year SR (95%CI) 5-year SR (95%CI) N 1-year SR (95%CI) 5-year SR (95%CI)
Astrocytoma 37 37.8 (29.9-45.8) 13.2 (6.2-20.3) 12 16.7 (5.9-27.4) 16.7 (5.9-27.4)
Anaplastic astrocytoma 39 25.6(18.7-32.6) 8.6 (3.6-13.5) 8 * *
Glioblastoma 173 24.3 (21.0-27.5) 6.3 (4.3-8.3) 57 21.1 (16.6-26.5) 7.0 (3.6-10.4)
Other glioma 31 51.6 (42.6-60.6) 18.3 (11.2-25.4) 9 * *
Meningioma 182 83.5 (80.8-86.3) 79.8 (76.7-82.9) 41 85.4 (79.9-90.9) 75.0 (66.6-83.4)
Neurinoma 23 73.9 (64.8-83.1) 73.9 (64.8-83.1) 9 * *
Other specified 79 59.5 (54.0-65.0) 44.8 (38.9-50.6) 13 46.2 (32.4-60.0) 30.8 (18.0-43.6)
Without histology 113 56.6 (52.0-61.3) 49.0 (44.2-53.9) 56 42.9 (36.3-49.5) 39.3 (32.7-45.8)
Total 677 53.5 (51.6-55.4) 40.7 (38.7-42.6) 205 42.4 (39.0-45.9) 32.3 (28.9-35.8)
*Not given due to a very small number (<10) of cases
Changes in survival
Table 21 shows 1-year survival rates for astrocytoma, glioblastoma, menin­
gioma, tumours without histological verification and all tumours by patient age 
group during three time periods (1986-1989, 1990—1993 and 1994—1996). 
Comparing the first (1986-1989) and the second (1990-1993) time period a 
statistically significant decline in 1-year survival for glioblastoma (32.7% and 
17.9%, respectively) and all tumours (59.8% and 53.6%, respectively) can be 
observed. In meningiomas, a similar tendency is evident only between 45 and 
64 years. Comparing the first (1986—1989) and the third (1994—1996) time 
period, no significant changes in survival, neither for meningioma nor
Table 21. 1-year survival rates (SR) by age for patients with low-grade astrocytoma, 
glioblastoma, meningioma and without histological confirmation and all brain tumours 
during 3 time periods. Estonia 1986-1996.
Histology Age - 
group
Year of diagnosis
1986-1989  
SR (95% Cl)
1990-1993 
SR (95% Cl)
1994-1996 
SR (95% Cl)
Astrocytoma 0-20 88.2 (80.8-96.1) 81.3(71.5-91.0) 92.3 (84.9-99.7)
(G l-2 ) 21-44 76.5 (66.2-86.8) 58.3 (44.1-72.6) 92.9 (86.0-99.7)
45-64 29.4(18 .4-40 .5) 28.6(16.5-40.6) 83.3 (68.1-98.5)
65+ 25.0 (3.4-46.7) * *
All ages 61.8 (55.3-68.4) 54.6 (47.0-62.1) 79.5 (73.0-86.0)
Glioblastoma 0 -2 0 * * *
21-44 45.0 (33.9-56.1) 22.2(12.4-32.0) 52.9 (40.8-65.1)
45-64 27.1 (21.8-32.5) 17.1 (12.6-21.6) 33.3(25.1-41.5)
65+ 25.0(14.2-35.8) 9.1 (3.0-15.2) 31.6 (20.9-42.2)
All ages 32.7 (28.2-37.2) 17.9 (14.2-21.5) 36.0 (30.5-41.5)
Meningioma 0 -2 0 * * *
21-44 90.5 (84.1-96.9) 95.8 (91.7-99.9) 92.3 (84.9-99.7)
45-64 86.0(81.4-90.6) 74.6 (69.1-80.1) 90.3(86.6-94.1)
65+ * 84.6 (74.6-94.6) 81.8 (73.6-90.0)
All ages 88.1 (84.6-91.6) 81.2 (77.3-85.1) 88.9 (85.7-92.1)
Without 0 -2 0 57.9 (46.6-69.2) 71.4 (58.7-83.5) 90.0 (80.5-99.5)
histology 21-44 87.5 (80.8-94.3) 83.3 (72.6-94-1) 76.7 (69.0-84.4)
45-64 52.5 (44.6-60.4) 67.7 (59.3-76.1) 52.4 (44.7-60.1)
65+ 69.2 (56.4-82.0) 31.8 (21.9-41.8) 38.1 (27.5-48.7)
All ages 64.6 (59.7-69.5) 60.8 (55.3-66.3) 60.2 (55.4-65.0)
Total 0 -2 0 65.7 (59.9-71.5) 72.5 (67.1-77.8) 72.7 (66.7-78.7)
21-44 78.1 (74.3-81.8) 69.4 (65.0-73.9) 76.1 (72.1-80.1)
45-64 51.8 (48.6-55.0) 46.0 (40.3-49.2) 64.8 (61.3-68.2)
65+ 47.1 (44.8-54.1) 37.0(31.3-42.6) 44.4 (38.9-50.0)
All ages 59.8 (57.6-62.1) 53.6 (51.3-55.9) 64.9 (62.7-67.2)
* Not given due a very small number of cases
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glioblastoma, have taken place. There were statistically significant improve­
ments in survival rates comparing the first (1986-1989) and the third (1994- 
1996) time period for patients with astrocytoma and for all other tumours. Age- 
specific rates showed that the increase in survival was more evident in older 
adults, between 45 and 64 years, both, for all tumours (51.8% in 1986 through 
1989 and 64.8% in 1994 through 1996) and for astrocytomas (29.4% and 
83.3%, respectively). In astrocytomas, a slight, but statistically not significant, 
improvement can be observed in younger adults, aged between 21 and 44 years.
6. Prognostic factors
In multivariate analysis, older age at diagnosis, the patient’s clinical condition 
(Kamofsky Performance Status <60), tumour histology and period of diagnosis 
were independent prognostic factors for survival (Table 22). Risk of death was 
more than eight times greater for glioblastoma (RR 8.31, p=0.0001), about 
seven times greater for anaplastic astrocytoma (RR 7.22, p=0.0001) and more 
than five times greater for other gliomas (RR 5.74, p=0.0001). The best 
prognosis was found in neurinoma, still having significantly greater risk of 
death (RR=1.87, p=0.04) compared with meningioma.
In multivariate analysis including only gliomas, age, patient clinical 
condition, tumour histology and treatment were found to be independent 
prognostic factors (Table 23). The best prognosis had low-grade astrocytoma, 
oligodendroglioma and ependymoma patients of younger age, better clinical 
condition which underwent surgery with additional radiation therapy or surgery 
combined with radiation and chemotherapy. The worst prognosis was found 
among patients who received only symptomatic treatment.
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Table 22. Multivariate analysis (Cox Model). Factors predicting survival in those 
patients with brain tumours.
Factor Variable Parameter
estimate
P value
Risk ratio 
(in best Cox 
model)
Gender Male vs female ns
Age as a continuous variable 0.014 0.0001 1.02
Karnofsky Perfor­
mance Status
<60% 60-100%  has been taken 0.600 0.0001 1.82
Not specified as a base category 0.552 0.0001 1.74
Period of diagnosis
1990-1993 1986-1989 has been ta­ ns
1994-1996 ken as a base category -0.190 0.0280 0.83
Histology
Astrocytoma 1.429 0.0001 4.18
Anaplastic Meningioma has taken
astrocytoma as a base category for all 1.977 0.0001 7.22
Glioblastoma types 2.117 0.0001 8.31
Other glioma 1.748 0.0001 5.74
Neurinoma 0.624 0.0376 1.87
Other specified 1.497 0.0001 4.47
Without histology 1.166 0.0001 3.21
Localisation
Hemispheres Infratentorial location ns
Central structures has been taken as a base ns
Other category ns
Not specified 1.461 0.0001 4.31
Table 23. Multivariate analysis (best Cox model). Factors predicting survival in 
gliomas.
Variable
Parameter
estimate
P value Risk ratio (RR)
Age 0.024 <0.0001 1.03
KPS 0.412 <0.0001 1.51
Histology*
Astrocytoma (G 1-G2) -1 .117 <0.0001 0.33
Ependymoma -0.742 0.01 0.48
Oligodendroglioma -0.871 <0.0001 0.42
Mixed glioma -0.558 0.03 0.57
Treatment**
Surgery+radiation -0.821 <0.0001 0.44
Surgery+radiation+chemotherapy -0.632 0.003 0.53
Symptomatic 1.390 <0.0001 4.02
*Glioblastoma taken as a base category
**Surgery taken as a base category
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7. Cancer registration
Of the 1665 patients included in our study, 996 (60%) were identified in the 
Estonian Cancer Registry as having CNS tumours. Since most gliomas are 
considered malignant, 98% of them were found in the registry. Differences were 
revealed in the histological subgroups (Table 24). Over-reported histological 
types included oligodendroglioma (124%) and astrocytoma (106%), under­
reported histological types included glioblastoma (91%) and lymphoma (70%). 
Reporting of non-malignant CNS tumours was very low: meningiomas (11%) 
and neurinomas (9%).
Table 24. Reporting of chosen CNS tumour types in the Estonian Cancer Registry 
(ECR), 1986-1996.
Tumour types ECR
(N)
Estonia
1986-1996
(N)
Reporting
%
Astrocytoma (G1-G3) 242 242 106
Glioblastoma 304 336 91
Oligodendroglioma 52 42 124
Ependymoma 38 37 103
Medulloblastoma 42 42 100.
Neurinoma 7 82 9
Neurofibroma 2 9 22
Meningioma 35 326 11
Haemangioblastoma 13 22 59
Malignant lymphomas 14 20 70
Pituitary adenoma 4 35 11
Craniopharyngioma 1 14 7
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DISCUSSION
1. Patients and methods
The vast range in incidence rates of primary brain tumours (Table 2) has been 
explained by differences in inclusion criteria and classification, methods of case 
researching and the number of patients included rather than on real variations of 
incidence in different geographical areas and populations. Most authors agree 
that, besides cancer registration, incidence rates are influenced by the 
availability of competent medical care, frequency of autopsy and improvement 
of brain imaging techniques (CT, MRI) (Bahemuka, 1988; Percy et al., 1972). 
Proceeding from the above evidence, epidemiological studies concerning 
primary brain tumours should be based both on as such a complete case 
research study as possible, as well as on clearly defined criteria for different 
populations and geographical regions. The search strategy used to identify cases 
has been found to have the greatest influence on results. The more methods that 
have been used to discover cases, the higher the incidence rates have been 
reported. Studies that used only a single source to identify patients (e.g. a cancer 
registry or records from a single hospital) reported incidences that were about 
30% lower than studies that used two or four methods (Counsel and Grant, 
1998).
Centralised health care and the population-based cancer registration in 
Estonia markedly facilitated the case finding procedure for our study. We 
attempted to achieve maximal case discovery by using several sources including 
different hospital records: patient registration lists, case histories, pathology 
reports and consulting the databases of the Estonian Cancer Registry. After 
linkage of our database to the Estonian Cancer Registry, a valuable contact 
database was established. This enabled the ECR to perform a tracing-back of 
missing cases to their original medical records to improve the registry. In 
Estonia, all suspected brain tumours are admitted to neurosurgical departments 
(Tallinn Mustamäe Hospital and Tartu University Clinics) where specialists 
make diagnostic and treatment decisions. We had very good co-operation with 
the neuropathologist who overviewed histologically obscure cases, according to 
the WHO histological classification of CNS tumours (Kleihues et al., 1993). 
The possibility was considered that some tumours have been diagnosed in 
outpatient or children clinics although the centralised system would minimise 
this. We believe that these few possible missed cases probably did not affect the 
total incidence numbers considering the number of identified cases. Some 
problems were caused by the incomplete data of medical records when 
estimating the clinical characteristics. This shortage is only inevitable in 
prospective studies. To identify sufficient cases of tumour sub-types the study 
was conducted on the whole Estonian population of approximately 1.5 million 
during a period of 11 years (1986-1996).
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2. Histological distribution
The distribution of pathologically confirmed cases according to histological 
types in Estonia is in many respects similar to the distribution reported for other 
geographic regions (Walker et al., 1985; Cole et al., 1989; Preston-Martin et al., 
1993).
In our study, gliomas comprised 50% (including glioblastomas 25%, 
astrocytomas 17%), meningiomas 24% and neurinomas 6% of all CNS tumours. 
The U.S. study (Surawicz et al., 1998) based on the National Cancer Data Base 
(NCDB) has found approximately the same distribution concerning astrocytoma 
(18.7%) and glioblastoma (29.6%), with a lower occurrence of meningioma 
(14.3%) and neurinoma (2.5%). Authors suggest that tumours of benign 
histologies are under-represented in the NCDB because of insufficient 
diagnostic accuracy and quality of data coding and entry in some institutions. 
The latest study (Surawicz et al., 1999) based on the Central Brain Tumour 
Registry of the United States showed that the frequency of meningioma is much 
higher (24%). A few studies (Percy et al., 1972; the Committee of the Brain 
Tumour Registry in Japan, 1987; Kuratsu et al., 2001) have revealed lower 
frequency for gliomas (28-38%) and higher frequency for meningiomas (33- 
37%). We found that pituitary adenomas accounted for only for 2.6% of cases, 
which is lower than figures in other studies where they accounted for 6% to 
18% (Gudmundsson, 1970; Counsell et al., 1996; D'Alessandro et al., 1995; 
Kuratsu et al., 2001). The observed difference may be partly due to low 
histological confirmation (58%), since inclusion of patients with clinically 
identified adenoma would increase the figure by any figure up to 5.4%. 
Generally, we suggest that the difference in histological distribution is mostly 
affected by methods of case ascertaining, the availability of brain imaging 
techniques and the percentage of histological conformation.
3. Incidence of primary brain tumours
Studies of the incidence patterns of nervous system tumours in adults show a 
remarkably consistent dependence on age and race as well as on the sex ratio in 
different population groups (Velema and Walker, 1987). All studies have 
confirmed that the incidence of primary CNS tumours, especially neuro­
epithelial and meningeal tumours, increases with age up to the years of 65-70 
(Counsell and Grant, 1998). Data concerning age-specific incidence rates in the 
elderly are controversial. Several studies (Gudmundsson, 1970; D'Alessandro 
et al., 1995; Preston-Martin et al., 1993) have found that maximum incidence 
occurs in the oldest age group. In a Japanese study, (Kuratsu and Ushio, 1997), 
of 271 intracranial tumours in elderly people, the annual incidence rate was 18.1 
per 100,000 population and was significantly higher than in other age groups,
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meningioma being the most common type (50.6%). Similar to other studies, 
(Fogelholm et a l ,  1984; Helseth et a l , 1988; Joensen, 1981; Van der Sandem 
et a l ,  1998), the present research shows an increasing incidence from the age of 
thirty, reaching a maximum in the age-range of 50-69 years and a decline in the 
elderly, with gliomas as the most frequent type (Greig et al., 1990; 
Radhakrishnan et a l ., 1995). The latter trend seems to occur as a result of under 
diagnosis influenced by autopsy rates (Percy et al ., 1972; Preston-Marin et al., 
1993), less investigation and diagnostic bias (stroke or dementia being 
diagnosed more readily than tumour) (Counsell et al., 1996) rather than a real 
decrease. We agree with Helseth (1993), who suggests that completeness of 
diagnosis, particularly in the case of the elderly, depend both on the autopsy rate 
and use of improved imaging techniques. However, like some other authors 
(Van der Sandem et al., 1998) we do not believe that the decline factor in the 
elderly is explainable mainly as the result of under-diagnosis. We propose to 
carry out more prospective epidemiological studies among the elderly, accom­
panied by neurological examination, using modem imaging techniques in 
different populations to prevent a missed diagnosis.
Meta-analysis has confirmed that significant differences exist in the 
incidence of neuroepithelial, meningeal and cranial nerve tumours between 
males and females and these cannot be explained by age differences (Counsell 
and Grant, 1998). Some authors have found a higher incidence of primary CNS 
tumours among males (Van der Sandem et al., 1998). Percy et al. (1972) 
showed that females have meningiomas more frequently, whereas gliomas and 
most other neoplasms occur at an equal rate in both sexes. In a study, carried 
out in Central Finland, meningiomas were shown to be eight times more 
frequent in females than in males (Fogelholm et al., 1984). Our data reveal no 
significant differences between males and females in the overall incidence of 
primary CNS tumours. Regarding the incidence rate according to histological 
types, gliomas were more common in men (with no significant difference when 
astrocytoma and glioblastoma were treated separately), while meningiomas and 
tumours of cranial and spinal nerves were more predominant in females as 
established in most other surveys (Barker et al., 1976; Helseth et al., 1988; Cole 
et al., 1989; Mahaley et al., 1989).
Spinal tumours constituted 8.3% of all primary tumours with an incidence 
rate of 0.8 per 100 000 population, which is lower than that presented in the 
Rochester, Finnish and Icelandic studies (Percy et al., 1972; Gudmundsson, 
1970; Fogelholm et al., 1984), and higher than that reported from South East 
Wales (Cole et al., 1989). Our study shows an age-dependant increase of spinal 
tumours (Figure 1), similar to all the above mentioned surveys.
The age-adjusted incidence of 8.46 per 100,000 population for all CNS 
tumours is comparable to the findings of surveys carried out in Iceland, 
Norway, Victoria (Australia), US (Connecticut, Missouri, Massachusetts, Utah) 
and Japan (Gudmundsson, 1970; Helseth et al., 1988; Preston-Martin et al., 
1993; Davis et a l ,  1996; Kuratsu et al., 2001). It is higher than that reported
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from Washington DC, Wales, Netherlands and England (Heshmat et al., 1976; 
Cole et al., 1989; Van der Sandern et al., 1998), and lower than that found in 
Israel, Finland, Rochester (Minnesota), Italy (Valle d'Aosta), Scotland and the 
US (Leibowitz et al., 1971; Fogelholm et al., 1984; Radhakrishan, 1995; 
DAlessandro et al., 1995; Counsell et al., 1996; Surawicz et al., 2001, Cordera 
et al., 2002). The incidence of two main tumour types, gliomas and 
meningiomas, was 3.4 and 1.6 respectively, which is comparable with most of 
the studies, but lower than in Finland, Italy and Scotland (Kallio, 1988; Tola 
et al., 1994; Cordera et al., 2002). Generally, the incidence of gliomas is about 
twice as high as that of meningiomas, except in Norway where the incidence 
ratio of gliomas to meningiomas was 4:1 (Helseth et al., 1988). Higher 
incidences were found in studies where the incidence of all brain tumours was 
higher as well. We surmise that a low autopsy rate and a lower overall incidence 
of CNS tumours in the elderly, influenced by less investigation and diagnostic 
bias, account for the overall lower incidence of brain tumours in Estonia.
Changes in incidence rates
Comparison of current rates with those of the 1951-1970 study carried out in 
Estonia, as well as with those of other studies (Schoenberg et al., 1976; Werner 
et al., 1995; Christensen et al., 2003), suggests that the increase in the incidence 
rates of intracranial tumours is histology-specific. A significant increase was 
observed in incidence rates for astrocytoma, glioblastoma and meningioma. In 
meningiomas and partly also in low grade astrocytomas, our data support the 
argument that the increase in rates may be due to the fact that some tumours, 
previously went undetected, are now diagnosed (Helseth, 1993). It is also 
important to note that the use of different histological classifications in the 
present and previous Estonian study cannot be disregarded either. Glioblastoma 
generally presents easily recognisable symptoms, which make diagnosis less 
dependent on imaging technology. In some works investigators have revealed a 
higher increase in incidence for meningioma than for glioma (Helseth, 1995; 
Christensen et al., 2003), while a Connecticut study (Davis et al., 1996) 
established a higher increase for astrocytoma, meningioma and ependymoma. 
Analysis of the data of the US Surveillance, Epidemiology and End Results 
(SEER) Program (Ahsan et al., 1995) showed a statistically significant increase 
only for lymphoma in men. In Estonia, 59% (126 cases) of meningiomas were 
diagnosed at autopsy (with an autopsy rate of 30%) from 1951 to 1970, i. e. in 
the period before dramatic changes in diagnostic technology had taken place. In 
our study, most cases (70%) diagnosed, post mortem, were identified as gliomas 
and only 8% (7 cases) were meningiomas (at the same time the autopsy rate has 
decreased significantly). Evidently, most of these tumours had been misdiag­
nosed like other CNS diseases, and only a small part was incidental findings. 
Taking into account the low proportion of autopsies in Estonia, silent tumours
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are likely to be underestimated. Comparing the age-specific incidence rates of 
our study with those of the previous Estonian study, a significant increase is 
evident in all age groups. The same tendency has been found in Denmark 
(Christensen et al., 2003). Whereas studies performed in Norway (Helseth et al., 
1988), Connecticut (Polednak, 1991) and France (Fleury et al., 1997) revealed a 
significant increase only in the over 60 age group. This suggests that some of 
the increase can be accounted for by recent medical interest in, and better 
understanding of, neurological disorders in the elderly, as well as by improve­
ment in diagnostic procedures. Desmeules et al. (1992) has demonstrated that 
new imaging technology is responsible for detection of about 20% of brain 
tumours in both younger and older patients. Proceeding from our data, one 
cannot exclude that some part of the increased incidence in all ages and in some 
histological types (glioblastoma) is the consequence of environmental effects or 
some etiological factors. The increase across all age groups suggests a real 
increase in parallel with the increase related to more effective detection owing 
to improved case ascertaining with new imaging technology. However further 
studies are required to define whether this increase is real and continuous in 
Estonia. For the sake of better comparability of data, we agree with Counsell 
and Grant (1998) who suggest the use of unified methodology and who have 
worked out provisional guidelines for further research into incidence of primary 
brain tumours.
4. Cancer registration
The incidence rates of primary CNS tumours are higher in our study compared 
with the figures reported by the Estonian Cancer Registry (ECR). Until recently, 
the ECR recorded only histologically malignant brain tumours excluding 
meningiomas, neurinomas, pituitary and other benign tumours. The traditional 
distinction with respect to malignancy is clinically not specific to brain tumours 
as benign tumours of intracranial location may have as poor a prognosis as 
malignant tumours. Of the 1665 patients included in our study, 996 (60%) were 
identified in the Estonian Cancer Registry as having CNS tumours. Since most 
gliomas are considered malignant, 98% of them were found in the registry. 
Differences were revealed in the histological sub-groups of gliomas: some types 
were over-reported (oligodendroglioma 124%, astrocytoma 106%) or under­
reported (glioblastoma 91%). Probably classification errors were not caused by 
incorrect reporting. As other authors (Counsell et al., 1997; Davis et al., 1997; 
Van der Sanden et al., 1998), we suggest that classification errors occur because 
there is no meaningful link between the ICD-O coding system used in cancer 
registries and the WHO classification system used by neuropathologists. The 
problem can be solved by better collaboration between clinicists, pathologists 
and the cancer registry. Since, according to the ECR, the proportion of
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meningiomas and neurinomas was very low (11% and 9%, respectively), this 
means that the total incidence of CNS tumours is significantly underestimated. 
We compared our data with those reported from Scotland (50% of all primary 
tumours and 85% of malignant tumours identified in the Scottish Cancer 
Registry) (Counsell et al., 1997) and Norway (errors in overall incidence rates 
and rates for main tumour groups accounting for 0.3% of the total) (Helseth et  
al., 1988). A recent study carried out in Devon and Cornwall revealed under 
registration of more benign tumours in younger patients. Better registration 
included patients over 60 years of age and having a tumour requiring operation 
and radiotherapy (Pobereskin, 2001). Unfortunately our study didn't analyse 
registration in different age groups and by the performed treatment. It becomes 
evident that the accuracy of registration of brain tumours in the ECR depends 
on tumour histology. Therefore, there may be limitations in using the cancer 
registry to identify incidence of primary brain tumours.
5. Epileptic seizures in brain tumours
Brain neoplasms account for about 4-5% of all cases with seizure disorders 
(Morris et al., 1989; Hauser et al., 1993). Concerning previous medical history 
in gliomas there has been found an increased risk associated with epilepsy 
(Schlehofer et al., 1999). The association has been considered weaker for 
epilepsy of more than 20 years duration. The presence of a tumour should 
always be considered in those patients with seizure disorders, especially in case 
of simple partial and secondarily generalised seizure types. Other symptoms, 
some of which may be of a diagnostic value, will appear several months or 
years later, whereas in a remarkable proportion of patients they are totally 
lacking.
Of cerebral neoplasms, 25 to 50% appear with seizures (Morris et al., 1993; 
Shady et al., 1994; Moots et al., 1995). Seizures are often reported as being the 
first and sometimes the only presenting symptom of intracranial tumours 
(Morris et al., 1993; Moots et al., 1995). In meningiomas, 27% of the patients 
have been reported to have epileptic seizures as their initial symptom (Lieu and 
Howng, 2000). Lühdorf et al. (1986) found seizures to be the first sign of brain 
tumour in 50% of patients who developed seizures after the age of 60 years. In 
our study, only 17% of all tumour patients had seizures as their first complaint. 
The difference may be caused by the retrospective design of this study including 
mistakes in the chronology of symptoms. The diagnosis of brain tumour is often 
made after years from the onset of seizures. Several authors have reported the 
mean interval from onset of seizures to tumour diagnosis or surgery to be from 
2 to 11 years with a maximum of more than 20 years (Hirsch et al., 1989; Smith 
et a l ,  1991; Bartolomei et al., 1997; Afra et al., 1999). In a study carried out in 
6 countries, (Schlehofer et al., 1999) including 1,178 glioma and 331
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meningioma cases, there was an increased risk associated with epilepsy at least
2 years before brain tumour diagnosis in glioma patients. In epilepsy of more 
than 20 years' duration, the risk was significantly weaker. No association 
between meningioma and previous epilepsy history was observed. In our study, 
the mean time from the first epileptic seizure to tumour diagnosis was 16 
months, ranging from several days to 20 years, while it was significantly longer 
in patients whose only presented complaint was seizures (18 months), compared 
with patients who had seizures accompanying other symptoms and signs 
(12 months). Shorter duration in our examination period may be due to the fact 
that our study group included patients with both acute and chronic epilepsy. The 
exact cause for the long duration of seizures prior to tumour diagnosis is still 
unclear.
Data on the incidence of seizure activity and patients’ age are controversial. 
The age distribution of cases depends largely on the biological type of the 
tumours (Ketz et al., 1974). Shady et al. (1994) found the 50% seizure inci­
dence to have no correlation between age at diagnosis and seizure activity in 
children with supratentorial astroglial neoplasms. In their study of 3291 children 
with brain tumours, Gilles et al. (1992) reported that 14% of them experienced 
seizures, while the incidence increased monotonically throughout childhood. In 
adults with malignant gliomas, seizures at presentation were found more 
commonly in those patients younger than 50 years (Moots et al., 1995). In a 
study of 1028 gliomas, the frequency of epilepsy at presentation decreased with 
age in high-grade glioma patients and increased with age in low-grade glioma 
patients to a plateau in the fourth decade of life (Lote et al., 1998). In our study 
of all intracranial tumours, there was no significant difference between children 
and young adults compared with seizure and seizure free patients. Seizures were 
significantly more common in the third and fourth decades of life.
Concerning tumour pathology, seizures are reported most frequently in those 
patients with low-grade, slowly growing tumours and tumours involving the 
cerebral cortex. The most common tumour types are low-grade astrocytomas, 
mixed gliomas and oligodendrogliomas. Pace et al. (1998) found preoperative 
seizures even in 83% of supratentorial low-grade astrocytomas. Gangliogliomas 
are found with a surprisingly higher frequency than could be expected (Morris 
et al., 1989, 1993; Shady et al., 1994). In our study, the most common tumour 
types were mixed gliomas (63%), oligodendrogliomas (53%) and astrocytomas 
(42%) which is comparable with the results obtained by other authors. There 
was no significant difference in the incidence of low grade astrocytomas 
(41.5%) and anaplastic astrocytomas (43%). In the case of glioblastomas 
seizure, the incidence was low (26%); these patients experience other symptoms 
and signs more commonly. Incidence of seizures was the lowest for metastatic 
tumours (15%) and in cases without histological confirmation (12%). Seizures 
at presentation were significantly correlated with tumour pathology and 
location.
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With regard to tumour location, seizures have been reported to occur in 22- 
68% of patients with supratentorial tumours involving most commonly the 
temporal and frontal lobes (Morris and Estes, 1993; Moots et al., 1995) and in 
only 1-6% of patients with infratentorial lesions (Shady et al., 1994). Super­
ficial tumours involving the isocortex without known deep extension were 
associated with the highest rate of seizures significantly more often than if the 
tumour had a deep extension (Gilles et al., 1992). Seizure rates associated with 
frontal or temporal tumours were also significantly reduced in the presence of 
deep extensions of the tumour. In supratentorial, convex meningiomas, evidence 
of severe peritumoural edema significantly contributed to that of pre-operative 
epilepsy (Lieu and Howng, 2000). In our series, the higher incidence of seizures 
involving the frontoparietal, frontotemporal, parasagittal and temporal regions 
was evident. We did not take into account peritumoural edema or cortical 
location of a tumour as data concerning these entities were not sufficient. A 
prospective study design is more appropriate to evaluate these parameters.
The reported incidences of neurological findings in seizure patients are quite 
different. Most commonly, patients with low-grade tumours and chronic 
epilepsy have normal findings on neurological examination. In their series of 
chronic epilepsy, Morris and colleagues (1993) found 97% of patients without 
neurological signs. Spencer et al. (1984) described neurological abnormality in 
12 of 19 neoplasm patients with intractable partial epilepsy. In our series of 165 
patients, 44 (27%) had seizures as the single symptom and 123 (75%) as the 
first manifestation. Controversy between these data may be due to the diffe­
rences between study groups. In our study group, 121 (73%) patients 
experienced at least one other symptom; among them, 58 (35%) had headache, 
31 (19%) papilledema, 92 (56%) neurological deficit and 25 (15% 9 mental 
disturbances. Occurrence of neurological deficit, headache and mental disorders 
was remarkably higher in those patients without seizures. Comparison of 
seizure and seizure-free patients revealed no difference in the incidence of 
increased intracranial pressure, which is supported by other authors (Gilles et 
al., 1992).
The probability of diagnosing an underlying tumour in a patient with 
epilepsy is related to seizure type, with simple and complex partial seizures 
being the most common (Le Blanc and Rasmussen, 1974; Lote et al., 1998). 
The authors who have compared several seizure etiologies and seizure types 
have found only simple partial seizures to be significantly related to tumour 
etiology (Spencer et al., 1984). Tumour location has been considered the most 
important factor. In our series, all patients with classifiable seizures had partial 
seizures with or without secondary generalisation, 37% had simple partial, 10% 
had complex partial and 51% had secondary generalised seizures.
Patients with seizures caused by brain tumours reveal normal EEG only 
infrequently. Expediency of EEG recording in localisation of underlying brain 
tumours is debatable. Blume et al. (1982) found that focal delta activity has a 
higher tumour-localising value than spikes, and showed that multifocal spikes
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are associated with the unifocal tumour, including discharges arising from the 
opposite hemisphere. Several studies have shown a significant association 
between focal slow (delta) activity and brain tumours (75-80%) while 
paroxysmal activity has been seen more seldom (Blume et al., 1982; Dam et al., 
1985). However, in these studies the patient population was too small to 
consider the result significant. In a study of 98 children with supratentorial 
astroglial tumours (Shady et al., 1994), 88% of EEG abnormalities lateralised 
the tumour exactly and 56% localised the tumour to a specific lobe. In another 
study (Spencer et al., 1984) of 19 tumour patients with intractable partial 
epilepsy, 37% of EEGs localised the lobe and 21% lateralised the tumour. In the 
present study, 16% of patients had normal EEG, 78% had focal slow activity 
and 35% revealed paroxysmal activity. EEG findings allowed exact localisation 
of the lobe and hemisphere in 41% of patients, which is comparable with other 
authors. Focal delta activity in EEG may be of diagnostic value in case of brain 
tumours, but the use of EEG is debatable in localisation of an underlying 
neoplasm, especially when MRI and CT are available.
6. Survival and prognostic factors associated with survival 
of primary brain tumours
Most studies concerning survival of CNS tumours are hospital based or 
restricted to histological subtypes of gliomas. Different study designs make the 
comparison of data very problematic. Our analysis provides population-based 
survival estimates for both histologically benign and malignant CNS tumours in 
Estonia. Observed one- and five-year survival, the prognostic importance of 
patient- and tumour-related factors were analysed in 1417 patients with CNS 
tumours.
Data on gender differences are controversial. Most authors report no 
association between the prognosis and patient gender in malignant CNS 
tumours (M0rk et al., 1985; Salminen et al., 1996). A study based on 45 
European population-based cancer registries reported the higher survival of 
women in all countries except Switzerland and Austria (Sant et al., 1998). 
Gender differences have previously been reported for non-malignant CNS 
tumours (Helseth, 1997; Preston-Martin et al., 1993; McCarthy et al., 1998). 
The prognosis for patients with benign meningiomas is better for females below 
60 years (Sankila et al., 1992; McCarthy et al., 1998). The cause of this 
difference is unknown.
In our series including all CNS tumours, survival is considerably longer 
among females: median survival 62.8 months compared with only 18.6 among 
males. This difference can be explained by the variations in the histologial 
distribution in men and women. There is a higher incidence of benign 
meningiomas in females, together with a better prognosis for this type of
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tumour. The poorer survival of men is attributable to the relatively greater 
frequency among men of more aggressive tumour types. In multivariate 
analysis, no difference in prognosis could be detected for male and female 
patients.
The importance of age in predicting the survival from CNS tumours has 
been well documented in studies from the U.S. (Mahaley et al., 1989; Chandler 
et al., 1993; Salcman et al., 1994; Barker et al., 1996; Davis et al., 1998; 
McCarthy et al., 1998; Bunin et al., 1998) as well as from other countries 
(Kallio, 1993; Preston-Martin et al., 1993; Salminener al., 1993; Lowry et al., 
1998; Billiar et al., 1999). Generally, survival rates are declining with 
increasing decades of age at diagnosis both in benign and malignant tumours. A 
similar pattern was found in our study. In our series both, univariate and 
multivariate analyses show better survival in those patients below 45 years, 
being the most favourable in children and adolescents. The survival pattern of 
patients aged 45 to 64 years resembles more closely that of older rather than 
younger patients. However, some authors suggest that influence of age is 
overestimated (Shaw et al., 1994).
The prognosis of glioma patients, in general, is considered to be poor. In 
low-grade astrocytomas, the median survival time is about 5 years. Our study 
shows the similar result of 4.5 years. Long-term survival at 5 years is rather 
different ranging between 30% and 60% (Preston-Martin et al., 1993; Kreth et 
al. 1997), depending primarily on the inclusion criteria and study design. A 
hospital-based study of the NCDB (Surawicz et al., 1998) including over 
60,000 patients with a CNS tumour, found 5-year survival of 30.3% for 
astrocytoma and 77.4% for pilocytic astrocytoma. Our data show 5-year 
survival of 49.8% for low-grade astrocytomas depending significantly on 
patient age. Both, one- and five-year survival of patients under 20 years is 3-4 
times better than those of over 65 years.
The overall median survival of grade 3 and 4 astrocytomas is less than 1 
year. Salcman with colleagues (1994) suggests that the median survival of grade
3 and 4 astrocytomas for patients less than 40 years of age, who receive some 
form of therapy beyond surgery and radiation, is more than 2 years. Younger 
patients with grade 3 astrocytomas have generally better survival extending over
4 years (Silverstein et al., 1996). The Finnish study (Salminen et al., 1996) 
reported the median survival of grade 3 and 4 gliomas, 24.0 and 7.7 months, 
respectively. Barker with co-authors (1996) found the median survival of 
glioblastoma 11.2 months, the 1- and 5-year survival, 48% and 4%, respecti­
vely. Our study found similar median survival for glioblastoma (6.2 months) 
and anaplastic astrocytoma (8.3 months), 1-year survival 28.0% and 36.1% and 
5-year survival 8.6% and 15.8%, respectively. These data show poorer outcome 
than in other studies, especially concerning anaplastic astrocytoma. The relative 
poor median survival of patients with anaplastic astrocytoma may be explained 
by difficulties in making the histological diagnosis. The biggest divergence 
between neuropathologists lies in the making of the diagnosis of anaplastic
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astrocytoma. We suggest that other reasons for poor outcome are being caused 
by the lack of treatment strategies and oncological systems concerning brain 
tumours in Estonia. Many patients get lost in “the system” between neuro­
surgeons and oncologists. There is not a final consensus as to who should per­
form the following-up of patients: oncologists, neurosurgeons or neurologists.
In oligodendrogliomas the median survival time is between 3 and 8 years 
(M0rk et al., 1985; Ludwig et al., 1986; Lindegaard et al., 1987). Our data show 
the survival of 2 years, which is significantly lower, but comparable with the 
median survival of non-irradiated patients (26.5 months) in the Norwegian 
study (Lindegaard et al., 1987).
Although patients with benign tumours have a more favourable prognosis 
compared with patients with malignant ones there is still significant mortality 
associated with these histologies. Many studies give only observed survival 
rates (Cornu et al., 1990; Surawicz et al., 1998; McCarthy et al., 1998), which 
do not consider mortality due to other causes. This fact may have a certain 
impact on survival rates, especially in older people and one must consider it 
when comparing different studies. In our study, only observed survival rates 
were estimated and were not adjusted for deaths due to other causes. According 
to our results both, 1-year and 5-year survival of meningiomas is about the same 
as in the Finnish study (Sankila et al. 1992) (83% and 79%, respectively). The 
Norwegian study reported survival of benign meningiomas 93% at 1 year and 
95% at 5 year (Helseth, 1997). The U.S. study (McCarthy et al., 1998) based on 
9000 meningioma cases found the 5-year survival rate 69% in meningiomas.
The clinical functional ability or Kamofsky score of the CNS tumour 
patient is known to be a strong predictor of outcome in most of the studies 
(Mahaley et al., 1989; Shaw et al., 1994; Barker et al., 1996; Van Veelen et al., 
1998). In our study, the clinical condition occurred as a statistically significant 
prognostic factor in both the univariate and multivariate analyses.
Of course, appropriate therapies are among the main determinants of 
prognosis. The better outcome in socio-economically advanced societies is due 
to earlier diagnosis and the combined effect of more effective therapies inclu­
ding centralisation of treatment and dissemination of effective therapeutic 
protocols. Several authors have found the extent of surgical resection one of the 
most relevant factors affecting survival in both low-and high-grade gliomas 
(Piepmeier et al., 1996; Scerrati et al., 1996; Barker et al., 1996; Davies et a l ,  
1996). The majority of the reports confirm that combined treatment by surgery 
and irradiation may give a distinctly longer median survival time than treatment 
by surgery alone (Shaw et al., 1994; van Veelen et al., 1998). The favourable 
association of radiation dose and tumour grade with prolonged survival has 
been confirmed (Salcman et al., 1994; Salminen et al., 1996). In anaplastic 
glioma an adjuvant chemotherapy among patients < 55 years of age has been 
reported to increase survival markedly (Gundersen et al., 1998). In 
glioblastomas, no post-operative adjuvant therapy, whether radiation therapy or 
chemotherapy or a combination thereof, has appeared to be more effective than
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any other practice (Chandler et al., 1993; Gundersen et al., 1998). We didn't 
investigate the extent of surgical resection and recurrence rate. We suppose that, 
possibly in most cases, a gross total resection was used. Postoperative radiation 
therapy and adjuvant chemotherapy or a combination is, for certain reasons (e.g. 
the lack of defined treatment protocols and insufficient co-operation between 
surgeons and oncologists), not so widely used in Estonia (Table 18). Most 
patients (51%) received only surgical treatment, 33% of patients were operated 
followed by radiation. In both, univariate and multivariate analysis treatment 
was found to be a significant prognostic factor. Multivariate analysis revealed a 
small but significant difference between treatment strategies and outcome in 
gliomas. Our series suggest that in multivariate analysis age, patient clinical 
condition, tumour histology and treatment are independent prognostic factors 
for gliomas. Low-grade astrocytoma, oligodendroglioma and ependymoma 
patients, of a younger age, had better clinical condition when they underwent 
surgery with additional radiation therapy or surgery combined with radiation 
and chemotherapy and had the best prognosis. The worst prognosis was found 
in those patients who had received only symptomatic treatment.
Changes in survival rates
During the last decades, an overall slight increase in survival of malignant 
tumours for all patients has been found both in the European (EUROCARE) 
study (Sant et al., 1998) and the US study (SEER programme) (Davis et al., 
1998). Most improvement is confined to the first year after diagnosis. Age- 
specific rates show that the increase is more evident in younger patients, up to 
54 years of age. Concerning tumour histology the improvement is evident in 
medulloblastoma, in adults with astrocytoma and oligodendroglioma (Piepmeier 
et al., 1996). The survival improvements reflect improvements in the therapy 
and treatment, taking place at an earlier stage of disease, whereas the newer and 
better diagnostic techniques help in identifying tumours earlier.
In meningiomas, both short-term and long-term survival has improved 
during the last decades (Helseth, 1997). The improved 1-year survival is likely 
to be caused by improved operative technique and improved post-operative 
care. The increased long-term survival may reflect the likelihood that more 
patients with small meningiomas are diagnosed early since CT became 
available. In benign meningiomas, a small tumour size is one of the factors 
independently associated with increased survival time (McCarthy et al., 1998).
Our survey follows the example of above-mentioned studies and statistically 
significant improvements in 1-year survival rates were found for all tumours 
and low-grade astrocytoma comparing the first and the third time period. Age- 
specific rates showed that the increase was more evident between 45 and 64 
years. Decline in survival during the second period (1990-1993) is statistically 
significant for all tumours, but the most striking decrease took place in
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glioblastoma. This discrepancy may reflect the economic condition and 
reorganisation of the health care system at the beginning of the nineties. It was 
the period of extensive changes in Estonia, both in political and economical 
systems including that of health care. Delay at diagnosis, especially in rural 
areas where availability of medical care has not been so good, may also cause a 
poorer outcome during the second period. Older patients are rather diagnosed 
with dementia or vascular disease by family doctors than suspected of CNS 
tumours and are sent to the neurologist.
6 8
CONCLUSIONS
1. In the period 1986-1996, 1665 cases (739 males, 926 females) of primary 
CNS neoplasms were identified in the resident population of Estonia. 
Histological verification was available in 81% of cases. The most common 
histological types were glioblastoma (25%) and meningioma, low-grade 
astrocytoma (11%), anaplastic astrocytoma (6%) and neurinoma (6%). The 
distribution of pathologically confirmed cases according to histologic types 
in Estonia is in many respects similar to the distribution reported for other 
geographic regions.
2. Categories that influenced the occurrence of seizures in brain tumour 
patients were the duration of symptoms, tumour location and histology. 
Epileptic seizures occurred more frequently in those patients with long 
duration of symptoms (6 months and more) who were diagnosed of astro­
cytoma, anaplastic astrocytoma, some other glioma or meningioma. Focal 
delta activity in EEG may be of diagnostic value in case of brain tumours, 
but the use of EEG is debatable in localisation of an underlying neoplasm, 
especially when MRI and CT are available.
3. The age-specific incidence rate was much lower in childhood, increased 
from the age of thirty, reaching a maximum in the age-range of 50-69 years, 
and declined abruptly in the elderly. The pattern of age-specific incidence 
rate for glioblastoma and meningioma were similar increasing with age and 
reaching a maximum at the age of 60-69. Astrocytoma showed a small peak 
in childhood, a plateau in middle age and an increase between 50 and 70 
years.
4. The age-adjusted incidence of 8.46 per 100,000 population for all CNS 
tumours is comparable to the findings of surveys carried out in Iceland, 
Norway, Australia and Japan. It is higher than that reported from 
Washington DC, Wales, Netherlands and England and lower than that found 
in Israel, Finland, Minnesota, Italy and Scotland. The incidence of two main 
tumour types, gliomas and meningiomas, was 3.4 and 1.6, respectively 
which is comparable with most of the studies, but lower than in Finland, 
Italy and Scotland. Gliomas occurred more commonly in males, while 
meningiomas and tumours of cranial and spinal nerves were significantly 
more frequent in females as established in most other surveys.
5. A comparison of current incidence rates with those of a previous study 
carried out from 1951 to 1970 suggests that the increase in the incidence 
rates of intracranial tumours is histology-specific. A significant increase was 
observed in incidence rates for astrocytoma, glioblastoma and meningioma. 
Looking at age-specific incidence rates, a significant increase is evident 
across all age groups. The same tendency has been found in Denmark.
6. The overall 1-year survival was 59% ranging from 89%in pituitary adenoma 
to 28% in glioblastoma. Five-year survival rates were very poor in
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gliomastama (9%) and anaplastic astrocytoma (16%). In gliomas, patients of 
younger age had a very significantly better survival compared with the 
elderly. Comparing the first (1986-1989) and the third (1994-1996) time 
period, statistically significant improvements in survival for patients with 
astrocytoma and for all tumours has taken place. Age-specific rates showed 
that the increase in survival was more evident in older adults.
7. Compared with other studies, the outcome of CNS tumours in Estonia, 
especially in anaplastic astrocytoma, is somewhat worse.
8. In multivariate analysis, older age at diagnosis, patient clinical condition, 
tumour histology and period of diagnosis were independent prognostic 
factors for survival. Risk of death was more than eight times greater for 
glioblastoma, about seven times greater for anaplastic astrocytoma and more 
than five times greater for other gliomas compared with meningioma. The 
best prognosis was found in neurinoma, still having a significantly greater 
risk of death compared with meningioma. In glioma patients, the best 
prognosis had low-grade astrocytoma, oligodendroglioma and ependymoma 
patients of younger age, better clinical condition for those who underwent 
surgery with additional radiation therapy or surgery combined with radiation 
and chemotherapy.
9. Of the 1665 patients included in our study, 996 (60%) were identified in the 
Estonian Cancer Registry as having CNS tumours. Ninety eight per cent of 
malignant tumours were represented in the registry. Differences were 
revealed in the histological subgroups of gliomas: some types were over­
reported (oligodendroglioma, astrocytoma) or under-reported (glioblastoma). 
Since according to the ECR the proportion of meningiomas and neurinomas 
was very low, this means that the total incidence of CNS tumours is 
significantly underestimated. It is evident that the accuracy of registration of 
brain tumours in the ECR depends on tumour histology. Therefore there may 
be limitations in using the cancer registry to identify the incidence of 
primary brain tumours.
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SUMMARY IN ESTONIAN
KESKNÄRVISÜSTEEMI KASVAJATE EPIDEMIOLOOGIA
EESTIS 1986-1996: 
kliinik, haigestumus, elulemus, ja prognoos
Kesknärvisüsteemi kasvajate haigestumuse näitajad kõiguvad erinevates 
populatsioonides ja geograafilistes piirkondades küllalt suurtes piirides: 4-16 
100 000 inimaasta kohta (Schoenberg et al., 1976; Cole et al., 1989; Counsell 
et al., 1996; Surawicz et al., 1999; Kuratsu et al., 2001), Põhja Itaalias isegi 
kuni 25 (Cordera et al., 2002). Eesti Vähiregistri andmetel ei kuulu aju ja 
kesknärvisüsteemi kasvajad Eestis ei naiste ega meeste seas kümne sagedamini 
esineva vähipaikme hulka (Thomson et al., 1996; Aareleid ja  Mägi, 1999). 
Erandiks on alla kolmekümne aastaste vanuserühm, kellel on ajukasvajad 
sageduselt 2.-3. kohal. Suremuse statistikale toetudes on ajukasvajad vähkide 
seas Eestis 9.-10. kohal. Elulemus on pahaloomuliste ajukasvajate korral üht­
viisi madal kõikides uuringutes. Siiski on leitud, et alates 1970-ndatest aastatest, 
kui hakati laialdasemalt kasutama radio- ja kemoteraapiat, on elulemus mõnin­
gate harvem esinevate kasvajavormide (medulloblastoom) osas paranenud.
Eestis on haigestumust primaarsetesse intrakraniaalsetesse kasvajatesse 
uurinud Virve Lukas (1979), kelle andmetel oli vastav näitaja ajavahemikus 
1951-1969 5,9/100 000. Haigestumus näitas tõusutendentsi, olles esimesel 
kümnendil 5,0 ja  teisel kümnendil 6,7.
Uurimuse eesmärgid
1. Leida primaarsetesse KNS kasvajatesse haigestumus Eestis 1986-1996 ja 
võrrelda saadud tulemusi teiste uuringute andmetega
2. Analüüsida haigestumuse võimalikke muutusi võrreldes eelmise, 1951-1970 
aastal, Eestis läbiviidud uuringuga.
3. Analüüsida epileptiliste hoogudega patsientide kliinilisi ja morfoloogilisi 
andmeid
4. Välja selgitada KNS kasvajate elulemus, hinnata selle muutumist uuritavate 
aastate jooksul ning võrrelda saadud tulemusi teiste uuringute andmetega.
5. Leida patsientide prognoosi mõjutavad faktorid
6. Hinnata KNS kasvajate registreerimise kvaliteeti Eesti Vähiregistris
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Patsiendid ja meetodid
Registreeriti Eestis ajavahemikul 1986 kuni 1996 diagnoositud kesknärvisüs­
teemi kasvaja juhud. Retrospektiivselt vaadati läbi Tartu Ülikooli Närvikliiniku 
ja Tallinna Mustamäe Haigla neurokirurgia osakondade meditsiinilised 
dokumendid (vastuvõtu nimekirjad, komputeriseeritud andmebaasid, haigus­
lood, lahangu ning histoloogilise uuringu protokollid). Lisaandmeid koguti 
Eesti Vähiregistri andmebaasist kasutades elektroonset linkimist. Uuringusse 
kaasamise kriteeriumiteks oli histoloogiline diagnoos või kasvaja diagnoosi­
mine radioloogilis-kliiniliste meetoditega. Patsientide selektsioon toimus 
vastavalt Rahvusvahelisele Onkoloogiliste Haiguste klassifikatsiooni (ICD-O-2) 
topograafilistele koodidele (aju, ajukelmed, kraniaalnärvid, hüpofüüsi ning 
käbinäärme piirkond ja teised KNS osad). Registreeriti ka metastaatilised kasva­
jad, mida kasutati ainult epileptiliste krampide esinemissageduse analüüsis. 
Elulemuse analüüsist arvati välja lahangul diagnoositud haigusjuhud, ning 
juhud, kus eelnevalt või jälgimise käigus diagnoositi mõni teine pahaloomuline 
kasvaja. Kasvajate klassifitseerimine toimus vastavalt Maailma Tervishoiu­
organisatsiooni ajukasvajate histoloogilisele klassifikatsioonile (1993). Eba­
selged histoloogilised diagnoosid vaadati üle neuropatoloogi poolt. Patsientide 
jälgimine toimus kuni 1. jaanuarini 1998. aastal, glioomi diagnoosiga patsienti­
del kuni 1. jaanuarini 2000. aastal.
Arvutati standarditud haigestumuskordajad 100 000 inimaasta kohta erine­
vates histoloogilistes gruppides ja haigestumuse vanuskordajad. Standardimisel 
kasutati maailma ja  Eesti standardrahvastikku. Elulemuse analüüsil arvutati 
tegelik 1- ja 5-aasta elulemusmäär kasutades elutabeli meetodit. Prognostilised 
faktorid leiti hulgitunnusanalüüsil Coxi regressioonimudeli järgi. Uuringu läbi­
viimiseks saadi kinnitus Tartu Ülikooli Inimuuringute Eetika Komisjonilt.
Tulemused ja järeldused
Kokku registreeriti 1665 primaarse KNS kasvaja juhtu, neist 739 meestel ja 926 
naistel. Metastaatilisi ajukasvajaid esines 330 juhul, 220 mehel ja  110 naisel. 
Samal ajavahemikul registreeriti Eesti Vähiregistris 996 KNS kasvaja juhtu. 
Keskmine vanus kasvaja diagnoosimise ajal oli 47 aastat (meestel 45 ja naistel 
49). Kasvaja histoloogia tehti kindlaks 81%-1 patsientidest. Kõikidest juhtudest 
5.3% diagnoositi lahangul.
Kõige sagedasemateks histoloogilisteks tüüpideks oli glioblastoom (30% 
meestel ja  21% naistel) ning meningioom (13% meestel ja 33% naistel), järg­
nesid astrotsütoom ja neurinoom (vastavalt 11 ja 6%). Alla 20-aastastel esines 
kõige sagedamini astrotsütoomi (25%) ja medulloblastoomi (17%). Kesknärvi­
süsteemi kasvajate histoloogiline jaotuvus Eestis on üldjoontes võrreldav teistes 
sarnastes uuringutes tooduga. Oluliselt väiksem hüpofüüsi adenoomide hulk 
(2,6%) on seostatav nende madala histoloogilise tõestatusega (58%) meie
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uuringus. Kliinilis-radioloogiliselt diagnoositud hüpofüüsi piirkonna kasvaja 
juhtude liitmine histoloogiliselt tõestatud juhtudega suurendab hüpofüüsi 
piirkonna kasvajate hulka oluliselt.
Kahekümne kolmel protsendil patsientidest esines enne kasvaja diagnoosi­
mist vähemalt 1 epileptiline hoog. Epileptilise sündroomiga patsientidel esines 
histoloogilistest tüüpidest kõige sagedamini segatüüpi glioomi (62%), oligo- 
dendroglioomi (53%), anaplastilist astrotsütoomi (42%) ja diferentseerunud 
astrotsütoomi (42%). Keskmine aeg esimesest epileptilisest hoost kuni diag­
noosini oli 16 kuud. Seitsmekümne viiel protsendil epilepsiaga patsientidest oli 
krambihoog esmaseks haigus-sümptomiks ja 26%-l patsientidest ka ainsaks 
kaebuseks. Epileptiliste krampide teke oli seotud kasvaja histoloogia ja lokali­
satsiooniga. Sagedamini esines krampe kasvaja frontoparietaalse, fronto- 
temporaalse, parasagitaalse ja  temporaalse lokalisatsiooni korral. Kirjanduse 
andmeil on oluline ka kasvajat ümbritseva turse suurus ning ajukoore haaratus, 
kuid kuna tegemist oli retrospektiivse uuringuga ei olnud võimalik nimetatud 
parameetreid hinnata. Hulgitunnusanalüüs näitas, et epileptiliste hoogude teket 
mõjutavad oluliselt sümptomite kestus enne kasvaja diagnoosi, kasvaja asukoht 
ja histoloogia. Samaselt teiste uuringutega oli 41 %-l patsientidest EEG-uurin- 
guga võimalik lokaliseerida kasvaja asukoht.
Ajavahemikul 1986-1996 Eestis diagnoositud kesknärvisüsteemi kasvajate 
haigestumuskordaja oli 9,8/100 000, meestel 9,4 ja naistel 10,3. Samaselt teiste 
uuringutega esinesid neuroepiteliaalsed kasvajad ja glioomid sagedamini mees­
tel (meeste ja naiste suhe 1,2). Meningioomi ja neurinoomi diagnoositi sageda­
mini naistel (suhe vastavalt 0,4 ja  0,6).
Haigestumuse vanuskordaja oli kõige väiksem lastel (3,7/100 000), tõusis 
alates 30-ndast eluaastast jõudes kõrgeimale tasemele (20,6/100 000) 50-69- 
aastaste vanusgrupis ja  langes seejärel kiiresti vanemaealistel. Samaselt meie 
tulemustele leiab üks osa uurijaid, et vanemaealistel haigestumus langeb. Teised 
autorid väidavad, et 65-aastaste ja vanemate hulgas haigestumus pigem tõuseb 
ja seda just histoloogiliset healoomuliste meningioomide sageduse tõusu tõttu. 
Madalamate haigestumusnäitajate üheks põhjuseks on ebapiisav tähelepanu 
vanurite piltdiagnostilisele uurimisele, samuti lahangute väike arv.
Vanuse järgi standarditud haigestumuskordaja oli 8,5/100 000, glioomil 3,4 
ja meningioomil 1,6. Reeglina on haigestumus kõrgem sotsiaalmajanduslikult 
paremini arenenud piirkondades, kus on hea tehnilise varustusega (kom­
puutertomograafia, magnetresonantstomograafia) ja kättesaadav meditsiiniline 
abi, väljakujunenud ja korralikult töötav registerteenistus (vähiregistrid) ning 
suurem lahangute arv. Samuti mõjutab haigestumuse näitajaid läbiviidud 
epidemioloogiliste uuringute metoodika: sissearvamiskriteeriumid, haigusjuh­
tude arv ja  kogumisviis, kasutatavad klassifikatsioonid. Meie uuringu tulemused 
lubavad oletada, et suhteliselt madala haigestumuse põhjuseks Eestis on 
võimalik aladiagnoosimine, eriti vanemaealistel, kellel diagnoositakse pigem 
dementsust või vaskulaarse tekkepõhjusega haigust kui mõeldakse ajukasvaja 
peale. Samuti mõjutavad haigestumusnäitajaid väike lahangute arv ja eriti
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maapiirkondades piiratud uurimisvõimalused. Seitsekümmend protsenti lahan- 
gul diagnoositud juhtudest olid glioomid ja  ainult 8% meningioomid. Nimetatud 
suhe lubab oletada, et enamasti diagnoositi mõnda teist närvisüsteemi haigust 
ning juhuleidude hulk oli väike.
Uuringu tulemuste võrdlemisel Eestis aastatel 1951-1970 läbiviidud uuringu 
tulemustega selgus, et haigestumuse kasv oli erinevates histoloogilistes gruppi­
des erinev. Statistiliselt oluline haigestumuse suurenemine esines astrotsütoomi 
(suhteline risk RR=1,5), glioblastoomi (RR=1,5) ja meningioomi (RR=2,0) 
grupis. Haigestumuse vanuskordaja suurenes kõikides vanusrühmades, kõige 
enam aga laste, noorukite ja üle 50-aastaste vanusrühmas (suhteline risk üle 
1,5). Samane trend on iseloomulik ka teistes populatsioonides läbiviidud uurin­
gutele. Osaliselt on haigestumuse kasvu põhjuseks (eriti astrotsütoomide ja 
meningioomide korral) kindlasti diagnostika paranemine. Silmas pidades 
haigestumuse suurenemist kõikides vanusegruppides ja  maliigsete glioomide 
hulgas, ei saa eitada ka mõne teise etioloogilise faktori või keskkonna toimet.
Kesknärvisüsteemi kasvajate 1 aasta tegelik elulemusmäär oli 59% ja 5 aasta 
elulemusmäär 46%. Kõige parem elulemus oli hüpofüüsi adenoomiga ja 
meningioomiga patsientidel (1 aasta elulemusmäär vastavalt 89 ja 86%). Gli- 
oblastoomiga patsientide 1 aasta elulemus oli 28% ja 5 aasta elulemus 9%, 
anaplastilise astrotsütoomiga patsientidel vastavalt 36 ja 16%. Kõikides histo­
loogilistes gruppides sõltus elulemus patsientide vanusest: mida vanem oli 
patsient, seda halvem oli elulemus. Teiste riikidega võrreldes on Eestis 
elulemusnäitajad mõnevõrra halvemad, eriti anaplastiliste astrotsütoomide osas. 
Selle põhjuseks on ilmselt teatud probleemid histoloogilises diagnostikas, 
samuti puudujäägid onkoloogilises süsteemis ja  kindlate ravijuhiste puudumine. 
Enamusel (51%) glioomiga patsientidest rakendati ainult operatiivset ravi, 
ainult 40% patsientidest said kombineeritud ravi. Osad patsiendid “kadusid” 
teel neurokirurgi juurest oknoloogi juurde. Samuti puudub lõplik otsus selle 
suhtes, kelle järelvalve alla jäävad patsiendid peale operatsiooni ja adjuvantravi. 
Nimetatud probleemid on enam aktuaalsed maapiirkondades, kus arstiabi 
kättesaadavus on halvem kui linnades.
Hulgitunnusanalüüsil Coxi regressioonmudeli järgi, kus võeti arvesse 
patsientide soo, vanuse, operatsioonieelse seisundi, kasvaja diagnoosimise 
aasta, histoloogia ning lokalisatsiooni seoseid, olid patsiendi vanus, ope­
ratsioonieelne seisund ning kasvaja histoloogia oluliselt seotud prognoosiga.
Eesti Vähiregistrisse oli kantud 60% patsientidest: glioomidest 98%, 
meningioomidest 11% ja neurinoomidest 9%. Registreerimine oli histoloogi­
listes gruppides erinev: võrreldes käesoleva uuringuga oli ülehinnatud oligo- 
dendroglioomiga (124%) ning astrotsütoomiga (106%), alahinnatud gli- 
oblastoomiga (91%) ning lümfoomiga (70%) patsientide arv. Nimetatud lahkne­
vuse põhjuseks on ilmselt erinevate klassifikatsioonide kasutamine.
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Abstract
During the period from 1986 to 1996, 1,665 
cases of primary central nervous system 
(CNS) tumors were identified in the resident 
population of Estonia. Histological verifica­
tion was available in 81% of the cases. Glio­
mas were more common in men, while me­
ningiomas and neurinomas were more com­
mon in women. No significant difference was 
observed between the sexes for all primary 
CNS tumors. The age-specific incidence in­
creased from the age of 30, reached a maxi­
mum in the age range of 50-6S years and 
declined in the elderly which may reflect un­
der-diagnosis. The age-adjusted incidence 
rate for CN S tumors was 8.5/100,000 popula­
tion. A  comparison of our results with those 
of a previous study carried out in Estonia 
revealed a significant histology-specific in­
crease in incidence in all age groups.
Copyright 02000 S. Karger AG , Basel
Introduction
The incidence of primary central nervous 
system (CNS) neoplasms in a defined popula­
tion has been reported in a number of studies. 
It varies from 4.9 to 15.7/100,000/year, while 
higher rates are generally found in socioeco­
nomically advanced societies where medical 
care is both available and competent, and 
where better organized registries for data col­
lection and possibly higher autopsy rates ex­
ist. The observed differences in populations, 
races and sexes suggest the possible role of 
environmental, genetic and hormonal factors 
in the etiology of brain tumors [1]. Some 
investigators have reported that the frequency 
of primary brain tumors, especially in the 
elderly, has increased substantially during the 
past two decades [2, 3]. The results of a 
Rochester study, which had a very high autop­
sy rate, indicate that the increase in incidence 
is an artifact reflecting improvement in diag­
nostic technology and practice [4]. A previous 
study of primary intracranial neoplasms in 
Estonia, carried out from 1951 to 1970, estab-
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lished the crude rate of primary intracranial 
tumors as 5.9 (6.1 for men and 5.8 for women) 
per 100,000 population [5]. Recent data 
(1994-1996) reported by the Estonian Cancer 
Registry (ECR) show 6.2/100,000 for men 
and 5.6/100,000 for women [6] for brain and 
other CNS tumors. The ECR was founded in 
1978, but retrospective data are available that 
date back to 1968. The ECR includes data 
from all hospitals and laboratories in Estonia 
and death certificates from the Estonian State 
Statistical Office. Since meningiomas and 
other histologically benign brain tumors were 
not recorded until recently, the registry can be 
considered complete with regard to malignant 
brain tumors but incomplete for benign tu­
mors. Since 1998, the ECT includes informa­
tion on all primary brain tumors according to 
the World Health Organization classification 
of CNS tumors [7].
The aim of this study was to evaluate the 
epidemiological characteristics of primary 
brain tumors in Estonia during the period 
1986-1996. In Estonia the first CT scan was 
introduced in 1983. The results of the study 
were compared with those of investigations 
carried out in other populations and with data 
from the pre-CT diagnostic era (1951-1970) 
in Estonia with the aim to assess the changes 
in incidence rates in Estonia and the reporting 
of brain tumors in the ECR.
Patients and M ethods
The study was based on the Estonian population of 
1.5 million who are served by two neurosurgical cen­
ters (Tartu Maaijamõisa Hospital and Tallinn Musta­
mäe Hospital) which admit all patients suspected of 
having CNS tumors. To maximize case ascertainment 
we obtained material from several sources including 
hospital records (case histories, autopsy protocols, pa­
thology reports), the ECR and the Estonian State Sta­
tistical Office. The records of all intracranial and spi­
nal tumors (including suspicious cases and brain me- 
tastases) at these hospitals from 1986 to 1996 were
reviewed. The criteria for inclusion were either histo­
logical confirmation or verification of neoplasms by 
radiological or clinical methods. Data collected for 
each case included age, sex, histological type, diagnos­
tic methods and tumor location. Selection of patients 
was carried out according to the guidelines of the Inter­
national Classification of Diseases for Oncology (ICD- 
0-2) including the codes C70, C71, C72, C75.1, C75.2 
and C75.3. Tumors were classified according to the 
histopathological type of brain tumor following the 
scheme approved by the World Health Organization. 
All histologically obscure cases (with the majority of 
pathological material having been preserved) were ret­
rospectively overviewed by a neuropathologist. Meta­
static tumors, tumors of the skull and vascular malfor­
mations were excluded. Average annual incidence 
rates per 100,000 population for primary CNS neo­
plasms from 1986 to 1996 were computed. Annual 
age-specific and age-adjusted incidence rates were cal­
culated for all CNS tumors and for each type separate­
ly. Population figures were obtained from the annual 
publications of the Statistical Office of Estonia for each 
year between 1986 and 1996. Age adjustment was per­
formed by direct standardization according to the 
World Standard Population and the Estonian Stan­
dard Population. The 95% confidence intervals (95% 
Cl) for incidence rates were estimated assuming a 
Poisson distribution for the studied cases. The differ­
ence in incidence between the CT and pre-CT eras was 
expressed as the incidence rate ratio and with 95% Cl.
A previous study of CNS tumors in Estonia was 
carried out from 1951 to 1970; however, it included 
only primary intracranial tumors. It was a retro­
spective, population-based epidemiological survey us­
ing histological classifications proposed by Smirnov 
and Hominski [5].
Results
General Characteristics 
In the period 1986-1996, 1,665 cases (739 
men, 926 women) of primary CNS neoplasms 
were identified in the resident population of 
Estonia. During the same period, 996 patients 
(179 without histological confirmation) were 
identified in the ECR. The mean age at diag­
nosis was 47 years (45 for men and 49 for 
women), and the median age was 52 years (52 
for men and 50 for women; range: 1 month to
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Table  1. Histological 
confirmation (%) according to 
tumor location (n = l ,665)
Tumor location All cases Histologically 
confirmed cases
n %
Supratentorial
Cerebral hemispheres 803 693 86.3
Central structures 63 39 61.9
Pituitary or pineal region 121 70 57.8
Other 162 138 85.2
Infratentorial 323 255 79.0
Intracranial, not localized 55 33 60.0
Spinal 138 117 84.8
Total 1,665 1,345 80.8
Table 2. Frequency of diagnostic methods before his­
tological confirmation to verify brain tumors (n = 
1,665)
Method Cases
n %
CT 1,085 65.2
MRI 176 10.6
Autopsy 88 5.3
Myelography 81 4.9
Angiography 67 4.0
Clinical examination 35 2.1
Ventriculography 13 0.8
X-rays 11 0.7
Histology 4 0.2
Pneumoencephalography 6 0.4
No diagnostic method recorded 99 5.9
85 years). Histological verification was avail­
able in 1,346 (80.8%) cases. This percentage 
varied depending on the tumor site, being 
lower (58%) in pituitary region tumors and 
higher in tumors of the cerebral hemisphere 
and tumors of spinal location (86 and 85%, 
respectively). Histological confirmation ac­
cording to tumor location is shown in table 1. 
Before histological confirmation, the majority
(76%) of tumors were diagnosed by CT or 
MRI (table 2). Taking into account the low 
proportion of autopsies in Estonia, a remark­
able number of tumors (5.3%) were diagnosed 
at autopsy, including both incidental findings 
and misdiagnosed cases. Forty-three percent 
of cases diagnosed post mortem were identi­
fied as glioblastoms, 19% were astrocytomas 
and only 8% were meningiomas.
Table 3 illustrates the distribution of histo­
logically confirmed cases of neoplasms ac­
cording to sex and average age at diagnosis. 
The most common histological type was glio­
blastoma, which accounted for 29.9% of all 
brain tumors among men and 21.2% among 
women, and meningioma (including both spi­
nal and intracranial), which accounted for 
13.1 and 32.8% of cases in men and women, 
respectively. Fourteen percent (47 cases) of 
meningiomas were spinal. The other two most 
common major histological groups were as­
trocytoma (12.5% in men, 10.1% in women) 
and neurinoma (5% in men and 7% in wom­
en). Among patients under 20 years of age, the 
most frequent were astrocytoma (25%), me­
dulloblastoma (17%), ependymoma and glio­
blastoma (both 6%). Forty-two cases (22%) 
were not histologically confirmed.
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Table 3 . Distribution o f pathologically confirmed brain tumors (n -  1,346) by histological 
diagnosis, sex and mean age o f patients (Estonia 1986-1996)
Tumor type Cases Mean age 
at diagnosis 
yearsmen women total
Neuroepithelial tumors
Astrocytoma (С|_г) 73(12.5) 77(10.1) 150(11.2) 36.4
Anaplastic astrocytoma 35 (6.0) 44(5.8) 79(5.9) 48.7
Glioblastoma 174(29.9) 162(21.2) 336 (25.0) 53.4
Oligodendroglioma 25 (4.3) 17(2.2) 42(3 .1) 44.0
Ependymoma 24 (4.1) 13(1.7) 37 (2.8) 34.5
Mixed glioma 10(1.7) 13(1.7) 23(1.7) 46.6
Pineal tumors 4(0 .7) - 4 (0.3) 39.8
Medulloblastoma 23(4.0) 19(2.5) 42(3.1) 14.8
Tumors o f  cranial and spinal nerves
Neurinoma 29(5.0) 53(7.0) 82(6.1) 47.8
Neurofibroma 2(0.3) 7 (0.9) 9 (0.7) 38.9
Meningeal tumors
Meningioma 76(13.1) 250(32.8) 326(24.2) 54.6
Anaplastic meningioma 5 (0.9) 13(1.7) 18(1.3) 56.5
Hemangioblastoma 8(1-4) 14(1.8) 22(1.6) 48.4
Malignant lymphomas 12(2.1) 8 (0.9) 20(1.5) 49.8
Germ cell tumors 4(0 .7) 2(0.3) 6(0 .5) 33.7
Sellar region tumors
Pituitary adenoma 16(2.6) 20 (2.6) 35 (2.6) 48.7
Craniopharyngioma 8(1.4) 6 (0 .8) 14(1.0) 30.1
Other, specified 55(9.5) 45(5.9) 100(7.4) 40.7
Total specified 583(100) 763(100) 1,346(100) 47.4
Figures in parentheses indicate percentages.
Incidence Rates
The average annual incidence rate for all 
primary CNS neoplasms was 9.8/100,000/ 
year (9.0 for intracranial tumors and 0.8 for 
intraspinal tumors). The age-specific inci­
dence rate of intracranial tumors was much 
lower in childhood (3.7), increased in the 30- 
to 39-year age group (6.5), reached a maxi­
mum in the age range of 50-69 years (20.6) 
and then declined abruptly in the elderly 
(7.6; fig. 1). Intraspinal neoplasms revealed a 
steady increase in incidence up to the age of 
60-69 years. Age-specific incidence rates for
glioblastoma, astrocytoma, meningioma and 
tumors without microscopic confirmation, in­
cluding both intracranial and intraspinal 
cases, are shown in figure 2. Some variations 
of the curves of individual histological types 
of brain tumors are noteworthy. Specifically, 
the annual incidence rate of astrocytoma 
showed a small peak in childhood (1.0) and a 
plateau in the age range from 30 to 49 years, 
then increased in the 50- to 69-year age group 
(2.4) and fell significantly in those aged 70 
and older. The age-specific incidence rate for 
glioblastoma increased with age, reaching a
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Fig. 1. Age-specific incidence rates 
for intracranial and intraspinal tu­
mors and for all brain tumors in 
Estonia (1986-1996).
Age (years)
Fig. 2 . Average annual age-spe­
cific incidence rates for astrocy­
toma, glioblastoma, and meningio­
ma cases in Estonia 1986-1996.
Age (years)
maximum of 6.1 at the age of 60-69 and 
declined in the elderly. Meningioma had a 
similar pattern with a peak incidence of 6.1 in 
the age range from 60 to 69 years.
There were no statistically significant dif­
ferences between the sexes either in the total 
incidence of tumors or in the incidence of
astrocytomas and glioblastomas (table 4). 
However, neuroepithelial tumors (p < 0.01) 
and gliomas (p < 0.05) were more common in 
men (male/female ratio 1.2), while meningio­
mas and tumors of cranial and spinal nerves 
(including neurinomas) were significantly 
more frequent (p = 0.001 and <0.005, respec­
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Table 4 . Incidence rates (per 100,000 population) by histological types and male/female ratio for primary brain 
tumors in Estonia (1986-1996)
Tumor type Crude rate 
men women
Male/female
ratio
Neuroepithelial tumors 4.90 (4.41-5.39) 4.01 (3.60-4.42) 1.22**
All gliomas 4.32(3 .86-4 .78) 3 .60(3 .21-3 .99) 1.2*
Astrocytoma 1.37(1.11-1.63) 1 .34(1.10-1.58) 1.02
Glioblastoma 2.20(1 .87-2 .48) 1 .79(1.51-2.07) 1.23
Oligodendroglioma 0.32 (0.20-0.44) 0 .19(0 .10-0 .28) 1.68
Ependymoma 0.30 (0.18-0.42) 0 .14(0 .06-0 .22) 2.14*
Mixed glioma 0.13(0 .05-0 .21) 0 .14(0 .06-0 .22) 0.93
Medulloblastoma 0.29(0 .17-0 .41) 0.21 (0.11-0.31) 1.38
Tumors o f cranial and spinal nerves 0.39 (0.25-0.53) 0.66 (0.49-0.83) 0.59*
Neurinoma 0.37 (0.24-0.50) 0 .59(0 .43-0 .75) 0.63*
Meningeal tumors 1.46(1.19-1.72) 3 .32(2 .94-3 .70) 0.47***
Meningioma 0.96(0 .74-1 .18) 2 .77(2 .43-3 .11) 0.35***
Hemangioblastoma 0.10(0 .03-0 .17) 0 .16(0 .08-0 .24) 0.63
Malignant lymphomas 0.15(0 .06-0 .24) 0.09 (0.03-0.15) 1.67
Sellar region tumors 
Pituitary adenoma1 0.42 (0.28-0.56) 0.44 (0.30-0.58) 0.96
Craniopharyngioma 0.10(0 .03-0 .17) 0.07 (0.02-0.12) 1.43
N o histological confirmation 1.98(1.67-2.29) 1 .80(1.52-2.08) 1.10
Intracranial tumors 8 .62(7 .97-9 .27) 9 .37(8 .74-10.00) 0.92
Spinal tumors 0.73 (0.54-0.92) 0.89 (0.70-1.08) 0.82
All tumors 9.36(8 .68-10.04) 10.25(9.59-10.91) 0.91
* p < 0 .0 5 , ** p <  0.01, *** p <  0.001. Figures in parentheses indicate 95% Cl.
1 Includes 38 unconfirmed cases o f pituitary tumors diagnosed clinically as adenomas.
tively) in women (male/female ratios 0.35 and 
0.59, respectively).
Average annual age-adjusted incidence 
rates for various histological types of prima­
ry brain tumors in Estonia are shown in 
table 5. The age-adjusted incidence was 3.41 
for gliomas, 1.63 for meningiomas and 8.46 
for all primary brain tumors. Among gliomas 
the most common types were glioblastoma 
and astrocytoma (incidence rates of 1.58 and 
1.27, respectively), oligodendroglioma and 
ependymoma being less frequent (incidence 
rate of 0.22 for both). The incidence rate for 
cases without microscopic confirmation was 
1.63.
A comparison of current rates with those of 
a previous study carried out from 1951 to 
1970 suggests that the increase in the inci­
dence rates of intracranial tumors is histology 
specific (table 6). A significant increase was 
observed in incidence rates for astrocytoma, 
glioblastoma and meningioma (incidence rate 
ratios of 1.49, 1.50 and 1.97, respectively; p = 
0.001). For age-specific incidence rates, a sig­
nificant increase is evident across all age 
groups (table 7), with the increase being most 
apparent in children, adolescents and age 
groups over 50 (incidence rate ratio over 1.5).
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Table 5 . Age-adjusted incidence rates (ASIR) per 
100,000 population for brain tumors by histological 
types in Estonia 1986-1996
Tumor type ASIR
Astrocytoma 1.27(1.10-1.44)
Glioblastoma 1.58(1.39-1.77)
Oligodendroglioma 0.22(0 .15-0 .29)
Ependymoma 0.22(0 .15-0 .29)
Mixed glioma 0.11 (0.06-0.16)
All gliomas 3.41 (3.13-3.69)
Medulloblastoma 0.32(0 .23-0 .41)
Neurinoma 0.40 (0.30-0.50)
Meningioma 1.63(1.44-1.82)
Pituitary adenoma1 0.36 (0.27-0.45)
Other specified 0.96 (0.81-1.11)
No microscopic confirmation 1.63(1.44-1.82)
All tumors 8.46 (8.02-8.90)
Rates are age-adjusted to the World Standard Pop­
ulation. Figures in parentheses indicate 95% Cl.
1 Includes 38 unconfirmed cases o f pituitary tumors 
diagnosed clinically as adenomas.
Discussion
According to the epidemiological literature 
[8-15] incidence rates for primary CNS tu­
mors vary greatly (from 4.9 to 15.7/100,000/ 
year, and in Northern Italy 26). This vast 
range may be explained by differences in 
inclusion criteria and classification, methods 
of case ascertainment and the number of pa­
tients included, rather than on real variations 
of incidence in different geographical areas 
and populations. While most authors agree 
that incidence rates are influenced by avail­
ability of competent medical care, frequency 
of autopsy, cancer registration level and im­
provement of brain imaging techniques (CT, 
MRI) [ 1, 14], a study of the incidence patterns 
of nervous system tumors in adults still shows 
a remarkably consistent dependence on age 
and race as well as on the sex ratio in different
population groups [16]. Proceeding from the 
above evidence, it appears necessary to carry 
out epidemiological studies based both on as 
complete a case ascertainment as possible as 
well as on clearly defined criteria for different 
populations and geographical regions.
This study was conducted on the Estonian 
population of approximately 1.5 million dur­
ing 11 years (1986-1996), and although we 
attempted to achieve maximal case ascertain­
ment by using several sources, it must be 
noted that some cases were most likely 
missed.
The distribution of pathologically con­
firmed cases according to histological types in 
Estonia is in many respects similar to the dis­
tribution reported for other geographic re­
gions [15, 17, 18]. In our study gliomas com­
prised 50% (including glioblastomas 25%, as­
trocytomas 17%), meningiomas 24% and 
neurinomas 6% of all CNS tumors. A recent 
US study [19] based on the National Cancer 
Data Base shows approximately the same dis­
tribution of astrocytoma (18.7%) and glio­
blastoma (29.6%), with a lower occurrence of 
meningioma (14.3%) and neurinoma (2.5%). 
The authors suggest that tumors of benign his­
tologies are underrepresented in the National 
Cancer Data Base because of insufficient 
diagnostic accuracy and quality of data cod­
ing and entry in some institutions. Some stud­
ies [9, 14,20] have revealed a lower frequency 
for gliomas (28-38%) and a higher frequency 
for meningiomas (35-37%). We found that 
pituitary adenomas accounted for only 2.6% 
of cases, which is lower than figures in other 
studies where they accounted for 6-14% [8, 9, 
21]. The observed difference may be partly 
due to low histological confirmation (58%), 
since inclusion of patients with clinically 
identified adenoma would increase the figure 
up to 5.4%.
All studies have confirmed that the inci­
dence of primary tumors, especially neuroepi-
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T able 6 . Changing incidencc rates (IR) over time for primary intracranial tumors in Estonia during 1951-1970  
and 1986-1996
Tumor type 1951 -1970 1986- 1996 Incidence rate p value
intracranial tumors intracranial tumors ratio
n IR n IR
Astrocytoma 128 0.51 150 0.76 1.49(1.18-1.89) 0.001
Anaplastic astrocytoma 61 0.25 78 0.46 1.84(1.32-2.57) 0.001
Glioblastoma 313 1.30 336 1.95 1.50(1.29-1.75) 0.001
Oligodendroglioma 45 0.18 42 0.25 1.39(0.91-2.12) 0.125
Ependymoma 34 0.14 24 0.15 1.07 (0.64-1.80) 0.789
All gliomas 678 2.77 651 3.81 1.38(1.24-1.54) 0.001
Medulloblastoma 45 0.18 42 0.26 1.44 (0.95-2.19) 0.083
Neurinoma 76 0.31 59 0.35 1.13(0.76-1.65) 0.478
Meningioma 214 0.87 297 1.71 1.97(1.65-2.35) 0.001
Pituitary adenoma 86 0.35 73 0.43 1.23(0.90-1.68) 0.195
N o histological confirmation 229 0.89 299 1.75 1.97(1.66-2.34) 0.001
All types 1,454 5.91 1.527 8.93 1.51 (1.41-1.62) 0.001
Rates are age-adjusted to the Estonian Standard Population (1989 census). Figures in parentheses indicate 
95% Cl.
Table 7. Changing age-specific incidence rates per 100,000 population of intracranial tumors 
in Estonia 1951-1970 and 1986-1996
Age 1951- 1970 1986- 1996 Incidence rate
years
cases age-specific
incidence
cases age-specific
incidencc
ratio
0-9 95 2.5 96 3.9 1.6(1.2-2.1 )*
10-19 74 2.2 83 3.5 1.6(1.2-2 .2)**
20-29 119 3.0 97 4.1 1.4(1.1-1.8)*
30-39 204 5.2 164 6.5 1.3 (1.0-1.5)*
40-49 277 8.5 241 11.3 1.3 (1 .1-1.6)**
50-59 340 12.5 422 20.6 1.7 (1.4-1.9)**
60-69 270 12.3 322 19.7 1.6 (1.4-1.9)**
> 7 0 75 4.4 100 7.6 1.7 (1.3-2.3)**
Total 1,454 5.9 (5 .91) 1,525 9 .0 (8 .91) 1.5 (1.4-1.6)**
* p <  0.005, ** p < 0 .0 0 1. Figures in parentheses indicate 95% Cl.
1 Rates were age-adjusted to the Estonian Standard Population (1989 ccnsus).
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thelial and meningeal tumors, increases with 
age up to 65 or 70 years [22]. Data concerning 
the age-specific incidence rate in the elderly 
are controversial. Several studies [9, 14, 15, 
21] have found that maximum incidence oc­
curs in the oldest age group. In a Japanese 
study [23] of 271 intracranial tumors in el­
derly people, the incidence rate was 18.1/ 
100,000/year which was significantly higher 
than in other age groups, meningioma being 
the most common type (50.6%). Other studies 
[11,12, 24,25] as well as the present research 
reveal an increasing incidence from the age of
30, reaching a maximum in the age range of 
50-69 years, and a decline in the elderly, with 
gliomas as the most frequent type [2, 4]. The 
latter trend seems to be an artifact of under­
diagnosis influenced by autopsy rates [ 14,15], 
less investigation and diagnostic bias (stroke 
or dementia being diagnosed more readily 
than tumor) [8] rather than a real decrease. 
Helseth [26], suggests that completeness of 
diagnosis, particularly in the case of the elder­
ly, depends both on autopsy rate and use of 
imaging techniques. Still, like some other au­
thors [25], we do not believe that the decline 
in brain tumors in the elderly is explainable 
mainly as the result of underdiagnosis. Meta­
analysis has confirmed that significant differ­
ences exist in the incidence of neuroepithelial, 
meningeal and cranial nerve tumors between 
men and women, and these cannot be ex­
plained by age differences [22]. Some authors 
have found a higher incidence of primary 
CNS tumors among men [25]. Percy et al. [14] 
showed that women have meningiomas more 
frequently, whereas gliomas and most other 
neoplasms occur at an equal rate in both 
sexes. In a study carried out in Central Fin­
land, meningiomas were shown to be 8 times 
more frequent in women than in men [11]. 
Our data reveal no significant differences be­
tween men and women in the overall inci­
dence of primary CNS tumors. Regarding the
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incidence rate according to histological types, 
gliomas were more common in men (with no 
significant difference when astrocytoma and 
glioblastoma were treated separately), while 
meningiomas and tumors of cranial and spi­
nal nerves were more predominant in women 
as established in most other surveys [12, 17, 
27,28].
Spinal tumors constituted 8.3% of all pri­
mary tumors with an incidence rate of 0.8/ 
100,000, which is lower than that presented in 
the Rochester, Finnish and Icelandic studies 
[11, 14, 21] and higher than that reported 
from South East Wales [17]. Spinal tumors 
show an age-dependent increase in all sur­
veys.
The age-adjusted incidence of 8.46/ 
100,000 for all CNS tumors is comparable to 
the findings of surveys carried out in Norway, 
Iceland and Victoria (Australia). This is high­
er than that reported from the eastern Nether­
lands, southern England (children were ex­
cluded) and Washington, D.C., and lower 
than that found in Finland, Rochester, Minn., 
and the Lothian region of Scotland [8,13, 15,
21, 25, 27, 29]. The incidence of two main 
tumor types, gliomas and meningiomas, was 
3.4 and 1.6, respectively. Generally, the inci­
dence of gliomas is about twice as high as that 
of meningiomas (except in Norway where the 
incidence ratio of gliomas to meningiomas 
was 4:1), with higher incidences found in 
studies where the incidence of all brain tu­
mors was higher as well. We surmise that a 
low autopsy rate and a lower overall incidence 
of CNS tumors in the elderly, influenced by 
less investigation and diagnostic bias, account 
for the overall lower incidence of brain tu­
mors in Estonia.
Cancer Registration
The incidence rates of primary CNS tu­
mors are higher in our study compared with 
the figures reported by the ECR. Until recent­
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ly the ECR has recorded only histologically 
malignant brain tumors excluding meningio­
mas, neurinomas, pituitary and other benign 
tumors. The traditional distinction with re­
spect to malignancy is clinically not specific to 
brain tumors as benign tumors of intracranial 
location may have as poor a prognosis as 
malignant tumors. Of the 1,665 patients in­
cluded in our study, 996 (60%) were identi­
fied in the ECR as having CNS tumors. Since 
most gliomas are considered malignant, 98% 
of them were found in the registry. Differ­
ences were revealed in the histological sub­
groups of gliomas: some types were overre­
ported (oligodendroglioma 124%, astrocyto­
ma 106%) or underreported (glioblastoma 
91 %), which was probably caused by classifi­
cation errors and can be solved by collabora­
tion between clinicians, pathologists and the 
cancer registry personnel [10]. Since accord­
ing to the ECR the proportion of meningio­
mas and neurinomas was very low (11 and 
9%, respectively), this means that the total 
incidence of CNS tumors is significantly un­
derestimated. We compared our data with 
those reported from Scotland (50% of all pri­
mary tumors and 85% of malignant tumors 
identified in the Scottish Cancer Registry) 
[30] and Norway (errors in overall incidence 
rates and for main tumor groups accounting 
for 0.3% of the total) [31]. It becomes evident 
that the accuracy of registration is different; 
therefore, there may be limitations in using a 
cancer registry to identify incidence of prima­
ry brain tumors.
Changes in Incidence Rates
Comparison of current rates with those of 
the 1951-1970 study carried out in Estonia as 
well as with those of other studies [3, 32] sug­
gests that the increase in the incidence rates of 
intracranial tumors is histology specific. A sig­
nificant increase was observed in incidence 
rates for astrocytoma, glioblastoma and me­
ningioma. In meningiomas and partly also in 
low-grade astrocytomas, these data support 
the argument that the increase in rates may be 
due to the fact that some tumors that pre­
viously went undetected are now diagnosed 
[26]. It is also important to note that the use of 
different histological classifications cannot be 
disregarded either. Glioblastoma generally 
presents easily recognizable symptoms which 
makes diagnosis less dependent on imaging 
technology. In his series Helseth [33] revealed 
a higher increase in incidence for meningioma 
than for glioma, while a Connecticut study 
[10] established a higher increase for astrocy­
toma, meningioma and ependymoma. Analy­
sis of the data of the US Surveillance, Epide­
miology and End Results Program [34] 
showed a statistically significant increase only 
for lymphoma in men. In Estonia, 59% (126 
cases) of meningiomas were diagnosed at au­
topsy (with an autopsy rate of 30%) from 
1951 to 1970, i.e. in the period before dramat­
ic changes in diagnostic technology had taken 
place. In our study, most cases (70%) diag­
nosed post mortem were identified as gliomas 
and only 8% (7 cases) were meningiomas (at 
the same time the autopsy rate has decreased). 
Evidently, most of these tumors had been 
misdiagnosed like other CNS diseases, and 
only a small part were incidental findings. 
Taking into account the low proportion of 
autopsies in Estonia, silent tumors are likely 
to be underestimated. Comparing the age-spe­
cific incidence rates of our study with those of 
a previous Estonian study, a significant in­
crease is evident in all age groups, whereas 
studies performed in Norway [12], Connecti­
cut [35] and France [36] revealed a significant 
increase only in the over 60 age group. This 
suggests that some of the increase can be 
accounted for by recent medical interest in 
and better understanding of neurological dis­
orders in the elderly, as well as by improve­
ment in diagnostic procedures. Desmeules et
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al. [37] have demonstrated that new imaging 
technology is responsible for detection of 
about 20% of brain tumors in both younger 
and older patients. Proceeding from our data, 
one cannot exclude that some part of the 
increased incidence in all ages and in some 
histological types (glioblastoma) is the conse­
quence of environmental effects or some etio­
logical factors. The increase across all age 
groups suggests a real increase in parallel with 
the increase related to more effective detec­
tion owing to improved case ascertainment 
with new imaging technology. However, fur­
ther studies are required to define whether
this increase is real and continuous in Estonia. 
For the sake of better comparability of data, 
we agree with Counsell and Grant [22] who 
suggest the use of unified methodology and 
who have worked out provisional guidelines 
for further research into the incidence of pri­
mary brain tumors.
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Abstract
The aim of this study was to analyze the clinical data of 
patients with epileptic seizures and diagnosed brain 
tumors. Analysis included 711 patients with primary and 
secondary brain tumors. 165 (23%) patients had experi­
enced at least one seizure before tumor diagnosis. The 
mean time from the first epileptic seizure to tumor diag­
nosis was 16 months. The patient's age, location and 
pathology of tumor were associated with occurrence of 
seizures. Seizures were more common in patients aged 
30-50 years. Tumors involving the frontal, frontoparietal, 
temporal and frontotemporal lobes were associated with 
occurrence of seizures. According to the histological 
diagnosis, patients with mixed gliomas (62%), oligoden­
drogliomas (53%) and astrocytomas (42%) experienced 
seizures most frequently.
C opyrigh t С  2001 S . K arger AG, Basel
Introduction
The incidence of epilepsy in patients with brain tumors 
is approximately 30% [ 1 ]. Patients w ith  slowly growing 
chronic lesions are more likely to h a v e  a  seizure disorder, 
with an incidence as high as 75% [1]. Le Blanc and Ras­
mussen [2] found the highest seizure incidences in pa­
tients with oligodendrogliomas (92%), astrocytomas 
(70%), meningiomas (67%) and glioblastomas (37%). Ac­
cording to reported data, seizures as th e  first manifesta­
tion of brain tumors are very variable (11-50%) [2, 3]. 
The aim of our study was to analyze th e  clinical data of 
patients with epileptic seizures and diagnosed brain tu­
mors.
Patients and Methods
We analyzed retrospectively 721 patients with primary and sec­
ondary intracranial brain tumors diagnosed between 1991 and 1995, 
in Estonia. Data were collected from the medical records o f the neu­
rosurgical departments o f  Tartu Maarjamõisa Hospital and Tallinn 
M ustamäe Hospital (the only two specialized neurosurgical depart­
ments in Estonia). Additional material was obtained from the Eston­
ian Cancer Registry (founded in 1978). The medical records were 
reviewed for the following information: patient gender, age at diag­
nosis, nature and duration of signs and symptoms (e.g. tim e o f the 
first seizure and the first symptom), histology, grade and location of
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ihe tum or. Л sign o r a sym ptom  was recorded if any phssician 
described ils prcscnce. As clinical da ta  varied in quality  and q uan ti­
ty. they were grouped in the  sim plest way: headache, papilledem a, 
neurological deficit and m enial disturbances. Seizure types were clas­
sified as sim ple o r com plex partial, secondarily generalized and 
unclassified (seizures were not described adequately  to  be classified 
according to the guidelines o f  the In ternational League against Epi­
lepsy) [4]. Inform ation  on tu m o r location was ob tained  from  C T  or 
M R T  and from  surgery reports. T u m o r location was analyzed by 
ind ividual sites and  as supra- and infra ten toria l.
Сla m fica tto n  o f  Tum ors
Histological classification was draw n up  using the histological 
classification o f  brain  tum ors approved by the  W orld H ealth  O rgani­
zation (W H O ) [5]. P atien ts were analyzed for tu m o r pathology and 
grade according to indiv idual W H O  histological diagnosis as well as 
groups. T he following categories were used: low-grade astrocytom a, 
anaplastic astrocytom a, glioblastom a and o ther gliomas: m eningio­
m a: o ther prim ary  brain  tum ors; m etasta tic  tum ors: cases w ithout a 
m icroscopically confirm ed diagnosis.
M ultivariab le  analysis was used to identify  the factors that asso­
ciate w ith seizures. T he tested categories were patien t age at diagno­
sis, gender, tu m o r histology as well as anatom ical location o f lum or 
and duration  o f  sym ptom s, y} and F isher's exact tests were used in 
com parisons involving category variables, and  the W ilcoxon rank- 
sum  test was em ployed for con tinuous variables. All analyses were 
perform ed by using a PC. SAS Version 6.12 (SAS Institu te . Cary, 
N.C., USA).
R esults
General
We analyzed 721 patients with diagnosed brain tu­
mors. Out of these, 711 patients remained in the study 
group, while 10 patients were excluded because o f incom­
plete data. 71% of tumors were revealed by CT and 14% 
were revealed by MR1 scans. 165 (23.2%) patients experi­
enced at least one seizure before their tumor diagnosis, 
546 patients had no history of seizures. The mean age in 
the seizure group was 47.4 years (95% Cl 45.0-49.8 years) 
ranging from 2 to 83 years, in the seizure-free group 49.2 
years (95% Cl 47.4-50.1 years) ranging from 1 to 87 
years. Age was associated (p <  0.05) with the presence of 
seizures. The occurrence of seizures was remarkably high­
er in the 30- to 39-year (p < 0.005) and 40- to 49-vear (p =
0.001) age groups (table 1). The male-to-female ratio was 
1:1.04 in the seizure group and 1:1.2 in patients without 
seizures. Gender was not associated with occurrence of 
seizures.
Presentation and Duration
Epileptic seizures were the single presenting symptom 
at diagnosis in 44 and the first manifestation in 123 
patients; 121 patients presented simultaneously seizures
Table  1. Incidence o f seizures and pa tien ts’ ages (n -  7 1))
Age All P a tien ts w ith seizures
p atien ts n %
0 -9  vears 37 5 13.5
10 - 19 vears 31 4 12.9
20-29  vears 36 I0 27.8
30-39 vears 70 26 37. I*
40-49  vears 123 43 35.0»*
50-59  vears 196 39 19.9
60 -6 9  vears 170 30 17.7
> 70 years 48 8 16.7
Toial 7 11 165 23.2
* p = 0.004. ** p  = 0 .0 0 l.
T ab le  2 . Clinical characteristics o f  seizures (22.9%  o f  ali patients)
Seizures n Patients with 
seizures 
(n = 165), 9b
Of all 
patients 
(n = 721), %
As the first m anifestation 123 74.6 17.1
As the single presentation 44 26.7 6.1
At diagnosis 35 21.2 4.9
One seizure 22 13.3 3.1
Recurrent ( > 2  seizures) 95 57.6 13.2
T a b le  3 . Presenting signs and  sym ptom s (n = 711)
O ther sym ptoms W ithout seizures W ith seizures
(n = 546) (n = 165)
Headache 367 58”
Papilledem a 141 31
Neurological dcficit 429 9 2 «
Mental disturbances 126 25*
* p <  0.05. ** p = 0.001. Seizures w ith o ther sym ptoms: n = 12 1. 
Patients could have m ore than one sym ptom .
and some other sign or symptom (table 2). Patients with 
seizures showed a significantly lower incidence of neuro­
logical deficit, headache (p = 0 .001) and mental distur­
bances (p < 0.05) compared with seizure-free patients (ta­
ble 3). We found no association between occurrence of 
epileptic seizures and increased intracranial pressure. In
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Tab le  4 . Tum or pathology and  occurrcncc o f  sci/.ures (n = "I I) Table 6 . Tumor location and the in cid en ceo f se izu res(n  = 711)
Patien ts W ith seizures 
n %
Low-grade astrocytom a 53 n 41.5***
Anaplastic astrocytom a 30 13 43.3**
Glioblastoma 106 27
Ol igodcndrogl ioma 19 10 52.6**
Ependymoma 8 2 25
Mixed glioma 8 5 62.5*
M edulloblastoma 15 0 0
Schwannoma 27 0 0
Meningioma 124 47 37.9***
Anaplastic meningioma 8 1 12.5
Hemangioblastoma 7 0 0
Lymphoma 6 1 16.7
M etastatic tum or 105 16 15.2*
Without histology 138 17 12 3***
The pathology o f  59 tu m o r patien ts with very low incidence (<5) 
is not given.
* p <  0.05, ** p <  0.005. *** p <  0 .0 0 1.
loca tion Patien ts W ith seizures
n %
Frontal lobe only 83 32 38.5***
Frontal and parietal 38 22 57.9***
Frontal and tem poral 36 16 44.4**
Frontal, tem poral and  parietal II 5 45.4
Parietal lobe only 64 22 43.4*
Tem poral lobe only 52 21 40.4**
Tem poral and  parietal 49 II 22.5
Occipital lobe only 9 1 111
Occipital and parietal o r tem poral 26 4 15.4
Central structures 30 6 20.0
Parasagittal region 29 12 41.4*
Hypophyseal region 46 0 0
O ther supraten torial 30 4 13.3
M ultilocular 55 6 10.9*
Infratentorial 148 3 2.0***
* p <  0.05, ** p <  0 .005. *** p <  0.001.
Table 5. Classification o f seizures (n = 151)
Seizure type Patients
n %
Secondarily generalized 77 51.0
Simple partial
W ithout secondary generalization 41 27.2
With secondary generalization 14 9.3
Complex partial
W ithout secondary generalization 14 9.3
With secondary generalization 1 0.7
Both simple partial and  com plex partial 1 0.7
Seizures were classifiable in 151 o f  164 patients.
26.7% of seizure patients, seizures were their only com­
plaint and in 74.6% as the first manifestation. 13% of 
patients presented only one seizure, 55% presented recur­
rent seizures and 21% had seizures at diagnosis (tumor 
was diagnosed Jess than 1 month after presentation). The 
median time from the first epileptic seizure to diagnosis 
was 3 months, with a mean of 16 months (range from 0 to 
240 months). Most brain tumors (72.8%) were diagnosed 
during the first year after seizure presentation, while 5 
patients had had seizures for more than 10 years (one of
48 Eur Neurol 2001;45:46-51
them for 20 years). Mean time was different (p = 0.02) for 
seizures as the single presenting sign (mean time 18 
months) and for seizures presenting with other symptoms 
(mean time 12 months).
Pathology
According to the histological typing, the most common 
histological types were glioblastoma, meningioma and 
low-grade astrocytoma (table 4). Patients with mixed glio­
mas (62%), oligodendrogliomas (53%), anaplastic astro­
cytomas (42%), low-grade astrocytomas (41%) and me­
ningiomas (37%) experienced seizures most frequently 
The association between tumor pathology and seizures ai 
presentation was highly significant (p <  0.001).
Seizure Types
Seizures could be classified in 91.5% (151 cases) of 
patients with epilepsy (table 5). Secondarily generalized 
and simple partial seizures, existing as the only type in a 
patient were the most common. Epileptic seizures were ol 
complex partial type and simple partial type with second­
ary generalization in 9.3% of cases.
Location
Of the 711 tumors. 71% had supratentorial and 21% 
had infratentorial location. 8% were multilocular, in the 
seizure group 94% of tumors were supratentorial, 2°/»
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were infratentorial and 4% were multilocular. The inci­
dence of seizure occurrence for different lobes differed 
significantly (p <  0.001; table 6). Higher incidence of sei­
zures were found in tumors involving the frontoparietal 
(58%), frontotemporal (44%), parasagittal (41%) and 
temporal (40%) regions. Seizures occurred in only 11 % of 
patients with tumors of the occipital lobe and the multi­
locular tumors. Only 3 patients out o f 148 with infratento­
rial tumors experienced seizures. Association with seizure 
occurrence was found for tumors involving the frontal 
and frontoparietal, temporal and frontotemporal, as well 
as the parietal and parasagittal regions. Seizures as the 
first manifestation of the tumor had no significant asso­
ciation with tumor location.
M ultivariable A nalysis
In multivariable analysis, patient gender and age were 
not associated with seizures. Categories that influenced 
the occurrence of seizures were the duration of symptoms, 
tumor location and histology. Epileptic seizures occurred 
more frequently in patients with long duration of symp­
toms (6 months and more) who were diagnosed as having 
astrocytoma, anaplastic astrocytoma, some other glioma 
or meningioma. Infrequently seizures occurred in tumors 
of infratentorial, central or multiple location.
Discussion
Brain neoplasms account for about 4-5% of all cases 
with seizure disorders [6, 7]. Of cerebral neoplasms 25- 
50% present with seizures [7-9]. Seizures are often re­
ported as being the first and sometimes the only present­
ing symptom of intracranial tumors [8-10]. In meningio­
mas 27% of the patients have been reported to have epi­
leptic seizures as their initial symptom [11]. Lühdorf et al. 
[12] found seizures to be the first sign of brain tumor in 
50% of patients who developed seizures after the age of 60 
years. In our study, only 17% of all tumor patients had 
seizures as their first complaint. This difference may be 
caused by the retrospective design of this study including 
mistakes in the chronology of symptoms. The diagnosis of 
brain tumor is often made after years from onset of sei­
zures. Several authors have reported the mean interval 
from onset o f seizures to tumor diagnosis or surgery to be 
from 2 to 11 years with a maximum of more than 20 years 
[13-16]. In a study carried out in 6 countries [ 17] includ­
ing 1,178 glioma and 331 meningioma cases, there was an 
increased risk associated with epilepsy at least 2 years 
before brain tumor diagnosis in glioma patients. In epilep­
sy of more than 20 years’ duration, the risk was signifi­
cantly weaker. No association between meningioma and 
previous epilepsy history was observed. In our series, the 
mean time from the first epileptic seizure to tumor diag­
nosis was 16 months, ranging from several days to 20 
years, while it was significantly longer in patients whose 
only presenting complaint was seizures (18 months) com­
pared with patients who had seizures plus other symp­
toms and signs (12 months). Shorter duration in our series 
may be due to the fact that our study group included 
patients with both acute and chronic epilepsy. The exact 
cause for the long duration of seizures prior to tumor diag­
nosis is still undear.
Data on the incidence of seizure activity and patients’ 
age are controversial. The age distribution of cases de­
pends largely on the biological type of the tumors [3]. Sha­
dy et al. [8] found the 50% seizure incidence with no asso­
ciation between age at diagnosis and seizure activity in 
children with supratentorial astroglial neoplasms. In their 
study of 3,291 children with brain tumors, Gilles et al. 
[18] reported that 14% of them experienced seizures, 
while the incidence increased monotonically throughout 
childhood. In adults with malignant gliomas, seizures at 
presentation were found more commonly in patients 
younger than 50 years [9]. In a study of 1,028 gliomas, the 
frequency of epilepsy at presentation decreased with age 
in high-grade glioma patients and increased with age in 
low-grade glioma patients to a plateau in the fourth 
decade of life [19]. In our study of all intracranial tumors, 
there was no significant difference between children and 
young adults compared with seizure and seizure-free pa­
tients. Seizures were significantly more common in the 
third and fourth decades of life.
Concerning tumor pathology, seizures are reported 
most frequently in patients with low-grade, slowly grow­
ing tumors and tumors involving the cerebral cortex. The 
most common tumor types are low-grade astrocytomas, 
mixed gliomas and oligodendrogliomas. Pace et al. [20] 
found preoperative seizures even in 83% of supratentorial 
low-grade astrocytomas. Gangliogliomas are found with a 
surprisingly higher frequency than could be expected [7, 
8,10]. In our series, the most common tumor types were 
mixed gliomas (63%), oligodendrogliomas (53%) and as­
trocytomas (42%) which is comparable with the results 
obtained by other authors. There was no significant differ­
ence in the incidence of low-grade astrocytomas (41.5%) 
and anaplastic astrocytomas (43%). In case of glioblasto­
mas seizure incidence was low (26%); these patients expe­
rience other symptoms and signs more commonly. The 
incidence of seizures was the lowest for metastatic tumors
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(15%) and in cases without histological confirmation 
( 12%).
With regard to tumor location, seizures have been 
reported to occur in 22-68%  o f patients with supratento­
rial tumors involving most commonly the temporal and 
frontal lobes [1 ,9 , 10] and in only 1-6% of patients with 
infratentorial lesions [8, 18]. Superficial tumors involving 
the isocortex without known deep extension were associ­
ated with the highest rate o f seizures significantly more 
often than if the tumor had a deep extension [18]. Seizure 
rates associated with frontal or temporal tumors were also 
significantly reduced in the presence o f deep extensions o f 
the tumor.
In supratentorial, convex meningiomas, evidence of 
severe peritumoral edema significantly contributes to pre­
operative epilepsy [11]. In our series, the higher incidence 
of seizures involving the frontoparietal, frontotemporal, 
parasagittal and temporal regions was evident. We did not 
take into account peritumoral edema or cortical location 
of a tumor as data concerning these entities were not suffi­
cient.
The reported incidences o f neurological findings in sei­
zure patients are quite different. Most commonly, pa­
tients with low-grade tumors and chronic epilepsy have 
normal findings on neurological examination. In their 
series of chronic epilepsy, Morris et al. [10] found97% of 
patients without neurological signs. Spencer et al. [21] 
described neurological abnormality in 12 of 19 neoplasm 
patients with intractable partial epilepsy. In our series of 
165 patients, 44 (27%) had seizures as the single symptom 
and 123 (75%) as the first manifestation. Controversy 
between these data may be due to the difference between 
study groups. In our study group, 121 (73%) patients 
experienced at least one other symptom; among them, 58
(35%) had headache, 31 (19%) papilledema, 92 (56%) 
neurological deficit and 25 (15%) mental disturbances. 
Occurrence o f neurological deficit, headache and mental 
disorders was remarkably higher in patients without sei­
zures. Comparison of seizure and seizure-free patients 
revealed no difference in the incidence of increased intra­
cranial pressure, which is supported by other authors 
[18].
The probability of diagnosing an underlying tumor in a 
patient with epilepsy is related to seizure type, with sim­
ple and complex partial seizures being the most common 
[2, 8, 9, 21]. The authors who have compared several sei­
zure etiologies and seizure types have found only simple 
partial seizures to be significantly related to tumor etiolo­
gy [21, 22]. Many authors consider tumor location the 
most important factor [3]. In our series, all patients with 
classifiable seizures had partial seizures with or without 
secondary generalization, 37% had simple partial, 10% 
had complex partial and 51 % had secondarily generalized 
seizures.
In conclusion, the presence of a tumor should always 
be considered in patients with seizure disorders, especial­
ly in case o f simple partial and secondarily generalized 
seizure types. Other symptoms, which may be o f diagnos­
tic value, may appear several months or years later, 
whereas in a remarkable proportion of patients they are 
lacking completely. Seizures at presentation are signifi­
cantly correlated with tumor pathology and location.
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Abstract
We studied  a popu latio n -b ased  survey th a t  included  1417 p a tien ts  w ith  a  p rim ary  cen tra l nerv o u s system  (C N S ) tu m o u r  d iag ­
nosed in E sto n ia  betw een 1986 a n d  1996. S urvival rates a t 1 and  5 years a n d  m ed ian  surv ival by  h isto lo g y  a n d  p a tie n t’s age a t 
diagnosis were estim ated . M edian  survival tim e fo r all tu m o u rs  w as 33.2 m o n th s  and  1- a n d  5 -year surv ival ra te s  were 59.3 an d  
46.0% , respectively. In  m u ltiv aria te  analysis, you n g er age, b e tte r  clin ical co n d itio n  (i.e. a  K a rn o fsk y  P e rfo rm an ce  S ta tu s  (K P S ) 
score o f  60 and  m ore) an d  tu m o u r h isto logy  w ere all dep en d en t p ro g n o stic  fac to rs  fo r b e tte r  surv ival. R isk  o f  d e a th  w as m o re  th an  
8 times greater for g liob lastom a (R isk  R a tio  (R R ) 8.31) an d  a p p ro x im ate ly  seven tim es g rea te r  fo r  an a p la s tic  a s tro c y to m a  (R R  
7.22) and  o th er g liom as (R R  5.74) co m p ared  w ith  m eningiom as. C o m p a rin g  th e  first (1986-1989) an d  th e  th ird  (1994-1996) tim e 
periods, s tatistically  significant im provem ents in surv ival occurred  fo r all tu m o u rs  and  as tro cy to m as. D eclines in su rv ival d u r in g  the  
second period  (1990-1993) were statistically  significant fo r  all the  tu m o u r  groups, b u t the  m o st str ik in g  decrease  to o k  p lace in 
patien ts w ith g lioblastom a. Age-specific ra tes  show ed th a t  th e  increase  in survival w as m ore  ev iden t fo r  p a tie n ts  aged  betw een  45 
arid 64 years. ©  2001 Elsevier Science L td . A ll r ig h ts  reserved .
Keywords: Survival; CNS tumours; Estonia; Prognostic factors
1. Introduction
Most of the published studies concerning survival of 
central nervous system (CNS) tumours are hospital- 
based and restricted to gliomas or their histological 
subtypes. Very few population-based studies including 
survival of all primary benign and malignant tumours 
have been published. Increased mortality rates for 
malignant CNS tumours, particularly among the 
elderly, have been attributed to improved diagnostic 
techniques and increased environmental carcinogens [1]. 
A study from the Estonian Cancer Registry [2] reported 
the 5-year relative survival rate among patients of diag­
nosed CNS tumours in Estonia (1983-1987) as 11.2% 
for males and 24.6% for females and the mortality rate 
(1988-1992) as 4.9 and 3.5 per 100000 population, 
respectively. Since meningiomas and other histologically 
benign CNS tumours were not recorded until 1998, the 
registry can be considered complete with regard to
* Corresponding author. Tel.: +372-7-381501; fax: + 372-7- 
381509.
E-mail address; aive.liigant@kliinikum.ee (A. Liigant).
malignant tumours, but incomplete concerning benign 
tumours. In the recent EUROCARE survey [3], includ­
ing malignant CNS tumours diagnosed between 1985 
and 1989 in 17 European countries, the mean European 
age-standardised 5-year relative survival was 17% in 
men and 20% in women with markedly lower rates in 
Scotland, Estonia and Poland. In the USA in 1986-
1991, 5-year relative survival of malignant CNS 
tumours was 20% according to the Surveillance, Epide­
miology and End Results (SEER) data [4].
Generally, in CNS tumours, survival rates decline 
with increasing age at diagnosis. Other patient-related 
prognostic factors for survival are gender and the clin­
ical condition of the patient. Histology and anatomical 
location are important tumour-related agents in esti­
mating survival. The prognosis for patients with benign 
meningiomas is better for females and depends on the 
patient’s age [5,6], being more favourable for patients 
below 60 years.
Clinically significant improvements in the survival of 
patients with CNS tumours has taken place over the last 
two decades [3,4]. Improvements in survival have been 
histology-specific, being more evident in medullo-
0959-8049/01/$ - see front m atter ©  2001 Elsevier Science Ltd. All rights reserved. 
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blastomas, astrocytomas and oligodendrogliomas. For 
glioblastomas, the most frequent primary CNS tumour, 
no striking improvement has taken place.
The aim o f this study was to determine the relative 1- 
and 5-year survival rates o f patients with primary CNS 
tumours diagnosed in Estonia between 1986 and 1996, 
to examine variations in the different age and histologi­
cal groups and evaluate changes in the length of survival 
that have occurred over recent years.
2. Patients and methods
2.1. D ata  collection and selection
The study was based on the Estonian population of 
approximately 1.5 million served by two neurosurgical 
centres (Tartu University Clinics and Tallinn Mustamäe 
Hospital) which admit all patients suspected of intra­
cranial tumours. Our data included all cases of primary 
CNS tumours diagnosed at these hospitals from 1986 to 
1996. We obtained information about patient’s gender, 
age at diagnosis, clinical condition, tumour location, 
histological type and follow-up results from case his­
tories, autopsy protocols and pathology reports. Addi­
tional information on date and cause of death was 
received from the Estonian Cancer Registry and the 
Estonian State Statistical Office.
We selected 1524 patients diagnosed between 1986 
and 1996 with CNS tumours by using the International 
Classification of Diseases for Oncology (ICDO) [7] 
including the following topography codes: C71.0-C71.9 
for brain, C70.0 and C70.9 for meninges, C72.2-C72.9 
for cranial nerves and other intracranial parts of the 
CNS, C75.1-C75.3 for pituitary gland, pineal gland and 
craniopharyngeal duct. 88 cases discovered at autopsy,
2 patients o f incomplete data and 17 patients diagnosed 
with another tumour previously or during the follow-up 
period were excluded.
2.2. D ata classification
The remaining 1417 tumours were classified according 
to the histopathological type of the CNS tumour fol­
lowing the scheme approved by the World Health 
Organization (WHO) [8]. All histologically obscure 
cases (with the majority of pathological material having 
been preserved) were retrospectively overviewed by a 
neuropathologist. The study population was divided 
into four age groups: children (< 2 0  years at diagnosis), 
younger adults (21-44 years), older adults (45-64 years) 
and the elderly (> 6 5  years), reflecting the fact that CNS 
tumours have specific characteristics including histol­
ogy, behaviour, anatomical location depending on age, 
and survival rates are varying by age at diagnosis. The 
clinical functional ability of the patient before therapy
was assessed according to the Kamofsky Performance 
Status scale. Three groups were considered: score 80— 
100, 60-70 and less than 60.
2.3. Time periods
Our study included CNS tumours diagnosed in Esto­
nia between 1986 and 1996. Follow-up of vital status 
was until 1 January 1998. Follow-up was based on the 
data of the Estonian Cancer Registry and the Estonian 
State Statistical Office.
To estimate potential changes in 1-year survival rates 
over time in the different age and histological groups, 
three time periods were defined according to the year of 
diagnosis: 1986-1989, 1990-1993 and 1994-1996. 
Advances in diagnostic procedures (the introduction of 
computerised tomography (CT) and magnetic reso­
nance imaging (MRI)) should not affect potential chan­
ges in survival, as the first CT scan was introduced in
1983 in Estonia. Changes in 5-year survival were not 
estimated because of too short a follow-up period.
2.4. Data analysis
Survival time was calculated from the date of diag­
nosis. One- and 5-year survival rates were estimated 
overall, by the above-mentioned age groups, for each 
histological group using the life table method with 
intervals of 1 month. Kaplan-Meier estimation was 
used to compute the median length of survival by gen­
der, age and clinical condition, histology and location of 
tumour, based on the whole study period. The logrank- 
test was used to compare survival in the subgroups. 
Proportional hazards models (Cox’s models) were used 
to determine the effect of different patient (gender, age, 
clinical condition before treatment) and tumour-related 
(anatomical location, histology) factors on survival. All 
analyses were performed by using PC: SAS Version 6.12 
(SAS Institute, Cary, NC, USA).
3. Results
3.1. General data
The 1417 patients included 628 men and 789 female 
with CNS tumours. The median age at referral was 49 
years (range 1-83 years) for men and 52 years (range 4 
months-84 years) for women.
The distribution and median survival of patients by 
gender, age, tumour location and clinical condition are 
shown in Table 1. Univariate analysis found that 
females (/> = 0.002), patients of younger age (<45  years, 
P —0.0001) and better clinical condition before treatment 
(/*= 0.0001) had the highest survival. Concerning tumour 
location, the worst prognosis was associated with those
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Characteristics o f  1417 brain tum our patients diagnosed in Estonia from 1986 to 1996
Characteristic
Gender
Male
Female
Age group (years)
2^0
21-44
45-64
>65
Location 
Frontal 
Parietal 
Temporal 
Two or more lobes 
Central structures and ventricles 
Other supratentorial 
Pituitary or pineal 
Infratentorial
< Location not available
Patients n (%)
629 (44.4) 
788 (55.6)
191 (13.5) 
344 (24.3) 
677 (47.8) 
205 (14.5)
164 (11.6)
113 (8.0) 
108 (7.6) 
336 (23.7)
58 (4.1) 
175 (12.4)
114 (8.0) 
311 (21.9)
38 (2.7)
n Deaths
371
396
90
140
401
136
107
63
71
231
36
82
28
133
Median survival (months)
18.6
62.8
/ > - 0.002
88.3 
136.9
15.8 
5.7
/> =  0.0001
17.8 
14.7
13.9
10.4
7.3
KPS
80-100
60-70
<60
KPS not available
370 (26.1) 
558 (39.4) 
321 (22.7) 
168 (11.9)
105
289
251
48.0
5.3
nc, median could not be computed, over 50% survived; KPS, Kamofsky Performance Status.
of central structures or ventricular location and the best 
prognosis with infratentorial and pituitary location.
3.2. Distribution by histology
The distribution of tumours by histology according to 
the WHO classification of CNS tumours with the cor­
responding ICDO morphology codes are presented in 
Table 2. The most frequently reported histologies were 
glioblastoma (21.0%), meningioma (18.8%) and astro­
cytoma (9.2%).
3.3. Survival by histology
One- and 5-year survival rates and median survival 
time by histology are presented in Table 3. The overall 
1-year survival was 59.3%, 5-year survival 46.0% and 
median survival 33.2 months. Tumours with the most 
favourable prognosis included pituitary adenoma 
(89.2%, both 1- snd 5-year survival rates), meningioma 
(1-year survival 85.9% and 5-year survival 82.4%) and 
neurinoma (76.4%, both survival rates). Patients with 
glioblastoma and anaplastic astrocytoma had the worst 
outcome (5-year survival 8.6 and 15.8%, respectively). 
In contrast, approximately half of the low-grade astro­
cytoma patients (49.8%) survived beyond 5 years. The
long-term prognosis for patients with medulloblastoma, 
ependymoma, oligodendroglioma and mixed gliomas 
appeared similar to each other (22.5, 26.9, 28.1 and 
28.1%, respectively), while median survival was not so 
homogenous.
3.4. Survival by age a t diagnosis
Survival rates by age at diagnosis for all CNS 
tumours and selected histology groups are given in 
Table 4. Including all histological groups, the worst 
outcome occurred in patients aged 65 years or older. 
Decreased survival associated with older age at diag­
nosis was generally observed in all histological groups. 
Differences were the most evident in the astrocytoma 
group (1-year survival 16.7% in the elderly and 87.0% 
in children, 5-year survival rates o f 16.7 and 79.3%, 
respectively), where survival decreased with age.
3.5. Comparison o f  1-year survival rates in the three 
time periods
Table 5 shows the 1-year survival rates for astro­
cytoma, glioblastoma, meningioma, tumours without 
histological verification and all tumours by patient 
age group during the three time periods (1986-1989,
29
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Table 2
Distribution o f CNS tum ours by histology in Estonia (1986-1996)
Histology by W HO ICDO M orphology Codes Cases 
n (% ) Male (% ) Female (%)
Tum ours o f neuroepithelial tissue
Astrocytom a (G l-2 ) 9400/3, 9410/3, 9411/3, 9420/3, 9421/3 138 (9.2) 64 (10.2) 66 (8.4)
Anaplastic astrocytom a 9401/3 72 (5.6) 36 (5.7) 44 (5.6)
Glioblastom a 9440/3, 9441/3, 9442/3 297 (21.0) 159 (25.3) 138 (17.5)
Oligodendroglioma 9450/3 24(1.7) 16 (2.5) 8 (1.0)
Anaplastic oligodendroglioma 9451/3 14 (0.9) 6(1.0) 8 (1.0)
Ependym oma 9391/3, 9393/1 12 (0.8) 7(1 .1 ) 5(0.6)
Anaplastic ependymoma 9392/3 10 (0.7) 6(1.0) 4 (0.5)
Mixed gliomas 9382/3 23 (1.6) 11 (1.8) 12 (1.5)
C horoid plexus tumours 9390/0, 9390/3 9 (0.6) 6(1 .0) 3 (0.4)
Neuroepithelial tum ours o f uncertain origin 9430/3, 9443/3, 9381/3 12 (0.8) 4 (0.6) 8 (1.0)
Pineal tum ours 9361/1,9362/3 3 (0.2) 3 (0.5) 0 (0.0)
M edulloblastoma 9470/3, 9471/3, 9472/3 39 (2.8) 20 (3.2) 19 (2.4)
Tum ours o f cranial and spinal nerves
Neurinom a 9560/0 55 (3.9) 18 (2.9) 37 (4.7)
Neurofibroma 9540, 9550/0 4 (0.3) 1 (0.2) 3 (0.4)
Tum ours o f  the meninges
M eningioma 9530/0, 9531/0, 9532/0, 9533/0, 9534/0, 
9537/0, 9530/1, 9538/1
267 (18.8) 62 (9.9) 205 (26.0)
Anaplastic m eningioma 9530/3 17 (1.2) 4 (0.6) 13 (1.6)
H aemangioblastom a 9161/3 21 (1.5) 8(1.3) 13 (1.6)
M alignant lymphomas 9590/3 18 (1.3) 10(1.6) 8 (1.0)
Germ cell tumours 9064/3, 9070/3, 9080/1, 9084/3 4 (0.3) 2 (0.3) 2 (0.3)
Cysts and tumour-like lesions 9084/0 9 (0.6) 7(1 .1) 2 (0.3)
Pituitary adenom a 8140/0 35 (2.5) 15 (2.4) 20 (2.5)
Pituitary carcinoma 8140/3 3 (0.2) 2 (0.3) 1 (0.1)
Craniopharyngiom a 9350/1 15(1.1) 8 (1.3) 7 (0.9)
All others * 38 (2.7) 20 (3.2) 18 (2.3)
Unclassified tum ours (no 
histological verification)
8000/0, 8010, 8000/1, 8001/1, 8000/3, 
8001/3, 8002, 8003
278 (19.6) 134(21.3) 144(18.3)
Total 1417 (100) 628 (100) 789 (100)
W HO, W orld Health Organization. 
a A m ount o f  cases in each histological group was very small, morphology codes are not given.
Table 3
One- and 5-year survival rates (SR), and median survival time (ST) by histology for patients with prim ary brain tumours in Estonia (1986-1996)
Histology n 1-year SR (% ) (95% Cl) 5-year SR (% ) (95% Cl) M edian ST (months)
Astrocytoma (G l-2 ) 138 64.5 (60.4-68.6) 49.8 (45.2-54.4) 54.2
Anaplastic astrocytom a 72 36.1 (30.4-41.8) 15.8 (11.3-20.4) 8.3
Glioblastoma 297 28.0(25.4-30.6) 8.6 (6.8-10.3) 6.2
Ependymoma 22 50.0 (39.3-60.7) 26.9 (16.5-37.4) 10.7
Oligodendroglioma 38 60.5 (52.6-68.5) 28.1 (18.7-37.3) 22.9
Mixed gliomas 23 56.5 (46.2-66.9) 28.1 (18.2-37.9) 22.4
M edulloblastoma 39 53.9 (45.9-61.8) 22.5 (15.3-29.7) 12.7
M eningioma 284 85.9 (83.9-88.0) 82.4 (80.0-84.8) nc
Neurinom a 55 76.4 (70.6-82.1) 76.4 (70.6-82.1) nc
Pituitary adenoma 35 89.2 (78.4-94.3) 89.2 (78.4-94.3) nc
Craniopharyngiom a 15 73.3 (61.9-84.8) 52.4 (37.4-67.3) nc
Other specified 121 62.6 (57.9-67.3) 43.8 (38.8-48.8) 36.5
W ithout histology 27? 61.9 (59.0-64.8) 53.8 (50.7-56.8) nc
Total 1417 59.3 (58.0-60.6) 46.0 (44.6-47.4) 33.2
95% C l, 95% confidence interval; nc, median could not be computed, over 50% survived.
1990-1993 and 1994—1996). Comparing the first (1986- 
1989) and the second (1990-1993) time periods, a sta­
tistically significant decline in the 1-year survival rate 
for glioblastoma (32.7 and 17.9%, respectively) and for 
all tumours (59.8 and 53.6%, respectively) was observed. 
In meningiomas, a similar result was evident only for 
those aged between 45 and 64 years. Comparing the first 
(1986-1989) and the third (1994-1996) time periods no 
significant changes in survival, either for meningioma or 
glioblastoma, have taken place. There were statistically 
significant improvements in the survival rates compar­
ing the first (1986-1989) and the third (1994-1996) time 
periods for patients with astrocytoma and for all 
tumours. Age-specific rates showed that the increase in 
survival was more evident in the older adults, between 
45 and 64 years, both, for all tumours (51.8% in 1986 
through to 1989 and 64.8% in 1994 through to 1996) 
and for astrocytomas (29.4 and 83.3%, respectively). In 
patients with astrocytomas, a slight, but statistically not 
significant improvement can be observed in the younger 
adults, aged between 21 and 44 years.
3.6. Multivariate analysis
In multivariate analysis, older age at diagnosis, 
patient’s clinical condition (Kamofsky Performance 
Status < 60), tumour histology and period of diagnosis
were independent prognostic factors for survival 
(Table 6). Risk of death was more than 8 times greater 
for glioblastoma (Risk Ratio (RR) 8.31, /* = 0.0001), 
about seven times greater for anaplastic astrocytoma 
(RR 7.22, P = 0.0001) and more than 5 times greater for 
other gliomas (RR 5.74, P  =  0.0001) The best prognosis 
was found for those with neurinomas, but these patients 
still had a significantly greater risk of death (R R = 1.87, 
P  =  0.0376) compared with those with meningiomas.
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4. Discussion
This analysis provides population-based survival esti­
mates for both histologically bcmgn and malignant 
CNS tumours in Estonia. One- and 5-year survival rates 
and the prognostic importance of patient- and tumour- 
related factors were analysed in 1417 patients with CNS 
tumours. The distribution of pathologically-confirmed 
cases according to histological type in Estonia is in 
many respects similar to the distribution reported for 
other geographical regions [6,9]. In our study, gliomas 
comprised 50% (including glioblastoma 21.0%, astro­
cytoma 14.8%), meningioma 20.0% and neurinoma 
3.9% of all CNS tumours. A recent US study [10] based 
on the National Cancer Data Base (NCDB), a data set 
that is limited to hospital reporting, has found approxi-
Table 4
One- and 5-year survival rates (SR) by age at diagnosis for selected histology groups
Histology Age at diagnosis
« 2 0 21-44
n 1-year SR (95% Cl) 5-year SR (95% Cl) л 1-year SR (95% C l) 5-year SR (95% Cl)
Astrocytoma (G l-2 ) 46 87.0 (82.0-91.9) 79.3 (73.1-85.6) 43 76.7 (70.3-83.2) 64.6 (56.8-72.5)
Anaplastic astrocytoma 4 * • 21 52.4 (41.5-63.3) 26.8 (16.8-36.8)
Glioblastoma 12 41.7 (27.5-55.9) 21.6 (8.9-34.3) 55 43.6 (37.0-50.3) 13.8 (8.6-19.0)
Other glioma 13 76.9 (65.2-88.6) 46.2 (30.3-62.0) 30 63.3 (54.5-72.1) 40.8 (30.8 -50.8)
Meningioma 3 1 * 58 93.1 (89.8-96.4) 93.1 (89.8-96.4)
Neurinoma 5 • • 18 88.9 (81.5-96.3) 88.9 (81.5-96.3)
Other specified 65 58.5 (52.4-64.6) 35.6 (29.3-41.8) 53 87.8 (83.1-92.4) 77.1 (70.6-83.6)
Without histology 43 69.8 (62.8-76.8) 55.3 (47.6-62.9) 66 81.8 (77.1-86.6) 72.8 (67.1-78.6)
Total 191 70.2 (66.9-73.5) 52.9 (49.1-56.6) 344 74.7 (72.4-77.1) 60.9 (58.1-63.7)
45-64 > 65
n 1-year SR (95% CT) 5-year SR (95% Cl) n 1-year SR (95% Cl) 5-year SR (95% Cl)
Astrocytoma (G l-2 ) 37 37.8 (29.9-45.8) 13.2 (6.2-20.3) 12 16.7 (5.9-27.4) 16.7 (5.9-27.4)
Anaplastic astrocytom a 39 25.6 (18.7-32.6) 8.6 (3.6-13.5) 8 * *
Glioblastoma 173 24.3 (21.0-27.5) 6.3 (4.3—8.3) 57 21.1 (16.6-26.5) 7.0 (3.6-10.4)
Other glioma 31 51.6 (42.6-60.6) 18.3 (11.2-25.4) 9 •
75.0 (66.6-83.4)Meningioma 182 83.5 (80.8-86.3) 79.8 (76.7-82.9) 41 85.4 (79.9-90.9)
Nqurinoma 23 73.9 (64.8-83.1) 73.9 (64.8-83.1) 9 *
Other specified 79 59.5 (54.0—65.0) 44.8 (38.9-50.6) 13 46.2 (32.4-60.0) 30.8 (18.0-43.6)
Without histology 113 56.6 (52.0-61.3) 49.0 (44.2-53.9) 56 42.9 (36.3-49.5) 39.3 (32.7-45.8)
Total 677 53.5 (51.6-55.4) 40.7 (38.7-42.6) 205 42.4 (39.0-45.9) 32.3 (28.9-35.8)
95% Cl, 95%  confidence interval.
“ Not given due to  a  very small num ber (<  10) o f  cases.
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Table 5
1-year survival rates (SR) by age for patients with low-grade astrocytoma, glioblastoma, meningioma and without histological confirmation and all 
brain tumours during the three time periods. Estonia 1986-1996
Histology Age group (years) Year o f diagnosis
1986-1989 SR (95% Cl) 1990-1993 SR (95% Cl) 1994-1996 SR (95% Cl)
Astrocytoma (G l-2 ) < 2 0 88.2 (80.8-96.1) 81.3 (71.5-91.0) 92.3 (84.9-99.7)
21-44 76.5 (66.2-86.8) 58.3 (44 1-72.6) 92.9 (86.0-99.7)
45-64 29.4 (18.4-40.5) 28.6 (16.5-40.6) 83.3 (68.1-98.5)
> 65 25.0 (3.4-46.7) * *
All ages 61.8 (55.3-68.4) 54.6 (47.0-62.1) 79.5 (73.0-86.0)
Glioblastoma <20 • • 1
21-44 45.0 (33.9-56.1) 22.2 (12.4-32.0) 52.9 (40.8-65.1)
45-64 27.1 (21.8-32.5) 17.1 (12.6-21.6) 33.3 (25.1-41.5)
>65 25.0 (14.2-35.8) 9.1 (3.0-15.2) 31.6 (20.9-42.2)
All ages 32.7 (28.2-37.2) 17.9 (14.2-21.5) 36.0 (30.5-41.5)
Meningioma <20 * *
21-44 90.5 (84.1-96.9) 95.8 (91.7-99.9) 92.3 (84.9-99.7)
45-64 86.0 (81.4-90.6) 74.6 (69.1-80.1) 90.3 (86.6-94.1)
>65 * 84.6 (74.6-94.6) 81.8 (73.6-90.0)
All ages 88.1 (84.6-91.6) 81.2 (77.3-85.1) 88.9 (85.7-92.1)
W ithout histology < 20 57.9 (46.6-69.2) 71.4 (58.7-83.5) 90.0 (80.5-99.5)
21-44 87.5 (80.8-94.3) 83.3 (72.6-94-1) 76.7 (69.0-84.4)
45-64 52.5 (44.6-60.4) 67.7 (59.3-76.1) 52.4 (44.7-60.1)
>65 69.2 (56.4-82.0) 31.8 (21.9-41.8) 38.1 (27.5-48.7)
All ages 64.6 (59.7-69.5) 60.8 (55.3-66.3) 60.2 (55.4-65.0)
Total <20 65.7 (59.9-71.5) 72.5 (67.1-77.8) 72.7 (66.7-78.7)
21-44 78.1 (74.3-81.8) 69.4 (65.0-73.9) 76.1 (72.1-80.1)
45-64 51.8 (48.6-55.0) 46.0 (40.3-49.2) 64.8 (61.3-68.2)
> 65 47.1 (44.8-54.1) 37.0 (31.3-42.6) 44.4 (38.9-50.0)
All ages 59.8 (57.6-62.1) 53.6 (51.3-55.9) 64.9 (62.7-67.2)
95% C l, 95% confidence interval.
* N ot given due a very small num ber o f  cases.
Table 6
M ultivariate analysis (Cox model). Factors predicting survival in patients with brain tumours
Factor Variable Parameter estimate P  value Risk ratio (in best Cox model)
Gender Male versus female ns 1.02
Age (years) as a continuous variable 0.014 0.0001
Kam ofsky Performance Status
<60% 60-100% taken as a base category 0.600 0.0001 1.82
N ot specified 0.552 0.0001 1.74
Period o f diagnosis
1990-1993 1986-1989 taken as a base category ns
1994-1996 0.190 0.0280 0.83
Histology
Astrocytoma M eningioma taken as a base 1.429 0.0001 4.18
Anaplastic astrocytoma category for all types 1.977 0.0001 7.22
Glioblastoma 2.117 0.0001 8.31
Other gliomas 1.748 0.0001 5.74
Neurinoma 0.624 0.0376 1.87
Other specified 1.497 0.0001 4.47
W ithout histology 1.166 0.0001 3.21
Localisation
Hemispheres Infratentorial location taken as ns
Central structures a base category ns
Other ns
N ot specified 1.461 0.0001 4.31
ns, non significant.
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mately the same distribution concerning astrocytoma 
(18.7 /о), with a lower occurrence of meningioma (15.5%) 
and higher occurrence o f glioblastoma (29.6%).
Gender differences in survival have previously been 
reported for non-malignant CNS tumours (5,6,11]. The 
prognosis for patients with benign meningiomas is bet­
ter for females below 60 years o f age [11,12]. The cause 
of this difference is unknown.
Most authors report no association between prognosis 
and patient gender in malignant CNS tumours [13,14].
In our series, including all CNS tumours, survival is 
considerably longer among females: median survival 
62.8 months compared with only 18.6 months for males. 
This difference can be explained by the variations in the 
histologial distribution in men and women. There is a 
higher incidence of benign meningiomas in females 
together with a better prognosis for this type of tumour. 
The poorer survival of men is attributable to the 
relatively greater frequency among men of the more 
aggressive tumour types. In multivariate analysis, no 
difference in prognosis could be detected for male and 
female patients.
The importance of age and histology in predicting the 
survival from CNS tumours has been well documented 
in studies from the US [4,11,15-19], as well as studies 
from other countries [6,13,20,21]. Generally, survival 
rates decline with increasing age at diagnosis, both in 
benign and malignant tumours. A similar pattern was 
found in our study. The survival pattern of patients 
aged 45-64 years has been reported to resemble more 
closely that of older rather than younger patients [22]. 
However, some authors suggest that the influence of age 
is overestimated. Shaw and colleagues [23] suggest that 
the patient’s age is not correlated with an improved 
survival in mixed gliomas.
In low-grade astrocytomas, the median survival time 
is reported to be approximately 5 years, similar to our 
result of 4.5 years (54.2 months). Long-term survival 
rates at 5 years have been documented as ranging 
between 30 and 60% [6,10,24], depending primarily on 
the inclusion criteria and study design. A hospital-based 
study of the NCDB [10] including over 60000 patients 
with a CNS tumour, found 5-year survival rates of 
30.3% for astrocytoma and 77.4% for pilocytic astro­
cytoma. Our data show 5-year survival rates of 49.8% 
for low-grade astrocytomas.
The overall median survival of grade 3 and 4 astro­
cytomas in our study was less than 1 year. However, 
Salcman and colleagues [17] reported that the median 
survival of grade 3 and 4 astrocytomas for patients less 
than 40 years o f age, who received some form of therapy 
beyond surgery and radiation, was more than 2 years. 
Furthermore, younger patients with grade 3 astro­
cytomas generally have a better survival, extending over 
4 years [25]. A Finnish study [13] reported the median 
survival of grade 3 and 4 gliomas to be 24.0 and 7.7
months, respectively. Barker and co-authors [15] repor­
ted a median survival rate of glioblastoma patients of
11.2 months, and 1- and 5-year survival rates o f 48 and 
4%, respectively. Our study deternuned a similar med­
ian survival rate for glioblastoma of 6.2 months and for 
anaplastic astrocytoma of 8.3 months, together with 1- 
year survival rates of 28.0 and 36.1 % and 5-year survi­
val rates of 8.6 and 15.8%, respectively. These data 
suggest patients had a poorer outcome than in other 
studies, especially those with anaplastic astrocytomas. 
The relative poor median survival of patients with ana­
plastic astrocytoma may be explained by difficulties in 
making this histological diagnosis The biggest diver­
gence in the results of neuropathologists lies in the 
diagnosis of anaplastic astrocytoma 
In oligodendrogliomas, the median survival time has 
been reported to be between 3 and 8 years [14,26,27]. 
Our data show patients had a survival rate o f approxi­
mately 2 years, which is significantly lower, but com­
parable with the median survival o f non-uradiated 
patients (26.5 months) in a Norwegian study [26]. 
Although patients with benign tumours have a more 
favourable prognosis compared with patients with 
malignant tumours, there is still significant mortality 
associated with these histologies. In our study, both the 
1- and 5-year survival rates for meningiomas was 
approximately the same as those reported in the Finnish 
study [12] (83 and 79%, respectively). The Norwegian 
study reported survival following the dignosis o f benign 
meningiomas to be 93% at 1 year and 95% at 5 years 
[5]. The US study [11], based on 9000 meningioma 
cases, found a 5-year survival rate o f 69%. The clinical 
functional ability or Kamofsky score o f the CNS 
tumour patient has been shown to be a strong predictor 
o f outcome in most studies [14-16,18,23,28]. In our 
study, the patient’s clinical condition was a statistically 
significant prognostic factor in both univariate and 
multivariate analyses.
Of course, appropriate therapies are among the main 
determinants of prognosis. The better outcome in the 
socio-economically advanced societies is due to earlier 
diagnosis and the combined effect o f more effective 
therapies, including centralisation of treatment and dis­
semination of effective therapeutic protocols. In Esto­
nia, the first CT scan was introduced in 1983 and MRI 
scans in early 1990s. Up to the present day, joint treat­
ment protocols for patients with CNS tumours are 
lacking in Estonia. In this study, we did not investigate 
the association between treatment strategies and out­
come. We suppose that in most cases only surgery, 
possibly a gross total resection was used. Post-operative 
radiation therapy and adjuvant chemotherapy or a 
combination is for certain reasons (e.g. the lack of 
defined treatment protocols and insufficient co-opera­
tion between surgeons and oncologists) not so widely 
used in Estonia.
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4.1. Changes in incidence rates
During the last 20 years an overall slight increase in 
survival o f patients with malignant tumours has been 
found both in EUROCARE study [3] and SEER pro­
gramme [4]. Most improvement is confined to the first 
year after diagnosis. Age-specific rates show that the 
increase is more evident in younger patients, up to 54 
years of age. Concerning tumour histology, the 
improvement is evident in medulloblastomas, in adults 
with astrocytomas and oligodendrogliomas [29]. The 
improvements in survival reflect improvements in ther­
apy and the treatment taking place at an earlier stage of 
disease, where new and better diagnostic techniques 
have helped in identifying the tumours earlier.
In meningiomas, both short-term and long-term sur­
vival has recently improved [5]. The improved 1-year 
survival rate is likely to be caused by improved opera­
tive techniques and postoperative care. The increased 
long-term survival may reflect the likelihood that more 
patients with small meningiomas are being diagnosed 
early since CT became available. In benign meningio­
mas, a small tumour size is one of the factors inde­
pendently associated with an increased survival time 
[11].
Our survey follows the example o f above-mentioned 
studies, statistically significant improvements in 1-year 
survival rates were found for all tumours and low-grade 
astrocytoma comparing the first and the third time per­
iods. Age-specific rates showed that the increase was 
more evident in patients aged between 45 and 64 years. 
A decline in survival during the second period (1990— 
1993) is statistically significant for all tumours, but the 
most striking decrease took place for patients with glio­
blastoma. This discrepancy may reflect economic fac­
tors and the reorganisation of the health care system at 
the beginning of the 1990s. It was a period of extensive 
change in Estonia, in both the political and economical 
systems, including healthcare. Delays in diagnosis, 
especially in rural areas where availability of medical 
care was limited, may also have caused the poorer out­
come during the second period. Older patients are also 
more likely to be diagnosed as having dementia or vas­
cular disease by their family doctors than as having 
CNS tumours.
In conclusion, the outcome of CNS tumours in Esto­
nia, especially malignant tumours, is somewhat worse 
compared with other studies. The causes of such a ten­
dency, especially with regard to treatment strategies, 
deserves further investigation.
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kesknärvisüsteemi kasvajad, klassifikatsioon, haigestumus, elulemus, prognoos
Kesknärvisüsteemi (KNS) kasvajaid iseloomus-tab 
füsioloogiliste vormide mitmekesisus, kliiniliste avalduste 
komplekssus ja sõ ltuva lt kasvaja h isto loogilisest 
struktuurist ning lokalisatsioonist head või tagasihoidlikud 
ravitulemused. See kõik on lekitanud segadust ja nihilismi 
nii arstide kui ka patsientide hulgas. Eesti Vähiregistri
andmetel (28) ei kuulu aju-ja kesknärvisüsteemi kasvajad 
Eestis ei naiste ego meeste seas kümne sagedamini 
esineva väh ipa ikm e hu lka. Erondiks on o lla  
kolmekümneaastaste vanuserühm, kellel on ajukasvajad 
sageduselt 2 .-3 . kohal Suremuse statistikale toetudes 
on ajukasvajad vähkkosvaiale seas 9 .-  10 kohal Eesli
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Vähiregister registreeris kuni 1998. aasfani ainult 
füsioloogiliselt paholoomulisi kasvajavorme, mistõttu 
registri statistikas ei kajastu oluline hulk histoloogiliselt 
healoomulisi kasvajaid (meningioomid, neurinoomid, 
hüpofüüsi adenoom id). Traditsiooniline kasvajate 
jagamine hea- ja pahaloomulisteks on ajukasvajate 
suhtes kliinilisest aspektist sobimatu, kuna sõltuvalt oma 
lokalisatsioonist võivad ka intrakraniaalsed healoomulised 
kasva jad sarnaselt pahaloom ulistega o lla  tõsise 
prognoosiga. Nagu eespool mainitud, on ajukasvajate 
histogeneetiline struktuur väga mitmekesine, olles seotud 
patsiendi soo ja vanuse ning kasvaja lokalisatsiooni ja 
prognoosiga. Näiteks lapse- ja noorukieas esineva 
väikeaju astrotsütoomi ravi annab reeglina häid tulemusi 
ja prognoos on hea, samal ajal kui glioblastoomiga 
patsient elab ravist sõltumata harva üle ühe aasta.
Klassifikatsioonid
Esmakordne püüe ajukasvajaid süstematiseerida 
pärineb 19. sajandist, kui Virchow eraldas glioomid 
sa rk oom ide  st ja k irje ld as  m õn inga id  g lioom e 
(ependümoom). Kaasaegne klassifikatsioon põhineb 
Bailey ja Cushingi (1926) töödel. Bailey ja Cushing 
uurisid KNS-i erinevate rakuliste kom ponentide 
em brüogeneesi, püüdes seejärel klassifitseerida 
kasvajaid vastavalt morfoloogilistele staadiumitele, mille 
need rakud läbivad ontogeneesis. Nende klassifikatsioon 
sisaldas 14 kasvajatüüpi, mis enamjaolt on esindatud ka 
tänapäevastes k lassifika ts ioon ides. Eesmärgiga 
lihtsustada klassifikatsiooni ja võtta arvesse anaplaasia 
olemasolu viis Kernohan koos kaastöötajatega (1949) 
sisse glioomide 4-järgulise maliigsuse hindamise süsteemi 
(sobis eelkõige astrotsütoomile ja ependümoomile), kus 
I staadium oli kõige healoomulisem ja IV staadium kõige 
pahaloomulisem. Kernohani süsteemil olid aga eelkõige 
prognostilisest küljest oma puudused: kuna anaplaasia 
on sageli väga lokaalne ja kasvaja areng dünaamiline 
(võimalik on üleminek ühest staadiumist teise), siis ei 
pruugi kasvaja biopsia peegeldada kogu kasvaja 
struktuuri, samuti ei arvestatud süsteemi tegemisel 
kasvaja lokalisatsiooni (22). Patsiendi prognoos ei sõltu 
mitte ainult kasvaja morfoloogilisest ehitusest ja selle 
maliigsuse astmest, vaid oluline on arvesse võtta ka 
kliinilisi aspekte ja seda igal üksikul juhul eraldi (27).
Esimene rahvusvaheline M aa ilm a  Tervishoiu­
organisatsiooni (MTO) poolt heaks kiidetud KNS-i 
kasvajate histoloogiline klassifikatsioon (26) avaldati 
1979. aastal. See klassifikatsioon on konsensus, mis on 
saavutatud aastaid kestnud uuringute ja mitmete 
koolkondade vahelise diskussiooni tulemusel. 1993. 
aastal ilmus selle klassifikatsiooni parandatud variant 
(15), mis on lühendatult ära toodud tabelis 1.
H istogeneetilin e  struktuur
Kõige sagedasem ajukasvajate rühm on glioomid, 
moodustades erinevatel andmetel 40 -67%  (nendest
pool kuni 2 /3  on glioblastoomid) kõikidest primaarsetest 
ajukasvajatest, järgnevad meningioomid (9 -3 5 % ), 
neurinoomid (1-11% ) ja hüpofüüsi adenoomid (5 - 
18%) (18, 25). Enamikus uuringutes on glioomide ja 
meningioomide suhe 2 : 1 või 3 : 1 glioomide kasuks. 
Rochesteri uuringus (18), kus oli suur lahangute hulk 
(70%), leiti 57% kõikidest meningioomidest lahangul ja 
vastav suhe oli 0,8 : 1 meningioomide kasuks. See viitab 
meningioom ide elupuhusele a lad iagnoosim ise le . 
Metastaasid moodustavad kuni 41% kõikidest KNS-i 
kasvajatest, kusjuures on alust arvata (toetudes lahan- 
guleidudele), et märkimisväärne hulk metastaasidest 
jääb kliiniliselt diagnoosimata (18, 22). Lastel vanuses 
alla 15 eluaasta moodustavad g lioom id 7 0 -8 5 %  
kõikidest KNS-i kasvajatest, sagedamini esinevad 
astrotsütoom (22-36% ), medulloblastoom (15-17% ), 
kraniofarügioom (6-13% ) ja ependümoom (3-14% )
(27). Harva on lastel meningioomi, neurinoomi ja 
hüpofüüsi adenoomi.
Haigestum us
V astava lt k irjanduse andm ete le  kõ iguvad  
haigestumuse näitajad erinevates populatsioonides ja 
geograafilistes piirkondades küllalt suurtes piirides: 4 -
16 juhtu 100 000 elaniku kohta aastas (2, 3, 6, 8, 10,
19, 20, 29), Põhja-ltaalias (5) isegi kuni 26 juhtu (vt 
tabe l 2). Reeglina on haigestum us suurem 
sotsiaalmajanduslikult paremini arenenud piirkondades, 
kus on hea tehniline varustus (kompuutertomograafia, 
m agne tresonan ts tom ograa fia ) ja kättesaadav 
meditsiiniline abi, väljakujunenud ja korralikult töötav 
registerteenistus (vähiregistrid) ning suurem lahangute 
arv (1, 18). Samuti mõjutab haigestumuse näitajaid 
läbiviidud epidem ioloogiliste uuringute metoodika: 
s issearvam iskriteerium id, ha igusjuh tude arv ja 
kogumisviis, kasutatavad klassifikatsioonid. Etnilised, 
rassilised ja soolised erinevused viitavad võimalikule 
hormonaalsete, geneetiliste ja keskkonna faktorite 
toimele ajukasvajate tekkes. On leitud (1), et valgetel 
on üldiselt suurem risk haigestuda ajukasvajatesse kui 
mustanahalistel. USA-s erinevatel rassidel läbiviidud 
uuringud (13) on näidanud, et afroameeriklastel esineb 
võrreldes valgetega rohkem meningioome ja hüpofüüsi 
kasvajaid ning vähem glioome. Haigestumuse soolise 
erinevuse ilmekaks näiteks on glioom ide sagedam 
esinemine meestel ja meningioomide ülekaal naistel. 
Spetsiifiliste hormonaalsete häirete seost primaarsete 
ajukasvajate tekkega ei ole aga õnnestunud siiani 
tõestada. Teadaolevalt sõltub haigestumus ajukas­
vajatesse pa tsientide vanusest. Haigestumus on 
suhteliselt stabiilne lapse- ja noorukieas, langeb pisut 
30. eluaastates, alates 40. aastatest hakkab aga kiiresti 
tõusma, saavutades maksimumi 50. ja 70. eluaasta 
vahel. Andmed haigestumuse kohta vanemaealistel on 
vastuolulised. Uks osa uurijaid (9, 20) väidab, et
K esknärvisüsteem i ka sva ja te  h isto loog iline k lassifikatsioon (M TO , 19 93 )
1. Neuroepiteliaalsed kasvajad
1.1. Astrotsütaarsed kasvajad
1.1.1. Astrofsütoom
1.1.2. Pahaloomuline astrofsütoom
1.1.3. Glioblasfoom
1.2. Oligodendrogliaalsed kasvajad
1.2.1. Oligodendroglioom
1.2.2. Pahaloomuline oligodendroglioom
1.3. Ependümaalsed kasvajad
1.3.1. Ependümoom
1.3.2. Pahaloomuline ependümoom
1.4. Segatüüpi glioomid
1.5. Soonpõimiku kasvajad
1.6. Ebaselge päritoluga neuroepiteliaalsed 
kasvajad
1.7. Neuronaalsed ja segatüüpi 
neuronaalgliaalsed kasvajad
1.8. Käbikeha kasvajad
1.9. Embrüonaalsed kasvajad
2. Kraniaal- ja spinaalnärvide kasvajad
2.1. Neurinoom
2.2. Neurofibroom
1. Ajukelmete kasvajad
1.1. Meningoteliaalsed
1.1.1. Meningioom (11 varianti)
1.1.2. Pahaloomuline meningioom
1.2. Mesenhümaalsed mittemeningoteliaalsed 
kasvajad
1.3. Primaarsed melanofsütaarsed kasvajad
1.4. Ebaselge histogeneesiga kasvajad
2. Lümfoomid ja hemopoeetilise koe kasvajad
3. Idurakkudest pärinevad kasvajad
4. Tsüstid ja tuumorilaadsed moodustised
5. Türgi sadula piirkonna kasvajad
5.1. Hüpofüüsi adenoom
5 .2 . Kraniofarüngioom
6. Regionaalsete kasvajate lokaalsed 
ekstensioonid
7. Metastaatilised kasvajad
8. Klassifitseerimata kasvajad
vanemaeal_ alistel haigestumus väheneb, kusjuures kõige 
sagedasemaks hisfoloogiliseks tüübiks on glioom. Teised 
autorid (5, 18, 16) leiavad, et 65-aastaste ja vanemate 
hulgas haigestumus pigem suureneb ja peamiseks tüübiks
on m ening ioom . A rva takse , et vä iksem ate 
haigestumusnäitajate üheks põhjuseks on, et ei pöörata 
p iisa va lt tähe lepanu vanurite  p iltd ia g n o s tilise le  
uurimisele, kuna traditsiooniliselt diagnoositakse neil
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Tabel 2. P rim aarse te  KNS-i kasvajate  h a igestu m u sko rd ajad  (1 00  0 0 0  e la n ik u  k o h ta ) 
erinevates  epidem ioloogilistes uuringutes
Piirkond Uuringu aeg Haigestumuskordaja
Davis 1996 Connecticut, Utah, 
Massachusetts, Missouri
1985-1989 9 ,4 *
Helseth 1988 Norra 1955-1984 M 8,2 N 6 ,8 * *
Counsell 1996 Lothian, Sotimaa 1989-1990 15,3
Van der Sanden 1998 Holland (kesk-, idaosa) 1989-1994 M 6,5 N 4 ,4 * * *
Preston-Martin 1993 Victoria, Austraalia 1982-1990 M 8,8 N 8,1 * * *
Radhakrishnan 1995 Rochester, Minnesota 1970-1989 12,5*
D'Alessandro 1995 Valle d'Aosta, Itaalia 1986-1991 M 21,6 N 28,1 *
Fogelholm 1984 Kesk-Soome 1975-19 8 2 13,6*
Cole 1989 Wales (kaguosa) 1981-1987 5,6
Stan dardimiseks * kohaliku riig i * * Euroopa * * * maailma
kasutatud rahvastikud: stan dardrah vastik stan dardrah vastik stan dardrah vastik
pigem dementsust või insulti Icui ajukasvajat.
T rend iuuringud on nä idanud, et viim aste l 
aastakümnetel on haigestumus ajukasvajatesse oluliselt 
suurenenud. Siiani käivad vaidlused selle üle, kas tegemist 
on tõe lise haigestum use tõusu või d iagnostika 
paranemisest tingitud artefaktiga. Rochester! uuringus 
(20) leitakse, et suurenenud on ainult magnetresonants- 
ja kompuutertomograafilisel uuringul juhuleidudena 
diagnoositud ajukasvajate hulk. Desmeules koos 
kaastöötajatega (7) näitab, et piltdiagnostika tehnilise 
külje paranemine mõjutab haigestumusenäitajaid ainult 
20% ulatuses. Tõus on kõige ilmsem üle 65-aastaste 
patsientide vanusegrupis, osaliselt põhjendatakse seda 
paranenud diagnostikaga selles vanusegrupis. Samuti 
on leitud, et haigestumuse tõus erineb histoloogiliste 
tüüpide osas. Sõltuvalt uuringust esineb suurim tõus kas 
meningioomide (12) või glioomide (k.a glioblastoom) 
rühmas (9). Samas on glioomide, eriti nende maliigsete 
vormide diagnoosimine vähem sõltuv hea tehnoloogia 
olemasolust, kuna kliiniline leid ilmneb haiguse varasemas 
staadiumis.
Haigestum us Eestis
Eestis on haigestumust primaarsetesse intrakraniaal- 
setesse kasvajatesse uurinud Virve Lukas, kelle andmetel 
oli ajavahemikus 1951-1969 vastav näitaja 5,9 juhtu 
100 000 elaniku kohta aastas (17). Haigestumus näitas 
suurenemistendentsi, olles esimesel kümnendil 5,0 ja 
teisel kümnen-dil 6,7. Kõige sagedasemaks histoloogliseks 
tüübiks oli glioblastoom (haigestumus 1,3), järgnesid
meningioom ja atrotsütoom (haigestumus vastavalt 0,9 
ja 0,5). Eesti Vähiregistri andmetel põhinevad uuringud
(28) annavad kesknärvisüsteemi kasvajate haigestumus- 
kordajaks 100 000  inimese kohta ajavahemikus 1988- 
1992 meestel 5,5 ja naistel 4,4, kusjuures arvesse ei 
ole võetud healoomulisi kasvajaid. Tartu Ülikooli Kliinikumi 
Närvikliiniku praegune uurimisprojekt hõlmab Eestis aja­
vahemikus 1986- 1996 diagnoositud intrakraniaalseid 
ja -spinaalseid kasvajajuhte. Haigestumus primaarsetesse 
kesknärvisüsteemi kasvajatesse 100 000 elaniku kohta 
on meestel 9,4 ja naistel 10,3; glioomide korral on 
vastavad näitajad 4,3 ja 3,6 ning meningioomide korral 
1,0 ja 2,8. Viimaste andmete võrdlusel V. Lukase poolt 
toodud haigestum usega (a rvesta tud on a inu lt 
primaarseid intrakraniaalseid kasvajaid, näitajad on 
standarditud vastavalt Eesti standardrahvastikule 
1989. a) ilmneb statistiliselt oluline haigestumuse 
suurenemine kõikides vanusegruppides ja mõningates 
histoloogilistes gruppides (astrostütoom, glioblastoom ja 
meningioom). Samal ajal on haigestumus ependümoomi, 
medulloblastoomi, neurinoomi ja hüpofüüsi adenoomi 
püsinud suhteliselt stabiilsena. Osaliselt on haigestumuse 
tõusu põhjuseks (eriti astrotsütoomide ja meningioomide 
korral) kindlasti diagnostika paranemine. Seda näitab 
asjaolu, et V. Lukase uuringus moodustasid enamuse 
lahangu l d iagnoositud juhtudest m eningioom id, 
käesolevas uuringus aga glioom id. Võttes arvesse 
haigestumuse suurenemist kõikides vanusegruppides ja 
maliigsete glioomide hulga kasvamist, ei saa eitada ka
mone teise etioloogilise faktori või keskkonna toimet 
haigestumuse tõusule.
Elulem us ja  seda m õ ju ta v a d  tegurid
Ajukasvajate korral on elulemust oluliselt vähem 
uuritud kui haigestumust. Kõige laiaulatuslikumad ja 
põhjalikumad on Euroopa 45 vähiregistril põhineva 
EUROCARE ja USA-s SEER (Surveillance, Epidemiology 
and End Result^ programmi raames läbiviidud uuringud 
(21, 23). Vaatamata suurtele piirkondlikele erinevustele 
haigestumuses, on elulemus pahaloomuliste ajukasvajate 
korral ühtviisi madal kõikides uuringutes. Siiski on leitud, 
et alates 70. aastatest, kui hakati laioldasemaltkasutama 
radio- ja kemoteraapiat, on elulemus mõningate harvem 
esinevate kasvajavorm ide (medulloblastoom) osas 
paranenud. Teiste, sagedamini esinevate histoloogiliste 
tüüpide, nagu glioblastoom, vastav näitaja on aga jäänud 
p ra k tilise lt m uutum atuks. M õ n inga s t elulem use 
paranemist põhjendatakse varasema ja paranenud 
diagnostikaga ning efektiivsema raviga (eriti noorematel 
pa ts ie n tid e l). V astava lt EUROCARE program m i 
tulemustele (sisaldab ainult maliigseid ajukasvaja vorme)
oli ajavahemikus 1 9 8 5 -1 9 8 9  Euroopa keskmine 5 
aasta suhteline elulemusmäär meestel 17% ja naistel 
20%. Kõige kõrgem oli meeste elulemus Soomes (21 %) 
ja naiste elulemus Saksamaal (26%), madalaimad 
näitajad olid meestel Eestis ja Poolas (vastavalt 8% ja 
10%) ning naistel Sotimaal (13%). Trendiuuringud on 
näidanud vähest elulemuse paranemist, seda just 
esimesel aastal pärast diagnoosimist. Sarnane positiivne 
trend esineb ka noorem ates vanusegrupp ides. 
Patsientide vanust peetakse üheks oluliseks ajukasvajate 
prognostiliseks faktoriks. Teadao leva lt on vanus 
omakorda oluliselt seotud ajukasvajate histoloogiliste 
tüüpide esinemissagedusega Nooremas eas esineb 
sagedamini kõrgemalt diferentseerunud gliialähtega 
kasvajaid, samuti alluvad mõningad selles vanusegrupis 
sagedam in i esinevad m a liigsed  vorm id (m edul­
loblastoom) paremini radio-ja kemoteraapiale. Uuringud 
on näidanud, et elulemus pahaloomuliste ajukasvajate 
korral on meestel mõnevõrra halvem kui naistel (14, 
21). Seda seletatakse b io loogilise lt agressiivsemate
kasvajavorm ide sagedasema esinemisega meestel, 
samuti naiste parem a b io lo o g ilis e  vastupanuga 
haigustele. Ravi suhtes on andmed vastuolulised, kuna 
selles va llas  puuduvad  s iian i p ro sp e k ti ivsed 
randomiseeritud uuringud, mis tõestaksid ühe või teise 
ravimeetodi statistiliselt olulist mõju elulemusele. Mõned 
autorid (14) on siiski näidanud, et postoperatiivset 
kiirifusravi saanutel on esimese aasta prognoos parem 
kui teistel patsientidel. Pahaloomuliste ajukasvajate kõige 
olulisemateks prognostilisteks faktoriteks peetakse haige 
vanust ja kliinilist seisundit ning kasvaja hisfoloogilist tüüpi.
Elulemust meningioomide korral on uuritud veelgi 
vähem. Norras aastatel 1975- 1992 läbiviidud uuringul 
(11) o li v iie  aasta suhte line e lu lem usm äär 95%  
(maliigsetel vormidel 49%), Soomes aastatel 1 9 53 -
1984 oli vastav näitaja kõikidel vormidel kokku 79% 
(24). Viimati mainitud uuringud näitavad, et elulemus 
on meningioomide korral viimastel aastakümnetel seoses 
kompuutertomograafia ja magnetresonantstomograafia 
kasutusele võtmisega oluliselt suurenenud, sõltudes 
kasvaja histoloogiast, patsiendi vanusest ning kliinilisest 
seisundist ja kasvaja eemaldamise ulatusest operatsioonil. 
Prognoos on reeglina hea alla 75-aostastel kliiniliselt 
heas seisundis ja operatsioonil täielikult eemaldatud 
ka sva ja g a  m e n in g io o m ih a ig e te i M a liig s e id  
meningioome esineb harva (erinevatel andmetel 1 -  
10%), sagedamini nooremas eas meestei ning nende 
prognoos on o lulise lt halvem kui teistel vorm idel. 
Meningioomi lokalisatsiooni otsest seost elulemusega 
leitud ei ole (14).
K o k ku v õ te
KNS-i kasvajate haigestumuse ajaliste, geograafiliste, 
vanuseliste ja sooliste erinevuste olemuse väljase l­
gitamiseks on tehtud rida metanalüüse (1, 4), mis 
näitavad uurimismetoodika olulist mõju tulemustele. Siiani 
ei ole lõp likku selgust haigestumuse suurenemise 
põhjustes. Edaspidiste ajaliste muutuste hindamiseks on 
vajalik jätkata pikema ajavahemiku jooksul ja võimalikult 
sarnase m etoodikaga läb iv iidud  ep idem io loog ilis i 
uuringuid.
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Sum m ary
Tum ours of H i«  central nervous system
The most modern classifications of brain tumours 
are based upon that of Bailey and Cushing. The 
first W orld Health Organization classification was 
published in 1 9 7 9 . Subsequently  some 
disagreements have persisted and slightly modified 
classifications have been published later (the last 
classification in 1993). Incidence rates for primary 
brain tumours vary in a wide range (4 -1 6 /1 0 0 ,0 0 0 /  
year), while higher rates are generally found in 
socioeconomically advanced societies with good 
availability of medical care, better organized  
registries of data collection and possibly higher 
autopsy rate. The frequency of primary brain 
tumours, especially in the elderly, has increased 
substantially during the past two decades.
Comparison of the data of two epidemiological 
studies carried out in Estonia suggests that increase 
in the incidence rates of primary intracranial 
tumours has occurred from the fifties till the nineties. 
Increase in incidence rates is histology-specific and 
is evident in all age groups. Survival in case of 
primary malignant brain tumours is very low in all 
countries. The mean European 5 -year relative  
survival rate is 17% for men and 20%  for women. 
Better prognosis has been found in younger patients, 
which can be attributed to particular histotypes 
occurring mostly in this age. O ther im portant 
prognostic factors are the clinical condition of a 
patient and the histological type of tumour. The 5- 
year relative survival rate of m eningiom as is 
between 80 and 90%  depending on the histological 
type and the extent of resection of tumour, as well 
as on the patient's age and clinical condition.
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